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Fragments of microcin B17 as a source of new topoisomerase 
inhibitors 
Abstract: 
DNA topoisomerases are a broad class of enzymes responsible for topological 
changes in DNA. DNA gyrase is a prokaryotic topoisomerase with the essential function of 
negatively supercoiling closed-circular DNA at the expense of ATP hydrolysis. There are two 
main known families of gyrase inhibitors: quinolones and aminocoumarins. A few bacterial 
toxins are also known for their inhibitory properties on gyrase, among them CcdB  and 
microcin B17. Microcin is a peptide produced by strains of Escherichia coli expressing the 
plasmid-borne mccB17 operon, which is post-translationally modified to convert serine- 
and cysteine- containing sequences into oxazole, thiazole, and oxazole-thiazole fused rings. 
Previous work has shown that these heterocycles are critical, and alterations of these 
residues proved to be detrimental to MccB17’s antibacterial activity. In spite of its 
attractive antibacterial properties, MccB17’s physico-chemical properties prevent it from 
being a good drug candidate. In the pursuit of smaller inhibitors derived from MccB17, we 
describe here how modifications of the whole toxin led to a better understanding of the 
elements that are critical for its activity. We generated fragments of MccB17 by chemical 
and biochemical methods and we show that some of these fragments are topoisomerase 
inhibitors. The active fragments generated, in addition to highlighting features responsible 
for MccB17 activity, will be valuable starting points for the design of new inhibitors. 
Additionally, novel small molecules topoisomerase inhibitors sharing structural features 
with the heterocycles found in MccB17 were identified and characterized. This work had 
mainly focused on E. coli gyrase as a model target, but we have shown as well that MccB17 
and its fragments had potential application on other topoisomerases. 
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CHAPTER I Introduction 
 
Overview 
 In the present health climate, where the occurrence of pathogenic bacteria resistant to 
most of the commonly used antibacterial drugs combined with the significant decrease in new 
antibiotics being brought to the market, threaten to bring us back to the dark ages of the pre-
antibiotic area, there is an urgent need to discover new bactericidal agents (Norrby, Nord et al. 
2005; Boucher, Talbot et al. 2009). The identification of new cellular targets through genomics 
has not lived up to its initial promises and so exploration of known targets with alternate ways 
to affect them is a safe strategy to overcome bacterial resistance. For this purpose a better 
understanding of the structure and mechanism of action of these enzymes as well as their 
interaction with known drugs is of major interest to develop new active entities. Present 
antibacterial agents interact with pathogens in various ways: they can interfere with the cell 
wall synthesis like penicillin (Waxman, Yocum et al. 1980), block protein synthesis via the 
ribosome similar to chloramphenicol (Vazquez 1966), inhibit essential metabolic pathways like 
sulfonamides with the tetrahydrofolic acid biosynthesis (Seydel 1968), or alter the nucleic acid 
synthesis as fluoroquinolones do (Wolfson and Hooper 1985). We have chosen to focus on this 
last cellular process and particularly on the family of enzymes targeted by fluoroquinolones: 
the topoisomerases. Topoisomerases are a broad class of ubiquitous enzymes controlling the 
topology of DNA in the cell, they deal with the interlinking and twisting of DNA molecules that 
are essential for DNA replication, transcription, recombination, as well as for chromosome 
compaction and segregation (Gellert 1981). This crucial role in the regulation of DNA topology 
has made them attractive and already successful targets, with DNA gyrase and topoisomerase 
IV for antimicrobial therapy and with human topoisomerase I and II for anticancer therapy. 
One of the most efficient ways to exploit these enzymes against their host is by stabilizing a 
covalent intermediate they form with the DNA during its topology modification this leading to 
the release of double-strand breaks that are lethal to the cell. This mechanism is often referred 
as topoisomerase poisoning. Examples of topoisomerase poisons are the drugs belonging to 
the fluoroquinolones family for gyrase and topo IV (Drlica and Zhao 1997), etoposide (Chen, 
Yang et al. 1984) and amsacrine (Nelson, Tewey et al. 1984) for topo II. Interestingly, two 
bacterial toxins are known to be gyrase poisons as well, namely CcdB (Bernard, Kezdy et al. 
1993) and microcin B17 (MccB17) (Heddle, Blance et al. 2001). These two peptides are not 
exploitable per se as antibacterial drugs due to their large size (12 kDa for CcdB, and 3 kDa for 
MccB17) and physical properties, but they are useful tools to understand the mechanism of 
cleavage-complex stabilization as well as potential templates to develop molecules bearing the 
same properties. Recent insight into the mechanism of action of CcdB suggested that its 
potential as a template to generate new compounds is limited. In fact it appears that the 
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activity of CcdB relies mostly on the steric hindrance of a gyrase cavity by the whole protein 
(Dao-Thi, Van Melderen et al. 2005); unfortunately this mode of action cannot be easily 
mimicked by small molecules. The precise mechanism of action of MccB17 is still unknown and 
this compound has not being widely studied in the context of designing novel antibacterial 
molecules. Considering the need for new antibacterials, MccB17 seems a promising model to 
inspire new inhibitors. We decided to investigate further the mode of action of MccB17 and 
generate related compounds as potential topoisomerase inhibitors. The following chapters will 
describe how these two aspects have been addressed. But first we will give a brief overview of 
the two therapeutic fields where topoisomerases are involved: antibacterial and anticancer 
drugs. We will then focus on topoisomerases and their inhibitors. Finally the present state of 
knowledge on MccB17 will be covered. 
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1 Antibacterial mode of action and rise of resistance 
 The discovery and uses of antibacterial agents with a broad-spectrum of activity on a 
large scale had brought us in the comfort of the antibacterial golden age: an era where we 
have the tools to fight infectious diseases and avoid epidemics; where pneumonia, scarlet 
fever, and syphilis are not anymore common causes of death; where wounds or surgery have 
no chance of killing from septicemia. Unfortunately this state is threatened by the rise of drug-
resistant species. Below are shown a few milestones of the history of antibacterials that led us 
to this golden age. 
1.1 Milestones of antibacterials history 
 
1670’s: identification of bacteria by A. P. Van Leeuwenhoek with the help of his 
invention, the microscope. 
1870’s: connection between diseases and bacteria with the work of L. Pasteur and R. 
Koch. 
1870’s: concept of antiseptic surgery by Baron J. Lister. 
1900’s: first synthetic antibacterial compounds by P. Herlich, salvarsan (arsphenamine) 
against syphilis. Concept of chemotherapy. 
1930’s: synthesis (J. Klarer and F. Mietzsch) and antibacterial potential (P. Domagk) of 
prontosil from Bayer. The later identification by J. Trefouel and T. Trefouel of prontosil 
as a pro-drug of sulfanilamide lead to the discovery of the sulfonamide antibacterial 
drug class. Sulfonamide was the first antibacterials class available on a large scale. 
1940’s: after the early discovery of penicillin potential by A. Fleming in 1929, it is only 
in the 40’s that penicillin through the work of H. Florey, N. Heatley, A. J. Moyer was 
brought to the mass production scale. The wide use of penicillin was followed a few 
years later by the occurrence of resistant strains. 
1949: clinical use of first broad spectrum antibacterial: chloramphenicol, soon after its 
discovery by D. Gottlieb. Chloramphenicol was the first antibiotic to be produced 
synthetically on a large scale.  
1953 E. Kornfeld isolates the first aminoglycoside antibacterial vancomycin from soil 
samples. 
1964: first cephalosporin (resistance to β-lactamase). 
1962: discovery of nalidixic acid, clinical use in 1967. This discovery led to the 
development and success of fluoroquinolones drugs. 
2000’s: declining new antibacterials, increasing bacterial resistances. 
1.2 Bacteria structure and antibacterial targets 
Antibacterials mainly affect three essential activities in bacteria: cell wall biosynthesis, 
protein synthesis and DNA synthesis. Other mechanisms of action include detergent-like 
destabilisation of cytoplasmic membrane, and activation of toxic species by the bacteria’s 
metabolism. We will detail further these aspects, but first give a brief description of bacteria 
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structures. Figure 1 is a diagram of Gram-positive and Gram-negative bacteria and their cellular 
antibacterial targets. The genomic DNA of the bacteria, the ribosome responsible for the 
protein synthesis, and the various elements of the cell function like plasmids and enzymes are 
contained in the cytoplasm. The cytoplasm is enclosed in the cytoplasmic membrane, a 
phospholipid bilayer that separates the intracellular components of the cell from the outside. 
The cytoplasmic membrane is surrounded by the peptidoglycan, this is a mesh structure 
composed of a linear polymer of alternating of N-acetylglucosamine and N-acetylmuramic acid 
units crosslinked by peptide chains. The peptidoglycan is thicker in Gram-positive bacteria and 
forms the external layer, it is the target of colour staining that defined the Gram classification. 
In Gram-negative bacteria, the thinner peptidoglycan layer is enclosed in another phospholipid 
bilayer: the outer membrane, this second membrane differs from the cytoplasmic membrane 
by the fact that it contains lipopolysaccharides on its outer layer, lipoproteins that anchor it to 
the peptidoglycan and porins that are responsible for the passive transport of metabolites 
through the outer membrane. The outer membrane gives Gram-negative bacteria a potential 
extra advantage against antibacterial agents. 
Figure 1 Schematic view of Gram-positive and Gram-negative bacteria and antibacterial action. 
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Figure 2 Details of cellular structure from Figure 1: top left, details of the peptidoglycan: glycan chains of β-1,4-
linked N-acetylglucosamine and N-acetylmuramic acid, are crossed-linked by interconnected peptides, sequences 
are given for illustration purpose and can vary between organisms. Middle left, details of the cytoplasmic 
membrane, a bilayer of phospholipids. Bottom left, details of the outer membrane, a phospholipid bilayer 
containing lipopolysaccharide on the external surface and lipoprotein on the internal surface. Right side: legend. 
 
1.3 General mechanism of bacterial resistance 
Bacteria have different ways of protecting themselves against antibacterials: the most 
obvious method is by not letting the antibacterial get into the cell or not stay in long enough to 
be harmful; this is achieved by alteration of membrane permeability, by reduction of the 
number of porins (in Gram-negative bacteria) or mutations to make them “too small” to allow 
antibacterials through, or expression of efflux proteins that will pump out the harmful 
molecule faster that it gets in. The second possibility is to destroy or modify the noxious 
compound so it will lose its activity. A typical example is the beta-lactamase that renders 
penicillin inactive by hydrolysing the beta-lactam ring. Another strategy is to mutate the 
antibacterial target so it will be not or less susceptible to the antibacterial drug: as an example 
the modification of the cross linking system of peptidoglycan synthesis gives resistance to 
vancomycin: the peptide sequence changes from terminal -D-Ala-D-Ala motif to -D-Ala-D-Lac 
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(lactate); the resulting dipeptide has a significantly decreased affinity for vancomycin. These 
different mechanisms will be illustrated in the following part where the different antibacterials 
commonly used are classified by mode of action will be described. Occurrence of resistance 
specific to a specific mode of action will be included within  this mode of action (Alekshun and 
Levy 2007). 
1.4 Common multi-drug-resistant bacteria  
 
Gram-positive: Staphylococcus aureus: meticillin-resistant S. aureus (MRSA), Enterococcus 
faecium: vancomycin resistant Enterococcus (VRE), Clostridium difficile, and Streptococcus 
pneumonia (Woodford and Livermore 2009). 
Gram-negative: Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, 
Enterobacter spp: ESBL producing Enterobacter, Salmonella, Klebisella pneumoniae, Serratia 
marcescens, Neisseria gonorrhoeae, Stenotrophomonas maltophilia (Slama 2008; Souli, Galani 
et al. 2008; Volles and Branan 2008) 
Other: Mycobacterium tuberculosis: multidrug-resistant M. tuberculosis (MDR-TB), extensively 
drug-resistant M. tuberculosis (XDR-TB) (Chiang, Centis et al.). 
1.5 Inhibitors of cell wall synthesis 
The peptidoglycan is what gives bacteria structure, without it the bacteria is not able to 
deal with its internal osmotic pressure caused by the gradient of electrolyte concentration 
between the inside and the outside of the cell. The peptidoglycan biosynthetic pathway being 
specific to bacteria, compounds disrupting it are less likely to affect human enzymes. These 
characteristics make the enzymes involved in peptidoglycan biosynthetic pathway the perfect 
targets for antibacterial: lethal and specific. 
1.5.1 Cell wall synthesis 
(Vollmer, Blanot et al. 2008) 
An overview of the constituents of peptidoglycan has been given with the description 
of the cell structure, we will describe here briefly how peptidoglycan is synthesized. 
Peptidoglycan is an assembly of long glycan chains cross-linked by peptides. The peptide gives 
flexibility to the structure whereas the glycan is the rigid part. The glycan chain is formed of an 
alternating sequence of β-1, 4-linked N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAC). The chemistry of the glycan is conserved among different bacteria. The peptide 
structure however varies among species. The peptide is bound to the carboxyl group of the 
muramic acid by its N-terminus, it is referred to as the peptide subunit. Peptide subunits can be 
connected by a peptide linker; this linker varies greatly through different species. The synthesis 
starts in the cytoplasm where UDP-GlcNAc and UDP-MurNAc-(peptide subunits) are formed. At 
the cytoplasmic membrane the lipid precursor is synthesized by the addition of phospho-
MurNAc-(peptide subunit) to bactoprenol to form lipid I: MurNAc-(peptide subunit)-
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pyrophosphoryl-undecaprenol. The formation of a 1, 4-β glycoside bond between GlcNAc from 
the UDP-GlcNAc and lipid I lead to lipid II. Lipid II: GlcNAc-β-1, 4-MurNAc-(peptide subunit)-
phosphoryl-undecaprenol, is the substrate that will provide the building block used to 
assemble the final peptidoglycan, once it has crossed the cytoplasmic membrane. The 
mechanism of the cytoplasmic membrane crossing is not clearly identified yet.  The assembly 
of the building blocks is carried out by the penicillin binding protein (PBP); this enzyme had two 
functions transglycosidase and transpeptidase. PBP with its transglycosidase activity will 
assemble the glycan chain, by link the precursor to an existing glycan strand, releasing the 
undecaprenylpyrophosphate that will dephosphorylate to bactoprenol and extending the 
glycan chain. PBP is involved as well with peptide cross-linking; PBP will replace the terminal a 
D-Ala in the D-Ala-D-Ala bond, thus activating the bond to react with another peptide subunit 
or a peptide bridge. These two events produce the mesh structure. The mechanism of 
formation of peptidoglycan shows how essential PBP is, and therefore a good antibacterial 
target. Figure 3 shows the peptidoglycan synthesis and its actors (Scheffers and Pinho 2005). 
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Figure 3 Peptidoglycan synthesis: A) membrane steps of peptidoglycan biosynthesis. M, G and the five coloured 
beads linked to M represent MurNAc, GlcNAc and the pentapeptide, respectively. C55-PP and C55-P are for 
undecaprenyl pyrophosphate and undecaprenyl phosphate, respectively. B) and C), building blocks and synthesis 
reactions of the peptidoglycan. Reproduced from Bouhss et al (Bouhss, Trunkfield et al. 2008). B) The basic unit of 
the peptidoglycan is a disaccharide-pentapeptide composed of the amino sugars N-acetylglucosamine and N-
acetylmuramic acid, which are linked together by -1,4 glycosidic bonds. The pentapeptide is covalently linked to 
the lactyl group of the muramic acid, and its composition can vary between different bacteria. In both E. coli and 
B. subtilis, the dibasic amino acid of the stem peptide, which allows the formation of the peptide cross bridge, is 
meso-diamoinopimelic acid (m-A2pm), while in S. aureus it is L-lysine (L-Lys), to which a pentaglycine cross bridge 
is bound. C) Peptidoglycan chains are synthesized by transglycosylation and transpeptidation reactions which 
lead to the formation of long glycan chains cross-linked by peptide bridges. In the transglycosylation reaction, the 
reducing end of the N-acetylmuramic acid (M) of the nascent lipid-linked peptidoglycan strand is likely 
transferred onto the C-4 carbon of the N-acetylglucosamine (G) residue of the lipid-linked PG precursor, with 
concomitant release of undecaprenylpyrophosphate (ppB). In the transpeptidation reaction, the D-Ala–D-Ala 
bond of one stem peptide (donor) is first cleaved by a PBP enzyme, and an enzyme-substrate intermediate is 
formed, with the concomitant release of the terminal D-Ala. The peptidyl moiety is then transferred to an 
acceptor, which is the last amino acid of the pentaglycine cross bridge in the depicted case of S. aureus, and the 
PBP enzyme is released. B) and C) are reproduced from Scheffer and Pinho (Scheffers and Pinho 2005).  
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1.5.2 β-lactam antibiotics 
The beta-lactam antibacterials are the heirs of penicillin (G). They all share the same 
mechanism of action, but display various degrees of stability and spectra of antibacterial 
activity. 
1.5.2.1 Mode of action 
(Waxman and Strominger 1983) 
The β-lactams are analogous to the terminal D-Ala-D-Ala of the peptidoglycan 
precursor. The serine residue of the penicillin-binding protein perform a nucleophilic attack of 
the amide bond of the β-lactam instead of the D-Ala-D-Ala peptide bond of the peptidoglycan. 
This reaction opens the β-lactam and forms a covalent bond with the antibacterial, rendering 
the enzyme inactive. The mechanism is illustrated in Figure 4. 
 Resistance to β-lactams is primarily achieved by the action of β-lactamases, enzymes 
that catalyze the hydrolysis of the β-lactam ring thus disarming the antibacterial warhead. The 
β-lactamases can be divided in two classes depending upon whether they have a serine active 
Figure 4 Mode of action of β-lactam antibacterials 
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site or a metal ion co-factor. Various substrate specificities to β-lactam and related 
antibacterial can be observed: penicillinase, cephalosporinase or carbapenamase; as well as 
different susceptibility to inhibitors like clavulanic acid (see below). Secondarily, resistance is 
achieved by mutation of the PBP reducing its affinity to the antibacterial like PBP2a for the 
infamous meticillin-resistant S. aureus (MRSA), or by modification of cellular permeability. A 
recent study reported an increase of Enterobacteriaceae carrying plasmids with multiple 
combinations of various extended spectrum β-lactamases and carbapenemases, thus 
conferring resistance to nearly all the β-lactam antibacterials, already worrying by itself, this 
kind of resistance can be easily transfered to other organism (Bush 2010). 
1.5.2.2 Penams (penicillins) 
The first representative that was widely used is the penicillin G, its only flaw was that it 
could not be orally administrated due to its instability at the stomach’s pH; Penicillin V 
however is less potent but orally active. A wide range of hemi-synthetic penams have been 
developed from the (+)-6-aminopenicillanic acid. Penams are classified depending on their 
spectrum of action on Gram-positive and Gram-negative bacteria, and their stability toward β-
lactamases. The initial appearance of resistance linked to penicillinase led to the development 
of meticillin, which is not anymore used clinically, and its substitutes oxacillin, cloxacillin and 
nafcillin. The need to broaden the types of bacteria affected by penams gave birth to the 
aminopenicillins: ampicillin and amoxicillin that are active on Gram-negative bacteria. Pro-
drugs of ampicillin like pivampicillin and metampicillin have a better bioavailability and will 
release ampicillin upon hydrolysis in the body. Finally carboxypenicillin like carbenicillin, 
ticarcillin, temocillin have a Gram-negative spectrum including Pseudomonas aeruginosa and 
the ureidopenicillin piperacillin is a broad range covering Pseudomonas aeruginosa as well. 
Figure 5 Penams: a few examples 
30 
 
 
1.5.2.3 Beta-lactamase inhibitors 
(Payne, Cramp et al. 1994) 
These compounds have no antibacterial properties but are directly involved with β-
lactam antibacterials. They have a protective role: clavulanic acid, a substrate of β-lactamase 
will be hydrolysed in place of the active species, whereas sulbactam and tazobactam, 
irreversible inhibitors, will trap the enzyme. 
 
 
 
1.5.2.4 Penems 
(Dalhoff, Janjic et al. 2006) 
Thienamycin is an antibiotic active on Gram-positive and Gram-negative bacteria but 
unstable under physiological conditions, its derivative imipenem although is an injectable 
broad spectrum antibacterial resistant to β-lactamases. Imipenem is used in conjunction with 
cilastatin that prevent its degradation by dehydropeptidase. Meropenem, ertapenem and 
Figure 6 Penams: prodrugs and carboxypenams 
Figure 7 Beta-lactamase inhibitors 
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doripenem are improvements of Imipenem, as they are not affected by dehydropeptidase. The 
use of penems is restricted to avoid development of bacterial resistance. 
 
 
1.5.2.5 Cephems (cephalosporins) 
The first cephalosporin, cephalosporin C, was isolated from Cephalosporium 
acremonium, the strain was collected from “self purifying” sea water next to a sewage outlet 
(Brotzu 1948). Cefalotin was the first cephalosporin to be clinically used, and is still in use 
nowadays (Griffith and Black 1964; Decroix, Chaumeil et al. 1984). The first generation 
cephems were active predominantly on Gram-positive bacteria (Nightingale, Greene et al. 
1975). Similarly to penicillins extensive research has been carried out on cephalosporin and 
yielded a broad range of antibacterial, over what is often described as four (or more) 
generations, each generation bringing improvement. The classification can be described as 
follows: the 1st generation cephalosporins are only active on Gram-positive bacteria, whereas 
2nd generation have a spectrum extended to some Gram-negative bacteria. The 3rd generation 
cephalosporins have a broad spectrum of activity, however some members have a diminished 
activity on Gram (+); ceftazimide, which belong to the 3rd generation, is active on Pseudomonas 
aeruginosa.  The 4th generation cephalosporins have a broad spectrum of activity including 
Pseudomonas aeruginosa, and possess an increased resistance to β-lactamase; some are able 
to cross the blood-brain barrier, which allows them to be used against meningitis (El-Shaboury, 
Saleh et al. 2007). The last developed cephalosporins, ceftobiprole (Fritscher, Sader et al. 2008) 
and ceftaroline (Morrissey, Ge et al. 2009; Zhanel 2009) are active against MRSA and other 
drug-resistant strain. Cephalosporin is the largest class of antibacterial drug in term of sales 
(Hamad 2010).  
Figure 8 Penems 
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1.5.3 Glycopeptides 
(Boger 2001) 
The main representative of glycopeptides is vancomycin; teicoplanin and ramoplanin 
belong to this family as well. The glycopeptides are active against Gram-positive bacteria, and 
vancomycin is considered as a last resort drug. Even so, resistance to vancomycin and 
teicoplanin has started to appear and became of clinical importance; however ramoplanin is 
active against certain vancomycin-resistant strains (Collins, Eliopoulos et al. 1993; Bozdogan, 
Esel et al. 2003). 
 
Figure 9 Cephalosporins: a few examples of cephalosporins from the various generations are 
shown with their spectrum of activity. 
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1.5.3.1 Mechanism of action 
 
 
Figure 11 Inhibition of peptidoglycan synthesis by vancomycin 
Figure 10 Glycopeptides  
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Vancomycin binds to the D-Ala-D-Ala motif of the peptide of the N-acetylglucosamin-
N-acetylmuramic building block of the peptidoglycan (Reynolds 1989), blocking the cross-
linking of the glycan polymers and thus weakening the peptidoglycan that can no longer 
contain osmotic pressure. The mechanism of other glycopeptides involve the same pathway, 
teicoplanin in the same way as vancomycin (Jung, Jeya et al. 2009), and ramoplanin but at 
different steps, the conversion of lipid I to lipid II (Walker, Chen et al. 2005). 
 
 
 
As mentioned before resistance to vancomycin has been achieved by a fundamental 
change in the peptidoglycan biosynthetic pathway: the terminal D-Ala-D-Ala vancomycin-
binding motif has been either replaced by a D-Ala-D-Lac motif, that provides one less hydrogen 
bond donor as illustrated in Figure 12, or by a D-Ala-D-Ser where the bulky side chain prevent 
vancomycin binding (Reynolds and Courvalin 2005). 
 
1.5.4 Fosfomycin 
Fosfomycin is a broad-spectrum antibiotic isolated from 
Streptomyces that was initially relegated only to treat urinary tract 
infections, but in the light of the present problem of bacterial 
resistance it may have a second life where old antibacterials 
seems a good place to look to find a way around bacterial 
Figure 12 Illustration of vancomycin resistance mechanism 
Figure 13 Fosfomycin 
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resistance (Samonis, Maraki et al. ; Falagas, Kastoris et al. 2009). Fosfomycin appears to 
produce a high rate of resistance, but can be used in conjunction with other antibacterials. 
Recent studies of combination with other antibacterials seems promising (Kastoris, Rafailidis et 
al. 2010). 
 
1.5.4.1 Mechanism of action 
Fosfomycin is an irreversible inhibitor of enolpyruvate transferase (MurA). MurA is 
involved in the synthesis of the N-acetylmuramic acid, one on the saccharide building block of 
the peptidoglycan (Figure 14) (Marquardt, Brown et al. 1994).  
 
 
  
Figure 14 Mechanism of action of fosfomycin: the top figure shows the MurA reaction with 
its natural substrate. The bottom figure shows the irreversible reaction of MurA with 
fosfomycin. 
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1.5.5 Lipopeptides 
Lipopeptides are an old class of antibacterial, but due to the recent addition of 
daptomycin and its activity against drug-resistant S. aureus in topic application, they have been 
put back in the front line. The mechanism of action of daptomycin is not clearly identified: it is 
a calcium-dependant process involving interaction of daptomycin with the membrane and 
oligomerisation leading to the destabilisation of the membrane in a way similar to detergents 
(Robbel and Marahiel ; Fowler, Boucher et al. 2006). Mutation in the chromosomal gene mprF 
coding for a lysylphosphatidylglycerol synthetase have be reported to give resistance to 
daptomycin (Baltz 2009). 
 
1.5.6 Polymyxins 
Polymyxins are cyclic peptides with a long hydrophobic tail that are produced by 
Bacillus polymyxa (Gram-positive) and are active against Gram-negative bacteria. They belong 
to the last resort antibacterials  against Pseudomonas aeruginosa and Acinetobacter (Zavascki, 
Goldani et al. 2007). 
Figure 15 Daptomycin 
Figure 16 Polymyxin B 
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1.5.7 Isoniazid 
Isoniazid is a pro-drug activated by an enzyme called KatG (catalase-
peroxidase) and forms a covalent entity with NADH that disrupts the mycolic 
acid biosynthetic pathway. Mycolic acid is an essential element of the 
mycobacterial cell wall (Timmins, Master et al. 2004). Isoniazid is a front line 
drug for treatment of tuberculosis, resistance to isoniazid has been observed 
by loss of catalase and peroxydase activity, or by mutation of KatG leading to 
an enzyme unable to activate the prodrug (Somoskovi, Parsons et al. 2001). 
1.6 Inhibitors of protein synthesis 
1.6.1 Protein synthesis by the ribosome 
The ribosome is a complex assembly 
of RNAs and proteins, divided into two main 
subunits, 30S and 50S, Figure 18 shows the 
two subunits and the important sites for 
protein synthesis. The ribosome translates 
the information encoded in DNA and 
transferred by mRNA into an amino acid 
sequence. The mRNA encodes a series of 
amino acids in the form of series of three 
bases called codons; start and stop signals are 
encoded the same way. Amino acids are 
brought to the ribosome by tRNAs, which are 
specific to a given amino acid and possess the 
corresponding anti-codon. The 30S unit is 
responsible for the “reading” of the mRNA. 
Protein synthesis is initiated when a start 
codon reaches the peptidyl (P) site and 
interacts with the initiator methionine-mRNA 
and the two subunits associate. A new tRNA is 
accepted matching the next codon and after validation of the match in the 30S A site, the 
methionine is added to the tRNA amino acid in the 50S subunit. The ribosome moves to the 
next codon placing the dipeptide in the P site, and the methionine-tRNA in the exit (E) site. This 
is repeated until a stop codon reaches the A site, the peptide chain is then released 
(Poehlsgaard and Douthwaite 2005). 
1.6.2 Mechanism of action 
The main mechanism used by antibacterials to inhibit the protein synthesis is the 
disruption of the ribosome complex. Bacterial and human ribosomes are structurally different 
and that makes the bacterial ribosome an attractive target for antibacterial drugs. Figure 18 
shows the ribosome subunits and their involvement in protein synthesis, whereas Figure 19 
Figure 18 Structure of the ribosome (Poehlsgaard 
and Douthwaite 2005) 
Figure 17 Isoniazid 
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details the binding site on the different subunits of various antibacterial agents (Poehlsgaard 
and Douthwaite 2005). 
 
 
1.6.3 Families 
1.6.3.1 Chloramphenicol 
Chloramphenicol inhibits protein synthesis by binding to 
the 50S subunit of the ribosome (Xaplanteri, Andreou et al. 
2003), it is a broad-spectrum antibacterial. Due to the 
development of resistance and toxicity issues chloramphenicol 
is not a first line agent in developed countries, apart from brain 
infections, due to its very good penetration of the blood-brain 
barrier (Feder 1986). Chloramphenicol is a cheap drug which 
makes it an attractive drug for developing countries. Inactivation 
by acetyltransferase is the most common mechanism of resistance against chloramphenicol 
(Sands and Shaw 1973; Schwarz, Kehrenberg et al. 2004). 
1.6.3.2 Aminoglycosides 
The first aminoglycoside to be discovered was streptomycin, it was the first treatment 
used against tuberculosis. Most of the aminoglycosides bind to the 30S subunit and interfere 
with the initiation complex causing misreading of the mRNA, their exact mode of action is still 
Figure 19 Binding sites of antibiotics on the bacterial ribosome: the 30S ribosomal subunit is shown on the left and 
the 50S ribosomal subunit is shown on the right. The antibiotic-binding sites were initially determined by 
biochemical and genetic techniques; subsequently, many sites were revealed in greater detail by X-ray 
crystallography. At the overlapping sites, antibiotic binding is usually mutually exclusive (for example, for 
macrolide, lincosamide and streptogramin B compounds), however, streptogramin A and B compounds bind 
synergistically at adjacent sites. Subunit models are based on the Thermus thermophilus 70S ribosome structure 
(Yusupov, Yusupova et al. 2001). In this figure, for clarity, part of the r-protein L9 has been omitted. Ribosomal 
RNAs are shown in yellow and grey and r-proteins in bronze and blue (reproduced from Poehlsgaard and 
Douthwaite (Poehlsgaard and Douthwaite 2005)). 
Figure 20 Chloramphenicol 
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under investigation (Edson and Terrell 1999). Among other aminoglycosides that can be cited 
are amikacin, tobramycin, and gentamicin that are used against severe Gram-negative 
infection including Pseudomonas aeruginosa, and are of particular interest against multi-drug 
resistant strains (O'Neil 2006). The important side effects shared by this class of drug are: the 
ototoxicity that can lead to loss of hearing, and nephrotoxicity had restricted their use (Edson 
and Terrell 1999). Resistance to aminoglycosides has been observed by mutation in the 16S 
rRNA, and alteration of the small ribosome protein S12 (Jana and Deb 2006). Enzyme able to 
modify aminoglycosides by N-acetylation, phosphorylation, and adenylation are widespread 
among resistant bacteria (Jana and Deb 2006). 
 
 
 
1.6.3.3  Macrolides 
Macrolides bind reversibly to the P site of the 50S subunit of the ribosome. 
Erythromycin has a spectrum of activity similar to penicillin. Azithromycin and clarithromycin 
have activity similar to erythromycin but with an activity extended to gram (-) bacteria, for 
azithromycin which made it a very successful antibacterial, and to Mycobacterium for 
clarithromycin. Erythromycin resistance takes place by mutation of the 23S rRNA (Zuckerman, 
Qamar et al. 2009). 
Figure 21 Aminoglycosides 
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1.6.3.4 Lincosamides 
Lincosamides are antibiotics binding to the 50S subunit of the ribosome, lincomycin 
and the more recent clindamycin are the two members of this class that are used clinically, 
they have bacteriostatic effect, and are active against Gram-positive bacteria (Spížek and 
Řezanka 2004). 
 
 
  
Figure 22 Macrolides 
Figure 23 Lincosamides 
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1.6.3.5 Streptogramins 
Quinupristin-dalfopristin is combination of two streptogramins with bacteriostatic 
activity that bind to the 50S subunit. Interestingly, used in conjunction they have bactericidal 
activity as quinupristin is an allosteric activator for dalfopristin. Pristinamycin belongs to this 
family as well. Streptogramins have found application against drug-resistant Staphylococcus 
and Enterococcus, they are delivered by injection (Johnston, Mukhtar et al. 2002). Mutations in 
the large ribosome protein L22 alter the activity of the quinupristin-dalfopristin combination. 
 
 
 
1.6.3.6 Note about macrolides, lincosamides, and streptogramins (MLS) 
These three families of compounds are often grouped together as MLS compounds, 
they share the same binding site, and mutation or methylation of this site confers resistance to 
all of them. It had been shown as well that mutation of the ribosome protein L4 and L22 alters 
susceptibility to MLS compounds. A secondary mechanism of resistance is the acquisition of a 
modifying enzyme: esterases and phosphotransferases for macrolides, nucleotidyltransferase 
for lincosamides, and hydrolase or acetyltransferase for streptogramin (Leclercq and Courvalin 
1991; Roberts 2008).  
  
Figure 24 Streprogramins 
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1.6.3.7 Ketolides 
Ketolides are newcomers, there is only one 
representative of this class of compounds used 
clinically since the 2000’s: telithromycin, but other 
compounds of this class are under development. 
Telithromycin is related to macrolides, but displays a 
broader spectrum of activity, it possess two 
different binding sites on the 50S subunit 
(Zuckerman 2004). Mutation in the 23S rRNA, in the 
large ribosome protein protein L4, and the large 
ribosome protein L22 induce reduced susceptibility 
and give resistance to telithromycin (Roberts 2008). 
 
1.6.3.8 Tetracyclines 
Tetracyclines are broad-spectrum polyketide antibiotic produces by Streptomyces. 
They bind to the 30S subunit. Minocycline and doxycycline are the tetracyclines currently used 
clinically. Resistance to tetracycline have been observed by point mutation in the 16S rRNA 
(Chopra and Roberts 2001). Evidence suggesting that resistance to tetracyclines is acquired 
through a monooxygenase that is regioselectively hydroxylating the antibacterial has been 
reported (Yang, Moore et al. 2004). 
 
 
 
1.6.3.9 Tigecycline 
Tigecycline is the first representative from a novel class of antibacterial related to 
tetracyclines developed to counter the resistances to tetracyclines. It is a broad spectrum 
antibacterial used against infection by drug-resistant S. aureus and A. baumanni  (Livermore 
2005). 
  
Figure 25 Ketolides: telithromycin 
Figure 26 Tetracyclines 
43 
 
1.6.3.10 Oxazolidinones: Linezolid 
Linezolid is the sole representative of this class to be used clinically. It had become 
however a major player in the treatment of infection caused by resistant strains. Linezolid 
prevents the formation of the complex between the 30S and 50S subunits (Swaney, Aoki et al. 
1998). Resistance to linezolid has been observed in the 23S rRNA (Kloss, Xiong et al. 1999). 
 
1.7 Antibacterials affecting nucleic acids 
1.7.1 Nitroimidazoles 
Nitroimidazoles are antibacterial compounds specific to anaerobic Gram-negative and 
Gram-positive bacteria, and protozoa. Once inside the organism, the compounds react with the 
reduced form of ferredoxin, the product of this reduction reacts with DNA (Edwards 1993). 
Metronidazole and ornidazole are members of this drug family. They are the drug of choice to 
treat human infections caused by various anaerobic and microaerophilic bacteria: Bacteroides, 
Clostridia, Helicobacter; as well as parasites like Trichomonas, Giardia, Entamoeba (Edwards 
1993). 
 
  
Figure 27 Tigecycline 
Figure 28 Oxazolidinone 
Figure 29 Nitroimidazoles 
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1.7.2 Sulfonamides (Sulfa drugs) and trimethoprim 
 
 
 
Sulfonamide and trimethoprim do not interact directly with DNA but instead disrupt 
the nucleic acid biosynthetic pathway by blocking the formation of a precursor, folic acid. 
Sulfonamides mimic the folic acid precursor para-aminobenzoic acid and compete with 
dihydropteorate synthetase and dihydrofolate synthetase. Trimethoprim is inhibiting a later 
step in this pathway by interacting with dehydrofolate reductase. Among the sulfonamide 
drugs are: sulfanilamide (active principle of prontosil), sulfamethoxazole, and sulfadiazine. 
Occurrences of resistance results from mutations in the gene coding for the dihydropteroate 
synthetase for the sulfonamides or the dihydrofolate reductase for trimethoprim (Skold 2001). 
 
Figure 31 Inhibition of the folic acid synthesis by sulfonamides and trimethoprim 
Figure 30 Trimethoprim & sulfa-drugs 
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1.7.3 Rifamycins 
Rifamycins are a class of antibacterials initially isolated from Amycolatopsis 
mediterranei, among them: rifampicin, rifapentine. These compounds inhibits bacterial RNA 
polymerase (Ho, Hudson et al. 2009). Rifampicin is a front line antituberculosis drug (van den 
Boogaard, Kibiki et al. 2009). 
 
 
 
1.8 Fluoroquinolones and aminocoumarins 
Fluoroquinolones and aminocoumarins target type II topoisomerases: DNA gyrase and 
DNA topoisomerase IV. Aminocoumarins are catalytic inhibitors, preventing the binding of ATP, 
required for enzyme function (Gellert, O'Dea et al. 1976; Lewis, Singh et al. 1996); whereas 
fluoroquinolones are topoisomerase poisons, stabilizing an enzyme-cleaved DNA intermediate, 
thus generating toxic species (Drlica and Zhao 1997). Topoisomerases and their use as drug 
targets will be more extensively covered in the following section. Resistance to 
fluoroquinolones involves mutation mostly in the GyrA or ParC subunit in what is referred to 
the quinolone-resistance-determining region (QRDR), that prevent the interaction with the 
DNA-topo complex (Hopkins, Davies et al. 2005). Another mechanism of resistance involve the 
production of the pentapeptide repeat protein Qnr. Qnr is able to bind gyrase subunits in the 
absence of DNA, thus by interacting at an early stage of the gyrase cycle it can prevent the 
binding of fluoroquinolones (Hopkins, Davies et al. 2005). Another member of this family found 
in M. tuberculosis MfpA is mimicking B-form DNA, and interacts with gyrase disrupting 
fluoroquinolone activity (Hegde, Vetting et al. 2005). These mechanisms give low-level 
resistance to the organism but provide the bacteria just enough room to acquire more efficient 
mechanisms of resistance. It is interesting to note that McbG, the MccB17-producing strain 
self-immunity protein, belongs to this family as well (Bateman, Murzin et al. 1998). 
Figure 32 Rifamycins 
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2 General information about topoisomerases  
 The first topoisomerase was discovered in 1971 (Wang 1971), it was E. coli  topo I (the 
E. coli-omega protein), it was characterized by its ability to remove negative superhelical twists 
from DNA. This finding was closely followed by a second in 1972, with the calf-thymus 
swivelase (Champoux and Dulbecco 1972), this protein was shown to relax both positively and 
negatively supercoiled DNA. Topoisomerases solve the topological problems occurring during 
DNA replication, transcription, recombination, and chromatin remodelling by introducing 
temporary single- or double-strand breaks in DNA. They regulate the steady-state level of DNA 
supercoiling in order to facilitate DNA-protein interaction and prevent the deleterious excess of 
supercoils. The initial classification of these enzymes relies on the mechanism used to change 
DNA topology: type I topoisomerases act via single-strand breaks, whereas type II 
topoisomerases work through a double-strand breaks (Wang 2002). Several families and 
subfamilies of these two types have been described in the three cellular domains of life 
(Archaea, Bacteria, Eukarya) as well as viruses infecting eukaryotes or bacteria (Forterre, 
Gribaldo et al. 2007). We will describe succinctly these different topoisomerases, their role and 
their pharmacological significance.  
2.1 Classification of topoisomerases 
(Forterre, Gribaldo et al. 2007) 
Topoisomerases are first divided into type I topoisomerases, designated with odd 
numbers, and type II topoisomerases designated with even numbers; this classification derives 
from the mechanism used by the enzyme to handle DNA topology: cleaving a single strand of 
the DNA duplex for type I and a double strand for type II. 
2.1.1 Type I DNA topoisomerases 
(Champoux 2001) 
 Type I topoisomerases are enzymes that affect DNA topology by transiently cleaving 
one DNA strand at a time. All share the same chemistry to break the phosphodiester bond: the 
enzyme attacks a phosphodiester bond of the DNA with a tyrosyl group forming a covalent 
bond on one side of the break and releasing a free hydroxylated strand on the other side. The 
reverse reaction: the attack of the phosphotyrosine by the free hydroxylated strand restores 
the phosphodiester bond and releases the enzyme for next catalytic cycle. The cleavage-
religation process does not require ATP hydrolysis as the final state of the phosphodiester 
bond is the same as the start. The subdivision of topo I into the A and B subfamilies is linked to 
the polarity of the strand cleavage. Topo IA forms a transient 5′-phospho-tyrosine covalent 
intermediate, releases a free 3′-OH strand and promotes passage of the intact strand through 
the broken strand; whereas topo IB forms a 3′-phospho-tyrosine covalent intermediate, 
releases a free 5′-OH strand and leaves the broken strand free to rotate around the intact 
strand. This subdivision is supported by the absence of sequence or structural similarities 
(Wang 2002). Almost all topo IA and topo IB are monomeric and formed by a single 
topoisomerase domain. The topo IA class includes bacterial topo I and topo III, eukaryotic topo 
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III, and the unique reverse gyrase which is able to introduce positive supercoils into DNA at the 
expense of ATP; this last enzyme is found uniquely in hyperthermophiles (Kikuchi and Asai 
1984; Shibata, Nakasu et al. 1987). The topo IB class includes eukaryotic topo I and poxvirus 
topo I. Topoisomerase V has been initially included in the type IB family, but structural analysis 
argue toward the possibility that topo V is the first identified member defining a new class, the 
type IC topoisomerases (Taneja, Patel et al. 2006). 
2.1.2 Type II DNA topoisomerases 
(Champoux 2001) 
 Type II DNA topoisomerases introduce double-strand breaks in a DNA duplex and force 
the passage of another duplex through this break before resealing it. The cleavage-religation 
reaction is similar to those performed by type I topoisomerases with the formation of a 
covalent bond between a tyrosine from the enzyme and the DNA phosphate, but the transient 
link is exclusively formed with the 5′ end of the DNA breaks. All type II topoisomerases are ATP-
dependent multimeric enzymes with a dyad symmetry. Each unit of the enzyme is composed of 
an ATP-binding domain and a catalytic breakage-religation domain that contains the covalent 
bond-forming tyrosine residue. In eukaryotic and viral topo II these two domains form a single 
entity organised as a homodimer whereas in bacterial and archeal gyrase and topo IV they are 
two separate subunits A and B organised as a A2B2 tetramer, in both case the dyad symmetry is 
conserved. The enzymes proceed through what is referred as a “two-gate” mechanism as 
follows: A first segment of DNA duplex is bound by the breakage-religation domain and will be 
referred as the gate segment (or G segment), a second DNA duplex is bounded by the N-
terminus domain of the enzyme or N-gate, it will be referred as the transported segment (or T 
segment) (Berger, Gamblin et al. 1996). The second DNA duplex belongs either to the same 
molecule in the case of supercoiling/relaxation and unknotting/knotting reactions, or to 
another in the case of decatenation/catenation reaction. The selectivity of the binding is driven 
by the topology of the substrate DNA. How the enzyme is able to sense this topology is still 
under investigation, hypotheses involving local geometry of cross-over and wrapping have 
been proposed (Liu, Mann et al. 2006; Schoeffler and Berger 2008). Upon binding of ATP, the 
two ATP-binding domains dimerise adopting a closed conformation of the N-gate and trapping 
the T-segment. At each catalytic cycle, the enzyme goes through a series of conformational 
changes allowing the cleaved duplex to be pulled apart, opening the G segment to the passage 
of the T-segment, this event is called strand passage. The link between ATP hydrolysis and 
strand passage is not clearly defined and may vary among the different type II topoisomerases. 
What is certain is that ATP hydrolysis and release of its products will induce the conformational 
changes that will reset the enzyme for the next catalytic cycle. Most of the type II 
topoisomerases belong to the type IIA family. Type IIB topoisomerases class consists of only 
one member: topo VI, it had been first discovered in archaea (Bergerat, Gadelle et al. 1994; 
Bergerat, de Massy et al. 1997), and other representatives were found later in plants (Hartung 
and Puchta 2001), algae, some bacteria (Malik, Ramesh et al. 2007), and in plasmodium 
(Aravind, Iyer et al. 2003). Topo VI possess the same mechanism of action as other type II topo 
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but differs by the absence an exit gate, there is no protein structure after the cleavage-
religation domain (Bergerat, Gadelle et al. 1994). 
2.2 The occurrence of DNA topoisomerases in different cell types 
(Champoux 2001; Forterre, Gribaldo et al. 2007) 
2.2.1 Eubacteria 
Four DNA topoisomerases are found in E. coli; DNA topoisomerases I and III, which are 
type IA topoisomerases, and DNA gyrase and DNA topoisomerase IV which belong to the type 
IIA family. Each enzyme has evolved to carry out a specific set of topological alterations 
although some overlap of function can occur. There is some variation in other bacteria: some 
mesophilic bacteria lack a homologue of topo III but possess the three others topoisomerases, 
this is probably the result of the apparent redundancy of function between topo III and topo IV; 
others seems to possess the minimal requirement for cell to function, only two 
topoisomerases, one homologous to E. coli DNA gyrase, the second homologous to E. coli topo 
I. Hyperthermophiles possess a reverse gyrase, which introduces positive supercoiling probably 
to counteract the helix unwinding and strand separation effects of growth at high temperature. 
Finally a topoisomerase V has been identified in hyperthermophiles; it is the only known type 
IB topoisomerases in bacteria, its recently solved crystal structure shows that it possesses a 
unique structure among topoisomerases and might be the first representative of a new class 
(Taneja, Patel et al. 2006). 
2.2.2 Archaebacteria 
Known archaea seem to share a common ensemble of topoisomerases: a reverse 
gyrase, a type IA topo, and topoisomerase VI. 
2.2.3 Yeasts 
Saccharomyces cerevisiae and Schizosaccharomyces pombe encode the following 
topoisomerases: topo I (IB subfamilly), topo II (IIA subfamilly), and topo III (IA subfamily). 
2.2.4 Higher eukaryotes 
All higher eukaryotes contain a single topo I which plays a major role in cell functions. 
Most higher eukaryotes appear to possess two type IIA isoforms termed topo IIα and topo IIβ. 
They also have two isoforms of topisomerase III, termed topo IIIα and topo IIIβ. 
3 Topoisomerases as drug targets 
 Among the topoisomerase family, some are of particular importance due to their 
relevance as drug targets in antimicrobial and anticancer therapy. The most efficient agents 
stabilise the topoisomerase-DNA covalent complex, so a special emphasis will be put on these. 
We will particularly focus on gyrase as it is the target of MccB17, but we will also cover topo IV 
the second prokaryotic topo II affected by fluoroquinolones and the eukaryotic topo I and topo 
II as they are prone to have their protein-DNA cleavage complex stabilized by inhibitors with 
some similarities to their bacterial counterparts. The various topoisomerases used as drug 
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target will be described with their inhibitors. A final part will deal with the different structures 
of topoisomerases in the presence of cleavage complex stabilizing agents observed by 
crystallography.  
3.1  Eukaryotic Topoisomerase I 
(Holden 2001) 
Among the type I topoisomerases, only human topo I had found its use for therapeutics; 
the bacterial type I topoisomerases might be useful targets for antibacterial compounds but 
none have been identified so far (Tse-Dinh 2009). A drug called camptothecin was isolated 
from the Chinese tree Camptotheca acuminata and showed in early studies some interesting 
anticancer properties (Wall, Wani et al. 1966), but unfortunately unacceptable toxicity was 
observed during clinical trials. Camptothecin’s molecular target was identified as being topo I 
and its mode of action was discovered to be the poisoning of the enzyme (Porter and 
Champoux 1989). Anti-cancer derivatives of camptothecin were successfully generated: 
topotecan and irinotecan are currently used in anti-cancer therapy and other derivatives are in 
clinical trials (Pommier 2009). The crystal structure of the topo I–DNA covalent complex in the 
presence of topotecan shows how the compound intercalates in the cleavage site between the 
(-1) and (+1) base-pairs and forms hydrogen bonds with topo I. In this position topotecan 
hinders the religation process and traps the complex in its open form (Staker, Hjerrild et al. 
2002). Camptothecin suffers three flaws detrimental to its activity: first the lactone ring is 
easily hydrolyzed at physiological pH leading to an inactive carboxylate form, second 
camptothecin is fairly insoluble, and last camptothecin has important side-effects. Topotecan 
and irinotecan successfully addressed the problem of solubility and they are two orally 
administered anti-cancer drugs, however new compounds in the pipeline and clinical trials are 
awaited as stability and toxicity issues remained to be addressed.  
3.2 Eukaryotic Topoisomerase II 
(Holden 2001; Pommier, Leo et al. 2010) 
 Anticancer drugs targeting topo II are among the most widely used chemotherapeutic 
agents, including doxorubicin, etoposide and mitoxantrone. These drugs fall in two different 
groups: topoisomerase poisons that generate toxic species by increasing the steady-state levels 
of the transient DNA-topo II intermediate, or topoisomerase catalytic inhibitors that block 
enzyme function. Topo II poisons can be further divided into two classes depending on which 
stage of the cleavage-religation reaction they affect: the first comprise ellipticine (Stiborova, 
Rupertova et al. 2010), azatoxin (NSC640737) (Cline, Macdonald et al. 1997), genistein 
(Yamashita, Kawada et al. 1990) and cytotoxic quinolones, that increases the amount of 
cleaved intermediate by stimulating its formation, whereas the second include etoposide, 
teniposide, doxorubicin, daunorubicin, and amsacrine that  inhibit the religation reaction 
(Pommier, Leo et al. 2010). Topo II catalytic inhibitors can act at different steps of the complex 
catalytic cycle. This cycle can be dissected in seven distinct events: 
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Event: inhibitor(s) acting during this event  
1) Binding of the enzyme to the DNA: anthracyclines (aclarubicin (Larsen, Escargueil et al. 
2003)), suramin (Larsen, Escargueil et al. 2003). 
2) Production of the double-strand break DNA: quinolones (CP-115953 (Bromberg, Burgin et al. 
2003), voreloxin (Hawtin, Stockett et al.)), merbarone (inhibition)(Fortune and Osheroff 1998). 
3) Binding of ATP, dimerisation of the N-terminal domains: coumarins (novobiocin, 
coumermycin)(Larsen, Escargueil et al. 2003). 
4) Strand passage. 
5) Religation of the DNA break after strand passage: etoposide (VP16), teniposide (VM26), 
doxorubicin, daunorubicin, amasacrine (m-AMSA) (Pommier, Leo et al. 2010), TAS-103 
(Fortune, Velea et al. 1999). 
6) ATP hydrolysis: bisdioxopiperazine derivatives  (ICRF-187,  ICRF-193) (Andoh and Ishida 
1998), staurosporine (Pommier, Leo et al. 2010). 
7) Dissociation and release of the DNA from the topoisomerase. 
Looking at this plethora of compounds and how they seem to cover every steps of the enzyme 
cycle, eukaryotic topo II can be regarded as a model of successful exploitation of a 
topoisomerase drug target. 
3.3 Prokaryotic topoisomerase II: 
In eubacteria, DNA gyrase and topoisomerase IV have been exploited by nature and the 
pharmaceutical industry as antibacterial targets. Two families of compounds have been 
successfully used on prokaryotic topo II, the fluoroquinolones (Drlica and Zhao 1997) and the 
aminocoumarins (Maxwell and Lawson 2003). The first has been extensively studied and had 
given a wide variety of antibacterial agents, the second possess only one member, novobiocin, 
that has been clinically used before being withdrawn from the market. These compounds 
display different level of activity on both gyrase and topo IV. These two targets and their 
inhibitors will be given an extensive treatment in the following part as they represent the 
primary enzymes we are studying. 
4 DNA gyrase and topo IV (in E. coli): 
Gyrase and topo IV are very closely related enzymes both in structure and in their 
interaction with inhibitors, therefore they will be described in parallel in the following sections. 
We will mainly focus on the E. coli version of these enzymes to describe their structure. 
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4.1 Biological activity 
 DNA gyrase and topo IV are two highly homologous type II topoisomerases that have 
both been shown to be affected by quinolones (Drlica and Zhao 1997) and aminocoumarins 
(Maxwell and Lawson 2003). Gyrase is the only known topoisomerase that can introduce 
negative supercoils at the expense of ATP, by doing so it can relax positively supercoiled DNA 
or negatively supercoil relaxed DNA (Gellert, Mizuuchi et al. 1976). In the absence of ATP, 
gyrase can relax negatively supercoiled DNA by the reverse mechanism of negative supercoiling 
(Gellert, Mizuuchi et al. 1977). The major in vivo activity of gyrase is the introduction of 
negative supercoils into the chromosome. Topo IV is primarily specialised in decatenating 
(Ullsperger and Cozzarelli 1996) and unknotting DNA (Deibler, Rahmati et al. 2001); its ability to 
relax negatively and positively supercoiled DNA with a preference for the latter enable topo IV 
to remove the positive supercoils generated ahead of the replication fork (Crisona, Strick et al. 
2000).  
Before topo IV was discovered, gyrase was thought to be involved in unlinking the 
catenated chromosome at the end of replication to allow segregation of one copy to each of 
the daughter cells. However it has been discovered that topo IV is the major cellular 
decatenase for both replication- and recombination-generated catenanes. The superhelical 
density of the E. coli chromosome is regulated by the combined action of gyrase, topo I and 
topo IV, with the two latter balancing the activity of the first (Schvartzman and Stasiak 2004). 
This global supercoiling level is essential for the initiation of DNA replication, and general 
transcription, which requires the assistance of negative supercoiling to unwind origins and 
promoters. Another important issue with DNA gyrase is its participation in the elongation 
phase of DNA replication and transcription. Actually both of these processes necessitate 
unwinding of long stretches of the DNA duplex, the 4.6 megabases of DNA for replication of the 
E. coli chromosome. Unwinding the duplex produces positive supercoils that accumulate, they 
must be removed in order to withstand superhelical stress; it is done by gyrase, which 
introduces negative supercoils. Similarly, gyrase removes positives supercoils generated ahead 
of the advancing polymerase during transcription elongation (Hooper 1998; Nollmann, Crisona 
et al. 2007). 
Figure 33 Illustration of type II topoisomerase mechanism (Bates 2001). 
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4.2 Structure 
4.2.1 Gyrase 
 
 
 
Gyrase is a type II-A topoisomerase composed of two subunits; GyrA with a molecular 
weight of 97 kDa (Swanberg and Wang 1987) and GyrB with a molecular weight of 90 kDa 
(Yamagishi, Yoshida et al. 1986), organized in a tetramer, A2B2. The main role of the GyrA is the 
cleavage-religation of DNA strands (Horowitz and Wang 1987); GyrB is responsible for the 
hydrolysis of ATP (Reece and Maxwell 1991). Limited proteolysis of GyrA and GyrB identified 
two domains for each subunit (Reece and Maxwell 1989; Kampranis and Maxwell 1998), these 
domains were later related to specific aspects of the enzyme activity: GyrA is divided into a 64 
Figure 34 Structure of E. coli gyrase, comparison with S. cerevisiae topo II: left side, crystallographic structures 
related to E. coli gyrase; the top structure is the dimer of the N-terminal part  of GyrB from Wigley et al (Wigley, 
Davies et al. 1991), the bottom structure is the GyrA N-terminal dimer from Edwards et al (2WL2)  (Edwards, 
Flatman et al. 2009). Right side,  S. cerevisiae topo II reproduced from Schoeffler and Berger (Schoeffler and 
Berger 2008) is displayed for comparison, the top structure is the topo II ATPase domain from Classen et al 
(1PVG), the bottom structure is the dimer of topo II (residues 410-1202) from Berger et al (1BGW). The different 
structures are colour coded according to their substructure: ADPNPs are shown as spheres, GHKL in light 
orange/yellow, transducer domain in orange, TOPRIM in red, WHD in pink, tower/shoulder in turquoise, and the 
coiled-coils in dark blue. No structure of E. coli gyrase TOPRIM domain is available. Catalytic tyrosines are show 
as red sticks (gyrase) or turquoise sphere (topo II). Note that the C-terminal domains are not present in the 
structures. 
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kDa N-terminal domain, which is the “breakage-reunion” domain and contains the quinolone-
resistance-determining region (QRDR), and a 33 kDa C-terminal domain around which the DNA 
wrapped (Costenaro, Grossmann et al. 2005). GyrB is divided into a 43 kDa N-terminal domain, 
which is the ATPase domain (Wigley, Davies et al. 1991) and contains the aminocoumarin 
interaction site, and a 47 kDa C-terminal domain, which interacts with GyrA and DNA (Brown, 
Peebles et al. 1979). This last 47 kDa domain can be further divided into the TOPRIM and Tail 
domains according to their structure (Costenaro, Grossmann et al. 2007). Figure 34 shows the 
domains division in the type II topoisomerases gyrase and topo II. Recently a model has been 
constructed from small-angle X-ray scattering (SAXS) data from the full length gyrase in 
presence of DNA, it provides a picture of gyrase structure in solution of gyrase (Figure 35) 
(Baker, Weigand et al. 2010). A hypothesis, derived from the SAXS model, has been proposed 
for the wrapping of DNA around gyrase (Figure 35), however we want to arise some cautions, 
as the DNA appears to be in an unlikely conformation to accommodate the DNA bending 
observed at the DNA gate in other type II topoisomerase structures, like S. cerevisiae topo II for 
example as shown in Figure 36. 
 
 
 
 
  
Figure 35 SAXS of full length E. coli gyrase with DNA: 
the top picture is the envelope extrapolated from 
SAXS data with the gyrase model fitted inside. The 
bottom picture shows the proposed model of DNA 
wrapping around gyrase (Baker, Weigand et al. 
2010). 
Figure 36 DNA bending by S. cerevisiae topo II 
(Dong and Berger 2007). 
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Structures of gyrases from organisms other than E. coli have been released recently: 
the TOPRIM and breakage reunion domain of M. tuberculosis (3M4I, 3IFZ)(Piton, Petrella et 
al.); the fusion protein of the C-terminus of GyrB (GyrB27) and GyrA N-terminus (GyrA56) of S. 
aureus in presence of DNA and cleavage complex stabilizing agents (2XCT and others)(Bax, 
Chan et al. 2010). These structures give insight on the general mechanism of gyrase, and 
additionally, if considered with the other elements available: the GyrA NTD (3ILW)(Tretter, 
Schoeffler et al.) and GyrB’ CTD (2ZJT) (Fu, Wu et al. 2009) for M. tuberculosis, and the GyrB 
NTD for S. aureus (3G75)(Ronkin, Badia et al.), they are direct source of information to design 
inhibitors for these organisms. 
 
 
 
The mechanism of supercoiling by gyrase has not been completely elucidated but a 
model, called the “two-gate mechanism”, supported by biochemical evidence and structural 
information, has been formulated and should reflect what is happening. If we consider the 
gyrase structure, three interfaces can be in an open or closed conformation: the N-terminal 
domain of GyrB referred as the N-gate, the GyrA-GyrB-DNA interface where the DNA is 
cleaved, referred as the DNA gate, and the C-terminal area of coiled coils that are forming the 
C-gate. These three gates are involved as follows: the G-segment of DNA associates with the 
enzyme, at the interface of N-terminus of the GyrA dimer and the TOPRIM domain of GyrB 
(Morais Cabral, Jackson et al. 1997; Bax, Chan et al. 2010). DNA supercoiling by gyrase involves 
the wrapping of a segment of DNA  around the enzyme in a right-handed supercoil of ~ 130 
base pairs (Kampranis and Maxwell 1996). Wrapping of DNA on the gyrase C-terminal domains 
helps a second segment (transported or T-segment) belonging to the same DNA molecule to 
reach the N-gate. Upon binding of ATP the N-gate closes, trapping the T-segment (Wigley, 
Davies et al. 1991; Brino, Urzhumtsev et al. 2000). Two tyrosines from the GyrA dimer react 
Figure 37 S. aureus gyrase (GyrB27–A56 fusion protein): a, b, Orthogonal views of 2.1 Å complex with 
GSK299423 (yellow, solid) and DNA (green). One fused GyrB27–A56(GKdel/Tyr123Phe) subunit is shown in 
grey, the other in red (GyrB) and blue (GyrA). c, 3 Å apo GyrB27–A56 structure. On formation of the complex 
the α3 helices slide approximately 6 Å past each other (indicated by red arrows) to align the red stripes 
(Ala68 and Gly72) underneath the compound (in b). Molecular figures generated with Pymol40. Reproduced 
from Bax et al (Bax, Chan et al. 2010). 
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with the G-segments forming DNA-phosphotyrosyls 4 bp apart, and thus creating the double-
strand break (Bax, Chan et al. 2010). This reaction requires the presence of Mg2+ (Noble and 
Maxwell 2002; Sissi, Chemello et al. 2008). The T-segment is pushed through the open DNA 
gate, the role of ATP hydrolysis and the involvement of the N-gate closing in the strand passage 
mechanism is still unclear. As the DNA gate closes and the DNA is resealed, the C-terminal gate 
opens to free the T-segment (Tingey and Maxwell 1996; Maxwell, Costenaro et al. 2005). The 
hydrolysis of ATP and release of ADP causes the N-gate to open and thus reinitializes the 
enzyme for the next cycle (Baird, Harkins et al. 1999; Baird, Gordon et al. 2001). One gyrase 
cycle introduces two supercoils in the DNA molecule at the expense of 2 ATPs. In the absence 
of ATP, gyrase can catalyse relaxation of negatively supercoiled DNA by the opposite 
mechanism (Gellert, Mizuuchi et al. 1977). The mechanism is illustrated in Figure 38. 
 
 
 
Figure 38 Gyrase supercoiling mechanism: The C-terminal domain of GyrA, responsible for wrapping DNA , has 
been omitted for two reasons: first it simplifies the scheme, and second it is a domain connected to GyrA N-
terminal domain by a flexible arm, the exact position of C-terminal domain during gyrase cycle is still unknown. 
The supercoiling reaction proceeds as follows: the GyrA dimer, two GyrB monomers and DNA form the DNA-
gyrase complex, the DNA segment (G-segment) becomes part of the DNA gate (1). Upon binding of ATP on each 
GyrB subunit they dimerise closing the N-gate around a second segment of DNA (the transferred or T-segment) 
(2). It had been proposed that hydrolysis of one ATP at this stage triggers conformational changes that push 
the T-segment through and opens the DNA gate. The DNA gate closes, and the GyrA C-gate formed by the 
coiled coils opens releasing the T-segment. Hydrolysis of the second ATP and release of the two ADPs reset the 
enzyme to step (1). 
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4.2.2 Topo IV 
Topo IV has a structure very similar to gyrase; it possesses two subunits ParC (84 kDa) 
and ParE (70 kDa), the two proteins are respectively homologous to GyrA and GyrB, and like 
gyrase they are associated in a C2E2 tetramer (Kato, Nishimura et al. 1990). Two crystal 
structures of E. coli topo IV subunits are available: the full length ParC (1ZVU) (Corbett, 
Schoeffler et al. 2005), and the 43 KDa N-terminal fragment from ParE (1S16) (Bellon, Parsons 
et al. 2004). From these structures we can build a picture of the topo IV overall organisation, 
even if the domain of ParE that interacts with ParC and is involved in cleavage is missing. 
 
The general mechanism of topo IV is very similar to gyrase, but unlike gyrase, the 
enzyme does not wrap DNA around itself and shows a higher affinity for supercoiled DNA 
(Crisona, Strick et al. 2000) or DNA crossovers (Stone, Bryant et al. 2003), which account for 
topo IV relaxation, decatenation and unknotting activity. As for gyrase, topo IV crystal 
structures of other organism have been released recently: the fusion protein of ParE CTD and 
ParC NTD of S. pneumoniae (3LTN) (Laponogov, Sohi et al. 2009), and A. baumannii (2XKJ) 
Figure 39 Topoisomerase IV structure: top structure is dimer of the N-terminal fragment of ParE from Bellon et 
al (Bellon, Parsons et al. 2004), in yellow is the GHKL domain, in orange the transducer domain. The bottom 
structure is the full length ParC dimer from Corbett et al (Corbett, Schoeffler et al. 2005). The various domains 
are colour-coded: CAP domain in purple, tower domain in blue, coiled-coil in red, C-terminal domain in green 
reproduced from Corbett et al (Corbett, Schoeffler et al. 2005). 
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(Wohlkonig, Chan et al. 2010), they gave important information about the general mechanism 
of topo IV. 
 
 
 
4.2.3 A word about type II topoisomerases C-terminal domain (CTD) 
As mentioned above, the selectivity of type II topoisomerases is dependent on their 
ability to wrap DNA and recognise crossovers, thus favouring inter- or intra-molecular DNA 
reactions and interaction with DNA of a particular topology. This selectivity has been shown to 
be related to the C-terminal domain of the enzyme. There is a significant difference between 
GyrA and ParC C-terminal domain (Figure 41); GyrA CTD is six bladed β-pinwheel, in 
comparison ParE CTD has only five blades and lacks the GyrA Box, an essential element for the 
gyrase supercoiling activity (Kramlinger and Hiasa 2006). 
Figure 40 Organization and structure of the enzyme–quinolone–DNA cleavage complex of topo IV. (a) Domain 
organization of S. pneumoniae topo IV. (b,c) Front (b) and top (c) views of the topo IV ParC55 and ParE30 
proteins complexed with the G-segment DNA and a quinolone drug (moxifloxacin), shown both in surface 
(above) and detailed cartoon (below) representations. DNA is in green, the TOPRIM domain (ParE30) is in yellow 
and the ParC55 is in blue. The drug molecules are shown in red. The WHD, ‘tower’ and C-gate are shown in cyan, 
orange and silver, respectively. The interface region between ParC and ParE subunits (involving the α1 helix) is in 
purple. Generated using VMD20 and POV-Ray (http://www.povray.org). Reproduced from Laponogov et al 
(Laponogov, Sohi et al. 2009). (d), (e), orthogonal views of the 3.27 Å A. baumannii topo IV ParE28-ParC58 
complex with DNA (green) and moxifloxacin (yellow) and (f), (g) equivalent views of the 2.2 Å apoParE28-ParC58 
structure. One covalently fused ParE28-ParC58 is shown in red (ParE) and blue (ParC), the other in grey. 
Reproduced from Wohlkonig et al (Wohlkonig, Chan et al. 2010) (Supplementary data). 
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4.3 Gyrase and topo IV Inhibitors 
DNA gyrase, is an essential enzyme for bacteria that is nearly only found in prokaryotes 
cells; in eukaryotes, it has been found in  plants (Forterre, Gribaldo et al. 2007), and in 
plasmodium (Wilson 2002). This predominance in prokaryotes cells has made the gyrase a 
target of choice for antibacterial agents. The most used are the quinolones and the coumarins. 
These two families have different mechanism of action. 
4.3.1 Coumarins 
Aminocoumarins, also referred as coumarins, are natural compounds produced by 
Streptomyces; novobiocin, clorobiocin and coumermycin A1. belong to the family of coumarins. 
Known since the 1950s for their inhibitory properties on nucleic acid synthesis in bacteria, it 
Figure 41 Comparison of GyrA and ParC CTD: top right, the crystal structure of Borrelia 
burgdorferi GyrA-CTD (Corbett, Shultzaberger et al. 2004), which is very similar to E. 
coli’s (Ruthenburg, Graybosch et al. 2005). Top left, the crystal structure of E. coli ParE 
CTD (Corbett, Schoeffler et al. 2005). GyrA CTD is a six bladed β-pinwheel, whereas 
ParE CTD has only five blades, and is lacking in particular the GyrA box which is 
essential for gyrase supercoiling activity (Maki, Takiguchi et al. 1992; Kramlinger and 
Hiasa 2006).  
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was found later, with the discovery of gyrase, that the coumarins inhibit gyrase-catalyzed 
supercoiling of DNA (Gellert, O'Dea et al. 1976). 
 
 
 
The classical coumarins inhibit the ATPase reaction by competing with ATP for binding 
GyrB. Coumarins bind to the 24 kDa amino-terminal subdomain of GyrB, a domain that does 
not bind ATP by itself (Lewis, Singh et al. 1996), however when they bind to this domain, they 
overlap the ATP-binding site preventing ATP binding (Maxwell 1999). Resistance to novobiocin 
has been obtained by site-directed mutagenesis of the following five residues: R136, D73, G77, 
I78 and T165 (Gross, Parsons et al. 2003). Studies have shown that topo IV is a less sensitive 
secondary target for aminocoumarins; the mutation of R132, equivalent to gyrase R136 
mutation, similarly confers some resistance. 
 
 
 
An antibiotic related to this family simocyclinone D8 (SimD8), a coumarin-polyketide 
hybrid, has been reported to have a different mechanism of action. Instead of inhibiting the 
ATPase, simocyclinone D8 (SimD8) prevents DNA binding by interacting with two different 
pockets on GyrA, one occupied by the polyketide, the other is interacting with the coumarin 
end. The crystal structure shows that four SimD8 molecules stabilise a tetramer of GyrA, with 
one simD8 bridging two GyrA molecules. A competing model is the occupation of the two sites 
Figure 43 Simocyclinone D8 
Figure 42 Aminocoumarins 
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of a GyrA monomer by a single SimD8 molecule bend over the two sites. Both models will lead 
to the inactivation of GyrA (Edwards, Flatman et al. 2009). The two models are under 
investigation to prove which one is relevant in vivo. The novel mechanism of action and the 
identification of two binding sites are valuable information for future development of new 
antibacterials. 
Coumarins are potent inhibitors of gyrase in vitro but their poor activity against Gram-
negative bacteria, mammalian cytotoxicity, and poor solubility prevent them being successful 
drugs. Nevertheless, study of these compounds gives important information about gyrase-
inhibition mechanisms and the molecular basis to develop new inhibitors. Moreover, their 
relative simocyclinone D8 highlights new binding sites that can be exploited in drug discovery. 
4.3.2 Quinolones 
Quinolones are totally synthetic drugs, with a lower affinity for gyrase than coumarins; 
but they are very potent antibacterial agents. The first generation quinolones, nalidixic acid 
(Goss, Deitz et al. 1965; Sugino, Peebles et al. 1977) and oxolinic acid (Staudenbauer 1976), 
have been surpassed by the fluoroquinolones, which have led to an explosion of new 
fluoroquinolones drugs such as ciprofloxacin and norfloxacin (2nd gen.) (Bauernfeind and 
Petermuller 1983), levofloxacin (3rd gen.) and the later moxifloxacin and gemifloxacin 
(Emmerson and Jones 2003). 
 
 
 
After the discovery of gyrase it was shown that its supercoiling activity can be inhibited 
by oxolinic acid (Gellert, Mizuuchi et al. 1977); it has been shown later that topoisomerase IV, a 
similar enzyme is also affected by the compounds (Kato, Suzuki et al. 1992; Chen, Malik et al. 
1996), and is likely to be the primary target in some Gram-positive bacteria (Drlica and Zhao 
1997). Quinolones act by disrupting the DNA-breakage-reunion reaction, thus inhibiting DNA 
Figure 44 A few fluoroquinolones and their ancestor nalidixic acid. 
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supercoiling (Sugino, Peebles et al. 1977; Snyder and Drlica 1979). They stabilise the cleavage 
complex in which the enzyme is covalently linked to the 5′ end of the DNA, disrupt the enzyme 
cycle and can lead in vivo to cell death (Drlica and Zhao 1997). The exact quinolone-binding site 
on the A subunit is still under discussion, but amino acids Ala67-Gln106 in GyrA and Asp426-
Lys447 in GyrB (in E. coli) are referred as the quinolone resistance–determining region (QRDR). 
Gyrase with changes in the polar residues S83 and D87, to hydrophobic residues exhibit high 
levels of resistance to quinolones, suggesting that these amino acids are involved in interaction 
with quinolones. Mutation at Ala67, Gly81, Ala84 and Gln106 confer lower level of resistance. 
Mutations out of the QRDR: Ala196Glu in clinical isolates, and Ala51Val in vitro, have been 
reported to confer resistance as well. Regarding GyrB, only the two positions delimiting its 
QRDR have been reported to confer resistance. If a reaction between gyrase, DNA, and a 
quinolone drug is terminated by the addition of sodium dodecyl sulphate, the DNA is broken in 
both strands and the GyrA subunits of the enzyme are attached to the 5′-phosphate at the 
break site via Tyr122, the active site tyrosine (Horowitz and Wang 1987). 
This stabilisation of the cleavage complex is the essence of their antibacterial effect; 
this mechanism is similar to the effect of antitumour topo II inhibitors. Various crystal 
structures of quinolones in complex with gyrase or topo IV have been recently released: A. 
baumannii topo IV (2XKJ, 2XKK (with moxifloxacin)) (Wohlkonig, Chan et al. 2010); S. 
pneumoniae topo IV (3LTN (with PD0305970), 3FOF (with moxifloxacin)) (Laponogov, Sohi et al. 
2009; Laponogov, Pan et al. 2010), S. aureus gyrase (2XCS (with GSK299423)) (Bax, Chan et al.). 
These structure shows that two quinolones molecules are interacting with the gyrase-DNA 
complex, each one is intercalated in the spaces opened by the formation of the covalent bond 
between the DNA strand and the catalytic tyrosine. The aromatic ring system of the drug is 
intercalated between the -1 and +1 bases at the break site, with the carbonyl of the quinolone 
pointing toward the WHD domain, whereas the C7 tail is pointing towards the toprim domain 
(Figure 45). An example of the interaction observed between DNA, gyrase and quinolones his 
reproduced below from Laponogov et al (Laponogov, Pan et al. 2010). Fluoroquinolones are 
among the most successful antibacterial drugs, they were a good alternative to overcome beta-
lactamase-related resistance. Unfortunately, resistance to fluoroquinolones has appeared 
mainly through mutation in the QRDR region as mentioned above, but also by acquisition of 
plasmid coding for protein like Qnr, which can shield the topoisomerase from quinolone action 
(Hopkins, Davies et al. 2005; Tran, Jacoby et al. 2005). 
 
62 
 
 
 
4.3.3 Quinolone-like compounds 
 
 
 
Figure 45 Example of stabilisation of the cleavage complex by quinolones: A and B, Cartoon/stick 
representations of the drug-binding pockets of topoisomerase IV-DNA in complex with PD 
0305970 and levofloxacin, respectively. The σA-weighted 2Fobs-Fcalc map is contoured around PD 
0305970 (pink) and levofloxacin (light-blue) at 1.5σ. C, Domain organization of topo IV from S. 
pneumoniae with the individual sub-regions are highlighted by individual colours. Resistance 
mutation sites within the topoisomerase sequence are indicated by red lines. Reproduced from 
Laponogov et al (Laponogov, Pan et al. 2010). 
 
Figure 46 Prospective novel gyrase inhibitors 
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Sometime referred to by the catch-all term of NBTI (new bacterial topoisomerase 
inhibitor), these compounds are antibacterial molecules not belonging to the quinolone 
chemical family but acting in a similar manner, and not affected by quinolone-resistance 
mutations. Among them are GSK299423 (Bax, Chan et al. 2010), tetrahydroindazoles 
derivatives (Gomez, Hack et al. 2007; Wiener, Gomez et al. 2007), PD0305970 and PD0326448 
two quinazoline-2,4-diones (Huband, Cohen et al. 2007). Some time will be required to 
evaluate the impact of these new compounds as antibacterials. 
 
4.3.4 Other gyrase inhibitors 
Other compounds targeting DNA gyrase exist outside the two previous categories, but 
even if generally they are not good candidates for antibacterial drugs they are good sources of 
information and inspiration. 
4.3.4.1 Cyclothialidine 
   Cyclothialidine is a cyclic peptide isolated from Streptomyces filipinensis, its inhibitory 
activity in vivo is limited to eubacteria, probably due to uptake limitation (Nakada, Shimada et 
al. 1993), but it shows in-vitro inhibition of the supercoiling and ATPase activity of DNA gyrase 
(Nakada, Gmunder et al. 1994). Mutations observed in cyclothialidine-resistant mutants in 
Staphylococcus aureus and binding studies suggest that the cyclothialidine binding-site in GyrB 
overlaps the ATP- and coumarin-binding sites (Kampranis, Gormley et al. 1999). This 
biochemical evidence was supported by the crystallographic data of cyclothialidine bound with 
the 24-kDa GyrB amino-terminal subdomain (Lewis, Singh et al. 1996). In this structure the 
resorcinol ring of the drug has a similar position to the adenine ring of the non-hydrolysable 
ATP analogue ADPNP in the structure of the 43-kDa 
domain (Maxwell 1999). The total synthesis of 
cyclothialidine was performed by Goetshi et al 
(Goetschi, Angehrn et al. 1993), the various 
derivatives that were synthesized showed that the 
macrocyclic system can be a template to design new 
inhibitors. Further investigation of derivatives of 
cyclothialidine led to compounds that display activity 
on Gram-positive pathogens (Angehrn, Buchmann et 
al. 2004). Cyclothialidine is still used as a template 
for the discovery of new antibacterial agents (Oblak, 
Kotnik et al. 2007; Brvar, Perdih et al. 2010). 
 
4.3.4.2 Cinodine 
Cinodine is a compound produced by Nocardia species that belongs to the 
glycocinnamoylspermidine antibiotic class (Martin, Kunstmann et al. 1978; Tresner, Korshalla 
Figure 47 Cyclothialidine 
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et al. 1978). It has been shown to bind to DNA (Greenstein, Speth et al. 1981) and inhibit DNA 
supercoiling by gyrase in Micrococcus luteus in vitro (Osburne, Maiese et al. 1990). Cinodine-
resistant mutants with enhanced nalidixic acid-sensitivity have been isolated in E. coli, and in 
vitro experiments place the mutations on DNA gyrase. Three cinodine species have been 
identified, they share the same general structure but differs in their pentose moiety (Figure 48) 
(Osburne, Maiese et al. 1990; Maxwell 1999). No exploitation of cinodine has been reported 
recently. 
 
 
 
4.3.4.3 Clerocidin 
The diterpenoid clerocidin was isolated from Fusidium 
viridiae, it is known as a cytotoxic and antibacterial agent 
(Andersen and Rasmussen 1984) that stimulates in vitro DNA 
cleavage, mediated by eukaryotic DNA topo II (Kawada, 
Yamashita et al. 1991) and gyrase (McCullough, Muller et al. 
1993). Clerocidin promote in vitro cleavage by the Streptococcus 
pneumoniae topo IV (Richter, Leo et al. 2006) and gyrase (Pan, 
Dias et al. 2008). Clerocidin acts differently from other 
topoisomerase poisons, it creates a break at the guanine 
immediately preceding the topoisomerase DNA-cleavage site. 
The break created cannot be resealed by heating or salt 
treatment. In the absence of topoisomerase, clerocidin is able to form adduct with the 
guanines of short unpaired oligos. This reaction was shown to involve the attack by clerocidin 
epoxide group of the guanine nitrogen at position 7, leading to strand scission at the modified 
site (Gatto, Richter et al. 2001; Richter, Gatto et al. 2003). The reactivity of clerocidin towards 
Figure 48 Cinodine variants structure  
Figure 49 Clerocidin 
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the other bases has been evaluated as well. No reaction was observed with thymine, but a 
two-site reaction of clerocidin with adenine or cytosine was reported, both for the bases in 
solution or in the context of small oligos. The mechanism involved the reaction of the base 
amino group with the clerocidin carbonyl, followed by the attack of the nitrogen at position 3 
for cytosine, or 1 for adenine, by the epoxide group (Richter, Menegazzo et al. 2004; Richter, 
Menegazzo et al. 2009). Among the different bases, it is noteworthy that only the reaction of 
clerocidin with guanine led to the cleavage of the glycosyl bond. It had been confirmed in vivo 
that topoisomerase II is the target of clerocidin in HeLa cells, and that it binds to the enzyme 
before the formation of the cleavage complex (Jamora, Theodoraki et al. 2001). Concerning 
clerocidin structure, additionally to the reactive epoxide function the carbonyl group (Richter, 
Gatto et al. 2003) and oxirane ring have been shown to be essential for its activity (Richter, 
Gatto et al. 2003). The replacement of the diterpenoid moiety by a naphthalene ring system 
was reported to have no effect on the reaction with the bases in absence of topoisomerase 
(Richter, Gatto et al. 2003), however it causes a loss of the clerocidin cleavage activity in 
presence of topo IV (S. pneumoniae)(Richter, Leo et al. 2006). With S. pneumoniae Topo IV, 
clerocidin was still able to create strand breaks with the quinolone resistant ParC(S79F), but 
not with cleavage-deficient ParC(Y118F) mutant, and a clear preference for the attack of 
guanine at position -1 from the cleavage site was confirmed. The same preference for guanine 
at position -1 was shown in presence of murine topo II, but additionally reversible cleavage at 
cytosine at -1 position has been reported (Binaschi, Zagotto et al. 1997). This profile of reaction 
was further confirmed with S. pneumoniae gyrase (Pan, Dias et al. 2008). This evidence 
suggests that during the formation of the DNA-topoisomerase cleavage complex, the DNA 
adopt a conformation favourable for the reaction of clerocidin with a guanidine occupying the -
1 and/or +5 position of the cleavage site; alternatively reversible cleavage will be favoured if a 
cytosine is present at one of these positions. The complete elucidation of clerocidin mechanism 
will require crystallographic structure (Pan, Dias et al. 2008). Clerocidin possess an unusual 
mode of action, the compound itself is too toxic to be used as a drug, but less toxic molecule 
able to mimic clerocidin activity will be of major interest. 
4.3.4.4 CcdB  
CcdB is of particular interest to us, its size of 11.7 kDa and the fact that it is a peptide 
structure able to poison gyrase give it a family likeness with MccB17 (Bernard and Couturier 
1992). CcdB is the killer protein of the F plasmid, it is produced as a part of a two-component 
system maintaining plasmid copy (Miki, Park et al. 1992). CcdB is the toxin and CcdA is the 
antidote. CcdB kills bacteria by a mechanism similar to quinolones, although there is evidence 
showing that interaction between CcdB and gyrase takes place in a different domain and is 
ATP-dependent (Bernard, Kezdy et al. 1993). The mutation of Arg462 to Cys, which confers 
gyrase resistance to CcdB, is located in the central cavity of GyrA dimer, close to the primary 
dimer interface far from the QRDR (Tyr122)(Bernard and Couturier 1992), and no cross-
resistance between CcdB and quinolones has been observed (Bernard and Couturier 1992). 
Biochemical evidence on the mode of action of CcdB pinpoints these differences: CcdB-induced 
cleavage of DNA by gyrase requires nucleotides (ATP for linear DNA and non-hydrolysable 
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nucleotide for negatively supercoiled DNA), and DNA templates of a minimum of 160 kb, 
whereas quinolone-induced cleavage does not require ATP and only 20 bp DNA template to 
proceed (Critchlow, O'Dea et al. 1997). In contrast to quinolones, CcdB is unable to mediate 
DNA cleavage with GyrA59 or GyrA64 associated with GyrB (Bahassi, O'Dea et al. 1999). Two 
types of activity have been observed with CcdB: the first requires several cycles of ATP 
hydrolysis and poisons gyrase, the second is a catalytic inhibition of gyrase. 
 
 
 
Recent crystallographic data of CcdB co-crystallized with an N-terminal fragment of 
GyrA (GyrA14) (Dao-Thi, Van Melderen et al. 2004) suggests that the toxin is binding the GyrA 
dimer in a cavity between the two subunits. The structure confirms the role of Arg462 in CcdB 
binding to GyrA, as the two residues form a network of interactions with Trp99, Asn92, and 
Asn95, and shows that Ile101 is interacting with a hydrophobic cleft comprising Ile379, Leu383, 
Figure 50 Complex of CcdB and GyrA14 and models: (a) Gyr-A14: CcdB complex viewed along its 2-fold axis. 
The two CcdB monomers are drawn in orange and red and the two GyrA14 monomers in two shades of blue. 
(b) Same as (a), but rotated 90°. (c) Model of closed GyrA59 (blue) with CcdB (green) docked onto it by 
superposition of the  GyrA14:CcdB complex on the crystal structure of GyrA59 (Morais Cabral, Jackson et al. 
1997). Residues Arg462 of both monomers of GyrA59 are highlighted. Strong steric overlaps (red) with the 
CAP domains are observed. (d) Model of the GyrA59: CcdB complex with GyrA59 in its open conformation. 
The open conformation of GyrA59 was modelled according to the corresponding yeast topoisomerase II 
structure (PDB entry 1BGW (Berger, Gamblin et al. 1996)). In this model, there is no steric overlap between 
CcdB and GyrA59. Reproduced from Dhao Thi & Van Melderen (Dao-Thi, Van Melderen et al. 2005). 
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Leu461 and Ala457. Modelling from the CcdB-GyrA14 and GyrA59 crystal structures shows that 
such interaction will block the GyrA59 dimer in an open conformation, preventing its 
association with GyrB or DNA, and thus explaining the catalytic inhibition of gyrase by CcdB 
(Dao-Thi, Van Melderen et al. 2005). This interaction can account for gyrase poisoning as well: 
during the supercoiling reaction of DNA by gyrase, CcdB can squeeze in a similar GyrA dimer 
cavity during a transition state of the strand passage as demonstrated by biochemical 
evidences (Smith and Maxwell 2006). The short period of existence of this transition state will 
explain the requirement of several cycle of ATP hydrolysis for the poisoning to happen. 
 
 
 
CcdB derivatives, about half the size of the native protein, comprising fragments of 
CcdB sequence connected by a 6-aminohexanoic acid flexible linker have been reported to 
have inhibitory activity on gyrase supercoiling and topo IV relaxation, this tend to suggest that 
Figure 51 Model of gyrase inhibition by CcdB: The individual components (1) free in solution (Chatterji, 
Unniraman et al. 2000) come together (2) to form the holoenzyme with the G segment binding across 
the DNA gate (Heddle, Mitelheiser et al. 2004). (3) The DNA is wrapped by the GyrA-CTD to present the T 
segment over the G segment and a positive node is formed. (4) Upon ATP binding, the GyrB monomers 
dimerise and (5) the G segment is cleaved and the DNA gate opens. Either (6a) ‘top-down’ passage of the 
T segment occurs upon hydrolysis of a single ATP or (6b) CcdB accesses its binding site to stabilize the 
cleavage complex. (7) The DNA gate closes, the G segment is religated and the T segment passes out 
through the bottom gate, with hydrolysis of the second ATP resetting the enzyme. (6c) A futile ATP 
hydrolysis/ATP binding cycle can occur as per Kampranis et al. (Kampranis, Howells et al. 1999). Several 
cycles of (5) to (6a) transition may occur prior to CcdB binding in a (5) to (6b) transition. Reproduced 
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substructure of CcdB might be of interest (Trovatti, Cotrim et al. 2008). The crystal structure of 
CcdB/CcdA complex, the CcdB dimer with two CcdA (3G7Z) had been recently released, it 
shows how the CcdA antitoxin interact with the CcdB, and can dissociate the CcdB-gyrase 
complex , a process called rejuvenation (De Jonge, Garcia-Pino et al. 2009). A similar toxin from 
Vibrio fischery, CcdBVfi, has been characterized by X-ray crystallography and NMR, it provides 
an additional tool to understand the mechanism of interaction with gyrase (De Jonge, Buts et 
al. 2007). 
 
 
 
4.3.4.5 Par E toxin 
ParE toxin is produced by the RK2 plasmid as part of a ParE/ParD toxin/anti-toxin 
addiction system (Johnson, Strom et al. 1996). The toxin has been shown inhibit DNA synthesis 
and to stabilize the gyrase-DNA cleavage complex (Jiang, Pogliano et al. 2002). The X-ray 
structure of the ParE dimer and ParD dimers co-crystallized has been released recently (Dalton 
and Crosson 2010). There is enough significant similarities between CcdB and ParE to justify the 
investigation of ParE in a way similar to CcdB. ParD possess features that look similar to the exit 
gate of GyrA, it would be interesting to make some modelling on these two fragments. 
Figure 52 CcdB and derived peptides: the various peptides evaluated by Trovatti et 
al, the green box highlight the peptide that shows a complete inhibition of on gyrase 
at 10 µM and of topo IV at 5 µM (Trovatti, Cotrim et al. 2008).  
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4.3.4.6 Microcin B17 
Microcin B17 is a 3.1 kDa glycine-rich peptide produced by enterobacteria carrying the 
pMccB17 plasmid (Davagnino, Herrero et al. 1986). MccB17 is active against many 
enterobacteria (Asensio and Perez-Diaz 1976) and has been shown to inhibit DNA replication, 
leading to rapid arrest of DNA synthesis, induction of SOS response, DNA degradation and cell 
death (Herrero and Moreno 1986). MccB17 is inappropriate to be used as a drug as it shows 
poor physico-chemical properties, although it had been chosen in this study to be the base for 
designing novel drugs based on its particular heterocyclic structure and mechanism of action. 
Microcin B17 will be described more extensively below. 
 
Figure 53 Structure of the ParE toxin: on the left the ParE dimer (turquoise and violet) in complex with ParD 
dimer (red and yellow) (Dalton and Crosson 2010), on the right the gyrA59 dimer for comparison (Edwards, 
Flatman et al. 2009). The orientation of the two structures had been chosen by the author to highlight visual 
similarities between GyrA and ParD, but is not representative of any published evidence. The reader should 
note that the CcdB orientation while interacting with GyrA is opposite of the shown ParE if we consider its 
helix/β-sheet structure organization. 
Figure 54 Microcin B17 
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5 Microcin B17 
 
 
 
5.1 The microcins 
 The microcins are bacterial toxins with a molecular weight below 10 kDa that have 
been isolated from strains of E. coli in 1976 (Asensio and Perez-Diaz 1976) and shown to inhibit 
the growth of a wide spectrum of microorganisms. Five types of microcins have been identified 
by cross-immunity. They have been initially classified depending on their mode of action: Type 
A, inhibition of metabolic enzymes, type B, inhibition of DNA replication, type D, impairment of 
the cell energy-generating system (Baquero and Moreno 1984). Microcins were proposed later 
to be classified depending on the presence or not of post-translational modifications (Pons, 
Lanneluc et al. 2002), this idea was further refined to take into account the nature of the 
modification and lead to the following classification of microcins of known structure 
(Duquesne, Destoumieux-Garzon et al. 2007): 
• Class I: MW < 5 kDa, major peptide backbone modifications: MccB17, MccC7/C51, 
MccJ25. 
• Class II : 5 < MW < 10 kDa:  
o IIa: contains only disulfide bonds as modification: MccL, MccV, Mcc24. 
o IIb: linear peptide, possibly contain a C-terminal modification: MccE492, 
MccM, MccH47, MccI47. 
Other microcins are not included in this classification, as their structure have only been 
predicted by genetic studies, like MccH47, MccI47 and Mcc24; or is not known as they have 
been only characterized by biochemical studies like MccD13, Mcc140, Mcc15m, Mcc15n. 
Microcin B17 is one of the most studied microcin, we will not develop further the other 
microcins as they relate to MccB17 neither in structure nor in mode of action.  
5.2 Activity of MccB17 
The primary physiological effect of the MccB17 is the inhibition of semi-conservative 
DNA replication which triggers the SOS response, and finally induces DNA degradation and cell 
death (Herrero and Moreno 1986). Genetic and biochemical approaches have shown that the 
effect of MccB17 is linked to its ability to induce E. coli gyrase-mediated double-strand 
cleavage of DNA (Vizan, Hernandez-Chico et al. 1991). The uptake mechanism of MccB17 has 
Figure 55 Microcin B17 
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been linked with two proteins: the porin Ompf in the outer membrane, and SbmA an ABC 
transporter of the inner membrane (Lavina, Pugsley et al. 1986) that have been linked as well 
to the transport of MccJ25 (Salomon and Farias 1995) and bleomycin (Yorgey, Lee et al. 1994). 
5.3 Interaction with gyrase 
Microcin B17 is a weak inhibitor of gyrase compared to quinolones. Some evidence of 
the gyrase-DNA-MccB17 interaction had been reported. MccB17 works through a different 
mechanism compared to quinolones and coumarins. The inhibition of supercoiling and 
relaxation induced by the toxin can only be seen when these reactions are run over an 
extended period. Kinetic simulation of the cleavage-religation reaction suggests that MccB17 
only enhances the cleavage of the second strand of DNA (Pierrat and Maxwell 2003): the 
conversion of open circular DNA to linear DNA. The effect of MccB17 on the DNA cleavage 
reaction is topology-dependent: in supercoiling conditions, with a relaxed DNA as substrate, 
the microcin can only weakly stabilize the cleavage complex in the absence of ATP, but more 
efficiently in its presence. Under relaxation conditions, with a negatively supercoiled DNA as 
substrate, microcin can more efficiently stabilize the cleavage complex in the absence of ATP 
(Pierrat and Maxwell 2003). It has been shown that MccB17 does not require the DNA-
wrapping domain of GyrA or the ATPase domain of GyrB. This evidence, added to the fact that 
the only known MccB17-resistant mutation is at amino acid 751 of GyrB (W751R), led to the 
hypothesis that the action of the toxin involves binding to the C-terminal domain of GyrB 
preventing strand passage by trapping a transient enzyme intermediate (Pierrat and Maxwell 
2005). Quinolone-resistance mutations GyrB (K447E) and GyrA (S83W) provide resistance to 
MccB17 as well; the CcdB-resistant mutant GyrA (R462C) was sensitive to MccB17. Limited 
proteolysis performed on GyrB in the presence of MccB17 showed that the C-terminal domain 
can be protected in the presence of GyrA and DNA, in comparison quinolones protected GyrB 
C-terminus alone, no protection was observed with the MccB17-resistant GyrB (W751R) 
(Pierrat and Maxwell 2005).  This various information argue for MccB17 interacting with a 
transition state of the gyrase-DNA complex generated after ATP binding.  
5.4 Resistance to MccB17 
(Lavina, Pugsley et al. 1986),(del Castillo, del Castillo et al. 2001) 
Spontaneous resistance to MccB17 appears with a frequency about 1 X 106. Two 
different mechanisms of resistance to MccB17 have been observed, the most prominent 
involves spontaneous mutation in the MccB17 uptake system, whereas the other involving 
mutation of the target has been artificially induced in strains where the uptake-related 
resistances have been disabled. Transport of MccB17 through the outer membrane is 
prevented by mutation of the genes ompF, the structural gene for OmpF, and ompR an OmpF 
positive regulator gene. These mutations give resistance to a wide range of compounds like 
other microcins or colicins. A second mediator of resistance linked with uptake is SbmA, 
mutation in the sbmA gene coding for this ABC transporter gives specific resistance to MccB17, 
bleomycin (Yorgey, Lee et al. 1994), and MccJ25 (Salomon and Farias 1995). When the putative 
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target of MccB17 was investigated, MccB17-resistant mutant strains were isolated through 
strategies that avoid uptake-related resistance. Two methods were used, the first uses a 
MccB17-producing strain lacking the mcbG gene coding for the immunity protein. This way the 
toxin is produced directly inside a sensitive strain, no uptake is involved, and the mcbEF genes 
responsible for MccB17 efflux, rescue partially the cells and allow them to grow slowly in 
favourable conditions. The second strategy involved a strain carrying a plasmid with multiple 
copies of the sbmA gene, so making sure that the protein will be expressed. As expected ompR 
and ompF mutants were isolated but a different type of mutation was isolated as well. Both 
strategies led to the same mutation: in gyrB an AT -> GC transition at position 2251, gives a 
GyrB with the Trp751 substituted by an Arg (W751R). In vivo, strains carrying this mutation are 
insensitive to MccB17, and in vitro, MccB17 is not able to stabilise the cleavage complex of 
gyrase carrying this mutation. Further investigation has been carried out by site-directed 
mutagenesis of GyrB W751: simple deletion led to an inactive GyrB; W751K, W751E, or W751G 
led to a resistance to MccB17 similar to W751R; W751F and W751H led to a low-level 
resistance to MccB17, in most of the cases the gyrase activity was altered. The substitutions 
that are not giving resistance to MccB17 are the ones with aromatic residues, suggesting that 
an essential aromatic or hydrophobic interaction is taking place between GyrB and MccB17 at 
this site. 
5.5 Biosynthesis and structure 
Microcin B17 is a 3.1 kDa post-translationally modified glycine-rich peptide (Davagnino, 
Herrero et al. 1986) produced by E. coli strains carrying the pMccB17 plasmid (formerly 
pRYC170) (Baquero, Bouanchaud et al. 1978; Baquero and Moreno 1984). This plasmid 
contains a 5.1 kb operon composed of the seven genes mcbABCDEFG: mcbA coding for MccB17 
precursor sequence, mcbBCD coding for the multi-component enzyme responsible for MccB17 
maturation (Genilloud, Moreno et al. 1989; Li, Milne et al. 1996; Videnov, Kaiser et al. 1996), 
and mcbEFG coding for export and immunity proteins (Garrido, Herrero et al. 1988). The first 
gene mcbA encodes a 69 amino acid peptide precursor of MccB17: preMccB17. This peptide is 
post-translationally modified to proMccB17 by the microcin synthetase, a multi-enzyme 
complex encoded by mcbBCD that converts specific sequences of residues from preMccB17 to 
five-membered heterocycles (Yorgey, Lee et al. 1994; Videnov, Kaiser et al. 1996). 
The leader peptide, composed of the first 26 residues of the proMccB17, is an 
amphipatic α-helix involved in the recognition of the preMccB17 by the synthetase (Madison, 
Vivas et al. 1997). It undergoes a proteolytic cleavage to lead to mature MccB17 (Yorgey, 
Davagnino et al. 1993).The post-translational modification are the following: letters A to F will 
designate the modified sites, site A, Gly39-Ser40-Cys41 to 2-[2’-aminomethyloxazole-4’-
yl]thiazole-4-carboxylic acid (oztz); Sites B and C, Gly47-Cys48 and Gly50-Cys51 to 2-
aminomethylthiazole carboxylic acid (tz); site D, Gly54-Cys55-Ser56 to 2-[2’-
aminomethylthiazole-4’-yl]oxazole-4-carboxylic acid (tzoz); sites E and F, Gly61-Ser62 and 
Gly64-Ser65 to 2-aminomethyloxazole-4-carboxylic acid (oz). 
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MccB17 synthetase has been intensively studied: McbB is a zinc-containing protein that 
probably catalyses the initial cyclisation by dehydration; McbC is a flavin protein that is likely to 
be involved in the dehydrogenation, and McbD is an ATP/GTPase that can act as a 
conformational switch (Milne, Roy et al. 1999). Tolerance of McbBCD to various substrates has 
been studied as well. The amino acids 39, 40, 41 corresponding to site A, and G42 were 
modified to evaluate the cyclisation product. Considering the wild type sequence being GSCG, 
GSCA gave the expected bisheterocyclic product, GSCN and GSCV only a monocyclic product, 
and ASCG, DSCG, KSCG, GSCD, GSTG, GTCG were not processed. This tends to show that the 
synthetase activity is very sensitive to steric hindrance both on the glycine and on the hydroxyl 
group involved in cyclisation; the downstream glycine seems slightly less sensitive (Sinha Roy, 
Belshaw et al. 1998). Kinetic studies of substrate sequences have been performed as well, 
using a maltose-binding protein linked to the first 46 amino acids of McbA with altered G39-
S40-Cys41 to produce all possible bisheterocycles combinations led to the following 
preference: GSC > GCC> GCS >GSS (Belshaw, Roy et al. 1998). Additionally the role of the N-
terminal polyglycine in MccB17 processing was evaluated by changing the number of glycines 
of the same MBP-McbA1-46 from 10 to 3, 5, 7, 9 or 11 and monitoring the rate of conversion of 
GSC to oztz (Sinha Roy, Belshaw et al. 1998). Shortening the polyglycine cause a significant 
decrease of the processing of the GSC sequence, this favours the polyglycine being a spacer 
between the leader sequence and the processed sequences (Belshaw, Roy et al. 1998; Sinha 
Roy, Belshaw et al. 1998). Finally, McbE and McbF form an ABC transporter responsible for 
exporting the toxin and conferring partial immunity; mcbG encodes a pentapeptide repeat 
protein that prevents the binding of MccB17 to the gyrase of  the producing organism (Garrido, 
Herrero et al. 1988). 
The primary structure of MccB17 has been completely elucidated by mass spectrometry 
(MS), Gas Chromatography/MS coupling, NMR with 13C- and 15N- labelled MccB17 (Bayer, 
Freund et al. 1993; Bayer, Freund et al. 1995) and total synthesis of MccB17 (Yorgey, Lee et al. 
1994; Videnov, Kaiser et al. 1996; Videnov, Kaiser et al. 1996). The total synthesis of MccB17 
will be described below, as it is the starting point for synthesis of the compound we are 
interested in. 
5.6 Structure-activity relationships in MccB17 
Features influencing microcin B17 activity have been studied on various derivatives of 
the native toxin mainly focussing on its heterocyclic residues. Modification of MccB17’s 
bisheterocyclic moieties of site A and D by in vivo processing has been reported. It shows that 
modification of the 4,2-fused oxazole-thiazole (oztz) in site A to oxazole-oxazole (ozoz) or 
Figure 56 Microcin B17 and site reference 
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thiazole-thiazole (tztz) show respectively 25% and 5% decrease of inhibitory activity on cell 
lawn of ZK4 E. coli strain compared to the wild type MccB17. Alteration of site B causes at least 
a 66% drop in activity on the same test. Further modification of site D led to compounds with 
marginal activity for the monoheterocyclic species, or no activity for the compounds where the 
tzoz has been completely deleted. An interesting variant of MccB17 containing one extra 
oxazole moiety has been isolated, it resulted from the conversion of the thiazole (50-51)-Ser52 
to Thia-Oxa. This mutant MccB17 shows a 50% increase in activity compared to MccB17, and 
can partially rescue the loss of activity caused by moderate site D modification. The various 
mutants and their activity are described in Table 1, based on the data reported by Sinha Roy et 
al (Sinha Roy, Kelleher et al. 1999) and Zamble et al (Zamble, Miller et al. 2001). 
 
 
Microcin B17 features two asparagines residues at position 53 and 59; deamination by 
mild alkaline hydrolysis of these residues has shown a complete loss of ability to stabilise the 
cleavage complex (Parks, Bottrill et al. 2007). Finally alkaline hydrolysis of microcin, for 168 h in 
refluxed DMSO, has been conducted and led to a mixture of heterocycle-containing fragments 
Table 1 Effect of heterocycle alteration on microcin B17 inhibitory activity: on the left, inhibition of altered 
MccB17, values are given in comparison with the native MccB17, they correspond to the maximum growth 
inhibition on lawn of ZK4 E. coli strain, bioefficacy is normalized to the native MccB17. On the right, schematic 
representation of the sequence of the altered MccB17. The brown line represents the peptide sequence with 
the oxazole ring in red and the thiazole ring in yellow. 
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that still shows inhibition of gyrase (Coquin 2005). Liquid chromatography coupled with mass 
spectrometry (LC-MS) has been used to characterize the following fragments. 
 
 
 
 These fragments will be the starting point for our investigation for new topoisomerase 
inhibitors. In order to investigate the activity of different fragments, we aimed to synthesize 
the basic oxazole and thiazole heterocyclic and bis-heterocyclic amino acids. The activity on 
gyrase of these compounds will be evaluated. These heterocyclic amino acids will be used as 
building blocks to construct topoisomerase inhibitor peptides and investigate the main 
features responsible for the activity. We will describe now the strategy chosen to obtain these 
different heterocyclic amino-acids. 
5.7 Total synthesis of MccB17 
 The total synthesis of Microcin B17 has been described (Videnov, Kaiser et al. 1996), 
part of that work is the production of the various heterocyclic moieties of MccB17. 
5.7.1 Synthesis of thiazole and oxazole amino acids 
 
 
Figure 57 Fragments found in microcin B17 alkaline hydrolysate (Coquin 2005). 
Figure 58 Synthetic route to thiazole and oxazole amino acids (tz, oz) (Videnov, Kaiser et al. 1996) 
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The synthetic route leading to these residues is derived from the Cornforth reaction for 
generation of the oxazole part (Cornforth and Cornforth 1947) and from the Hantzsch reaction 
for the thiazole part (Metzger 1979). Figure 58, Figure 59, and Figure 60 reproduced from 
Videnov et al (Videnov, Kaiser et al. 1996) describe respectively: the synthesis of thiazole and 
oxazole amino acids; the thiazole-oxazole amino acid; and the oxazole-thiazole amino acid. 
 
 
 
 
  
Figure 60 Synthetic route to thiazole-oxazole amino acid (tzoz) (Videnov, Kaiser et al. 1996) 
Figure 59 Synthetic route to oxazole-thiazole amino acid (oztz) (Videnov, Kaiser et al. 1996) 
77 
 
5.7.2 Synthesis of MccB17 
The different amino acids, natural and heterocyclic were assembled using an Fmoc solid 
phase strategy with a Wang resin. Starting from a Fmoc-Ile-Wang resin, Fmoc protected amino 
acids were coupled using 2-(1 H-benzotriazol-1-yl)-1, 1, 3, 3-tetramethyluronium 
tetrafluoroborate (TBTU), N-hydroxybenzotriazole (HOBt), and diisopropylethylamine (DIEA). 
Intermediate peptides were used to solve the problems cause by the synthesis of the 
polyglycine: in order of introduction, Fmoc-Gly-Gly-OH, Fmoc-Gly-Gly-Gly-OH, Fmoc-Ile-Gly-OH, 
and the final Boc-Val-Gly-OH. The final peptide was cleaved from the resin with a mixture of 
3:3:3:91 dimethylsulfide, meta-cresol, ethanediol, and trifluoroacetic acid. 
5.8 A synthetic approach to MccB17 chemistry 
The previous paragraph described how MccB17 has been initially synthesized, it involved 
basically creating five-membered, or bis-five-membered heterocyclic amino acids. We will 
develop further this aspect, in order to include the progress in related synthetic methods and 
to give an insight on the variation that can be introduced in MccB17 through that kind of 
strategy.  
5.8.1 Generating five-membered ring heterocyclic residues 
Our intention here, is not to give an extensive analysis of the reactions leading to 5-
membered heterocyclic rings, but a few alternative relevant routes to generate compounds 
similar to MccB17’s heterocycles. We will cover here various methods to generate oxazole and 
thiazole, and the related isostere imidazole. 
5.8.1.1 Thiazole synthesis 5.8.1.1.1 From a protected Cysteine 
(You, Razavi et al. 2003): 
 
 
Figure 61 Alternative route to synthesize a thiazole ring using a cysteine 
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A dipeptide with a protected C-terminal cysteine can be converted into a thiazoline by 
cyclodehydration mediated by hexaphenyloxodiphosphonium trifluoromethanesulfonate. 
Further oxidation as described above will lead to the corresponding thiazole. 
Method: 1.5 eq trifluoromethanesulfonic acid are added slowly to 3 eq triphenylphosphane 
oxide in dichloromethane at 0°C. The fully protected X-Cys, 1 eq is added, and the mixture is 
stirred 10 min at 0°C. The reaction mixture is quenched with 10% aqueous NaHCO3, extracted 
with CH2Cl2, dried filtered and concentrated. 5.8.1.1.2 From a β-hydroxythioamide 
(Khapli, Dey et al. 2003): 
 
 
 
This method uses the Burgess reagent dehydrating properties to induce the cyclisation 
of a serine with an N-thioamide bond.  
Method: A solution of the thiamide in THF is treated with 1.1 eq of Burgess reagent and heated 
10 min at 65°C. The reaction is cooled to RT, concentrated, and purified by chromatography. 
5.8.1.2 Oxazole synthesis 
(Wipf and Miller 1993; Phillips, Uto et al. 2000) 
Methods to convert a dipeptide with a C-terminal serine into an oxazoline have been 
reported, two different conditions can lead to this result: the use of Burgess reagent as above, 
or the use of fluorinating agents like DAST and deoxo-fluor®. An oxidation step can be 
integrated in the last method without any other treatment to lead to the oxazole in a one-pot 
method. 
 
Figure 63 Alternative route to synthesize an oxazole from a beta-hydroxylamide with the Burgess reagent 
Figure 62 Alternative route to synthesize a thiazole ring from a β-hydroxythioamide. 
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Method with Burgess reagent: A solution of the β-hydroxyamides in THF is treated with 1.1 eq 
of Burgess reagent and heated 10 min at 65°C. The reaction is cooled to RT, concentrated, and 
purified by chromatography. 
 
 
Method with Deoxofluor®: 1.2 eq deoxo-fluor is added to 1 eq of Cbz-Val-Ser-OMe in 
dichloromethane, cooled at -20 °C. After 30 min 4 eq bromotrichloromethane, and 4 eq DBU 
are added. The reaction mixture is stirred for 8 h at 2-3°C. The mixture is then quenched with a 
saturated sodium bicarbonate solution. The mixture is extracted with ethyl acetate, dried, and 
concentrated.  
5.8.1.3 Imidazole synthesis 
There is two interesting routes to produce imidazole amino acids, one similar to the 
oxazole synthesis used by Videnov et al (Stankova, Videnov et al. 1999), the other uses a 
peptide with a C-terminal 2,3-diaminopropanoic acid (Biron, Chatterjee et al. 2006).  
 
 
 
Method: the triethyloxonium hexafluorophosphate was added to a solution of Boc-glycinamide 
in chloroform at 0°C, and stirred for 20 h. After treatment the product is mixed with 0.9 eq of L-
2,3-diaminopropionic acid methyl ester hydrochloride in chloroform to lead to the imidazoline. 
The imidazoline can be oxidized using standard method. 
Figure 64 Alternative route to synthesize an oxazole ring from a beta-hydroxylamide using a 
fluoronating agent 
Figure 65 Synthesis of imidazole amino acid 
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Method: 1.5 eq of trifluoromethanesulfonic anhydride is added to 3 eq triphenylphosphine 
oxide in anhydrous dichloromethane at 0°C. The reaction mixture is stirred for 10 min at 0°C 
and the dipeptide is added. The mixture is stirred for 4 h at RT. After being isolated, the 
imidazoline can be oxidized to form the imidazole. The tosyl group on the 
imidazoline/imidazole can be removed by treatment in 20% pyridine in NMP. 
6 Context and aims of this work 
This chapter initially stated the desperate need in present days for new antibacterials, as 
underestimation of the resilience and adaptability of bacteria, added to the misuse of the 
panel of antibacterial at our disposition, has led to the loss of the advantage we had initially 
over pathogens. The various ways antibacterial molecules use to kill bacteria have been 
described with the different chemical families they belong to and their mode of action. Focus 
had been put on topoisomerases as major therapeutic targets, both for the present success 
with the fluoroquinolones and for the antibacterial efficiency represented by the 
topoisomerase poisoning mechanism. A glimpse of the application for topoisomerases in the 
context of anti-cancer therapy had been given as well. Antibacterial inhibitors of 
topoisomerases are targeting only two members of the type II family: gyrase and topo IV, and 
we stated that they will be our central interest in the present work. Inhibitors for these two 
enzymes have been described and a special emphasis had been put on MccB17. We have 
stated that MccB17’s activity as a topoisomerase poison, different from quinolones, make it a 
particularly attractive molecule in the context of new drug development, and so more 
information on MccB17 was provided covering its bioactivity, biosynthesis, and related 
chemistry. 
We have described a wide variety of antibacterial compounds that are working by very 
different mechanism on a set of essential bacterial targets. This panel was what produced the 
antibacterial golden age, unfortunately bacteria have their own set of tools to adapt to and 
resist such threats if they are given the chance, as demonstrated by the occurrence of 
resistance described in this chapter. As there is a need for novel antibacterials, our aim was to 
provide novel inhibitors or gather evidence that will lead to such discovery. We decided to use 
MccB17 for this purpose, because it is a molecule with a mode of action that involves the 
Figure 66 Synthesis of imidazole from a C-terminal (2, 3-diaminopropanoic acid)-containing peptide 
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already clinically validated target gyrase, and thus by a mechanism reminiscent of the very 
successful fluoroquinolone drugs, but different. It is not possible to use MccB17 itself as a drug, 
mainly because of its size and bad solubility, however the design of smaller molecules with 
better physico-chemical properties mimicking this mode of action, is likely to provide new 
antibacterials. To achieve this goal, one first must have a better understanding of the 
mechanism of MccB17, its interaction with gyrase and particularly how it stabilises the 
cleavage complex. Information concerning gyrase-MccB17 is scarce: the cleavage-complex 
stabilisation by MccB17 is ATP-dependent and so the toxin probably requires a specific 
conformation during the enzyme cycle to bind to the complex. MccB17-resistant mutants map 
to GyrB and some cross resistance is observed with the fluoroquinolones, this tends to prove 
that MccB17 binding site involves GyrB, and maybe the GyrA QRDR. Concerning the MccB17 
molecule, its primary structure is known, it has been proven that the bisheterocycles play an 
important role in its activity, and that some of the amide residues are necessary to maintain 
the ability to stabilise the cleavage complex. There are a lot of gaps to fill before a clear picture 
of MccB17’s mode of action can be drawn. Essential questions we want to address in the 
present work are: what are the elements in the MccB17 molecules that are required for its 
activity, and is it possible that fragments from the toxin able to retain some of its activity? 
Previous work on the heterocycles contained in MccB17 suggested that small peptide 
inhibitors can be built up from these structures, we wonder to what extent such derivatives 
can be used as inhibitors by improving their activity, and if stabilisation of the cleavage 
complex can be achieved with that kind of structure. To address these different questions, our 
study of MccB17 has taken on three main aspects that will be covered in separate chapters. An 
initial focus has been placed on improving our understanding of MccB17’s mode of action, the 
significance of its different features, and particularly what is responsible for its ability to 
stabilise the cleavage-complex; this will be covered in Chapter II. Our second interest involved 
the production of inhibitors, two convergent approaches have been carried out for this 
purpose: the first one used MccB17 has a starting material, and generated fragments as 
potential topoisomerase inhibitors and information about the whole toxin; this aspect will be 
covered in Chapter III. The second approach starts from the unique amino acids found in 
MccB17 or related molecule to evaluate their potency and build from them to generate new 
compounds, this part will be explained in Chapter IV. The outcome from these different 
chapters will be summarized and discussed in Chapter V. A final chapter VI will cover the 
technical aspects and describe the experimental details of the methods used through the 
different chapters.  
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CHAPTER II Microcin B17 properties and characterisation 
This chapter will focus on the native microcin B17 molecule itself and derivatives retaining 
the overall structure. The first part of this chapter will describe the techniques commonly used 
to produce microcin B17 and characterise its activity on gyrase. These techniques are directly 
inspired from the literature with few variations but are described here as they are the core 
tools available to generate and evaluate MccB17 derivatives. Having considered MccB17 
activity on E. coli gyrase we will widen the scope of targets and describe our investigation on 
other topoisomerases. The second part of this chapter will describe how analytical methods 
have been used to study Microcin B17 and its interaction with E. coli gyrase. Finally the effect 
of alteration of the ends of MccB17 as well as amide residues will be described. 
1 Nomenclature:  
MccB17 amino acids will be numbered accordingly to their counterparts in preMccB17, 
the peptide product of the mcbA gene. Concerning the heterocyclic amino acids, they will be 
numbered and referred to as follow: N-terminus; oztz; tz1; tz2, tzoz; oz1; oz2; C-terminus. This 
numbering has been chosen because it is the most commonly used in the literature and so it 
will be easier to link information from this work and the literature. MccB17 species lacking 
amino acids will be noted as follow: MccB17 minus Val27= Mcc\V27 or Mcc\V as there is only 
one V in MccB17. Microcin B17 species with extra or less heterocycles will be noted as follow: 
extra heterocycle MccB17Δ+1, with two less heterocycles MccB17Δ-2.  
 
 
 
Figure 67 Microcin B17 
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2 Production of microcin B17 
We produced the antibacterial peptide using a protocol inspired by Roy et al (Sinha Roy, 
Kelleher et al. 1999), for more details refer to Materials and Methods. The toxin was expressed 
in E. coli DH5α carrying the plasmid pUC19-mccb17: a pUC19 carrying the full biosynthetic 
operon mcbABCDEFG. Overnight cultures of DH5α-mccb17 in 12 X 5 ml LB media were used to 
inoculate 12 X 1 L of M63 glucose-Ampicillin media. After incubation for 48 h at 37°C the cells 
were pelleted by centrifugation at 4250 g. The pellets were disrupted by adding them to 500 
ml of a boiling solution of 1 mM EDTA and 100 mM acetic acid, and allow the stirred mixture to 
boil for 10 min. The cellular debris was removed by centrifugating the solution at 4600 rpm for 
15 min. The supernatant was loaded on 4 X 35 cc (10 g) Sep-Pak® C18 reverse phase cartridge 
each equilibrated with 250 ml acetonitrile and 250 ml water. Contaminants were removed by 
successive elution of 300 ml water and 300 ml 12% acetonitrile in water. The fraction 
containing MccB17 was collected by elution with 300 ml of 50% acetonitrile in water. The 
solution was concentrated under vacuum before being freeze dried, which led to solid crude 
MccB17. The crude microcin was solubilised in DMSO at ~3mM concentration and purified by 
HPLC using a preparative reverse phase column with a gradient of 13 to 23% acetonitrile in 
water with 0.1 %TFA over 40 min. The various fractions collected were concentrated under 
vacuum before being freeze dried. 
3 Development of a methanol-water HPLC method 
Due to the global shortage of acetonitrile in 2008-2009 the HPLC purification of 
microcin B17, which consumes a lot of solvents had to be rethought to accommodate a 
substitute for acetonitrile. We developed the method with methanol, which is a solvent with a 
higher polarity than acetonitrile (relative polarity H2O=1; MeOH=0.762; CH3CN=0.460) 
Figure 68 Microcin sequence numbering: the first row is the direct numbering of MccB17 residues, considering 
each amino acid including the post-translation modified products; the second row is the sequence of MccB17; the 
third row is the numbering associated with the mcbA protein product preMccB17; fourth and fifth rows shows 
residues and preMccB17 numbering of post-translationally modified residues. 
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(Reichardt 2003) but is known to be a good solvent for microcin. Following directions from 
HPLC suppliers concerning equivalence between acetonitrile/water and methanol/water 
system we started from the rough assumption that 10% CH3CN was equivalent to 15% MeOH 
and 30% CH3CN was equivalent to 40% MeOH. The microcin B17 was eluted with a gradient 
from 20% to 85% methanol in water with 0.1% TFA. The microcin peak is collected between 
RT=25 min to 28 min. 
4 Isolation of microcin B17 by-products 
During the purification of MccB17, our attention was drawn by series of small peaks ahead 
of the various MccB17 species. These peaks were isolated as they might be related to MccB17 
and retain some of its properties.  
 
Maldi-ToF MS analysis and study of fragmentation confirmed that indeed these isolates 
contain compounds related to MccB17. The main compounds observed had MWs of 1700.6, 
1393.5, and 857.4 Da. The MS fragmentation spectra of the main peaks found in this isolated 
fraction are shown below: 
  
Figure 69 MccB17 HPLC purification trace. 
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4.1 MW = 1700.6 
A very clear fragmentation spectrum by MALDI-ToF of this molecule has been obtained. 
We can clearly see the sequential removal of amino acids from the N-terminus with the typical 
polyglycines. This coupled with the fragment observed with m/z = 469.9 Da which correspond 
to GGtzGtz (MW = 469.07 Da) allowed us to conclude with confidence that this molecule 
corresponded to the 21 N-terminal residues of MccB17. 
 
 
 
  
Figure 70 MALDI-Tof spectra of MW = 1700.6 fragmentation 
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4.2 MW = 1393.4 
Analysis of this fragment was less straightforward, but low molecular weight fragments 
corresponding to HI (MW = 268.09 Da) and SHI (MW = 355.12 Da) which are the last 3 amino 
acids of MccB17 gave hints that this fragment was related to the C-terminal part of MccB17. 
Using this starting point, fragmentation can be traced backwards showing the expected m/z 
values as shown on Figure 71 below thus validating our assumption. This molecules contains 
the 13 C-terminal residues (residues Asn53 to Ile69) of MccB17, which correspond to a MW of 
1323.37 Da (m/z = 1324.43 Da observed), addition of the next amino acid, Ser52 will lead to a 
MW of 1410.4 Da which was higher than what we observed. The molecular weight of the 
fragment isolated was between a 13- and a 14-residue long N-terminal fragment. Our 
assumption was that this fragment is a 17 Da lighter derivative of the 14 residue-long 
fragment. This molecule is likely to result from the elimination of an ammonia molecule. 
 
 
 
Figure 71 MALDI-Tof spectra of MW=1393.4 fragmentation 
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4.3 MW = 857.4 
Spectra of MW = 857.4 Da were not as clear but the molecule was definitely a fragment 
containing the N-terminal VGIG residues and a cascade of glycine typical of the N-terminus of 
MccB17. The oztz ring that follows the polyglycine was not observed and would give a higher 
MW fragment of 1007.37 Da. If we forgot the strict MccB17 sequence, the MW would match 
the following formula VGI (G)10, which corresponds to the whole N-term fragment of MccB17 
preceding the oztz heterocycle but with an extra G. Our hypothesis is that this compound was 
not related to the mature MccB17 but to a MccB17 precursor which carries the GSC sequence 
instead of oztz ring. However MW = 857.4 was present as well in the digest of MccB17 by a 
carboxypeptidase, as a weak signal. It should have been degraded if the C-terminus residue is a 
Gly, this suggest that the C-terminus was likely to be a fragment of oztz. 
 
 
 
 
Figure 72 MALDI-Tof spectra of MW = 857.4 fragmentation 
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4.4 Comments 
These molecules probably result from spontaneous cleavage occurring in the experimental 
conditions related to MccB17 preparation. Fragments MW = 1393 Da and 1700 Da appear to 
both result from a single cleavage of the peptide bond between tz2 and Ser52, and MW = 857 
is probably a by-product of a MccB17 precursor. These structures are summarized in Figure 73 
below. These compounds where added to our pool of MccB17 fragments even if they are 
unlikely to retain inhibitory activity, and therefore will be described further in Chapter 3. 
 
 
5 In vitro activity on E. coli gyrase: 
The activity of microcin B17 on E. coli gyrase has been characterized in vitro by its ability 
to stabilise the gyrase-DNA cleavage complex in presence of ATP by Heddle et al (Heddle, 
Blance et al. 2001) and its ability to slow down the supercoiling and relaxation reactions by 
Pierrat et al (Pierrat and Maxwell 2003). We will describe here the methods inspired by these 
sources that have been used to characterize produced MccB17 and other inhibitors of interest. 
 
 
Figure 73 Fragments of MccB17 isolated from MccB17 preparation: the sequence of MccB17 is shown in orange, the 
coloured boxes correspond to MccB17 fragments with their corresponding MW, in bold are the fragments isolated, 
in italic are related fragments for information. 
Figure 74 Effect of MccB17 on the supercoiling reaction over time: the ratio of supercoiled dna 
species to all dna species (ratio SC) is shown as a function of time. At time-point A the slowing 
down effect of MccB17 can be observed as opposed to time-point B where the MccB17-
containing reaction had catched up with the control reaction. 
A 
B 
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Inhibition of supercoiling and relaxation by MccB17 is not straightforward to 
characterize as the toxin is only slowing down these processes. Experimental conditions 
require a precise tuning so that the reaction advancement will be at a point where this 
inhibitory activity can be observed, as illustrated by Figure 74. 
5.1 Supercoiling  
We have mentioned in the previous chapter how gyrase removes stress caused by 
accumulation of positive supercoils in the cells by introducing negative supercoils at the 
expense of ATP. We will describe here how this event can be reproduced in vitro and its 
alteration by MccB17 studied.  
Time course
In order to stop the reaction at the optimum 
time, the supercoiling reaction was tracked over 
time as follows: a mixture containing 50 µM 
MccB17, 5.4 nM relaxed pBR322 DNA, 2.7 nM 
gyrase and 1 mM ATP was incubated at 25°C, 
samples were collected at t = 0.25, 0.5, 1, 1.5, 2, 
3, 4 h. Samples were treated with one volume 
chloroform/isoamyl alcohol (24:1) and one 
volume STEB just after collection. Samples were 
analyzed on a 1% agarose gel. The same 
experiment but with no drug or with 8.5 µM 
ciprofloxacin were used as controls. 
: MccB17 is only slowing down the 
supercoiling reaction of gyrase so it is necessary 
to stop the reaction before it reaches its plateau 
as illustrated by Figure 75. 
This experiment shows that the reaction 
should be stopped after 2 h incubation at 25°C as 
most of the DNA is supercoiled but not 
completely in the absence of MccB17, and 
MccB17 inhibition is clearly shown. Following this 
study, our standard supercoiling conditions are 
the following: 50 µM MccB17, 5.4 nM relaxed 
pBR322 DNA, 2.7 nM gyrase and 1 mM ATP are incubated at 25°C, after two hours samples are 
treated with one volume chloroform/isoamyl alcohol (24:1) and one volume STEB. Samples are 
analyzed on a 1% agarose gel. The same experiment but with no drug or with 8.5 µM 
ciprofloxacin were used as a controls. 
 
Figure 75 Time courses of gyrase supercoiling: the 
top gel shows the gyrase alone, the bottom gel the 
same reaction in presence of 37 µM MccB17. For all 
gels: the top ladder corresponding to relaxed DNA is 
converted over time into the bottom band 
corresponding to supercoiled DNA.  
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Example of final assay 
5.2 Relaxation 
Relaxation is the opposite of the supercoiling reaction, it is driven by the gain of 
entropy of the DNA going from the supercoiled topological state to relaxed. The reaction does 
not require ATP to occur but is a less favourable reaction kinetically than supercoiling, so a 
larger amount of enzyme is used in order to stay in the same time frame. As gyrase is not a 
very good relaxing enzyme the effect of MccB17 is easier to observe than for the supercoiling 
reaction. As for the supercoiling assay the length of the reaction time was optimised using a 
time course. The relaxation reaction was conducted by incubating a mixture containing 50 µM 
MccB17, 5.4 nM supercoiled pBR322 DNA and 20 nM gyrase at 37°C, samples were collected at 
t= 0.5, 1, 2, 3h. Samples were treated with chloroform/isoamyl alcohol (24:1) and STEB just 
after collection. Samples aqueous phase was loaded on a 1% agarose gel. As before, reactions 
with no drug or 8.5 µM ciprofloxacin instead of MccB17 were used as controls. 
 
 
 
Figure 76 Example of gyrase supercoiling assays with the optimised conditions: the first two lanes 
are the enzyme alone, the next two are gyrase in presence of 8.5 µM ciprofloxacin, and the final 
two lanes in presence of 50 µM Mcc17. The top ladder corresponding to relaxed DNA is converted 
by gyrase into the bottom band corresponding to supercoiled DNA. CFX completely inhibits this 
reaction, whereas the reaction is partially inhibited by MccB17 in the conditions of the assay. 
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Following further tests, the final conditions retained for relaxation are the following: 5.4 
nM of supercoiled pBR322 DNA and 80 nM of gyrase were incubated in presence of no 
inhibitor, 50 µM MccB17 or 8 µM CFX for 2 h at 37°C. Samples were treated with 
chloroform/isoamyl alcohol (24:1) and STEB before being loaded on a 1% agarose gel.  
 
Figure 77 Time course of gyrase relaxation: for each time, lane one is without enzyme, lane two gyrase alone, lane 
three gyrase plus 8.5 µM ciprofloxacin, lane four gyrase plus 50 µM of MccB17. The supercoiled DNA band at the 
bottom of the gel is converted by gyrase to a ladder of band corresponding to relaxed DNA species. Ciprofloxacin 
completely blocks the reaction, whereas MccB17 slows it down. 
Figure 78 Example of gyrase relaxation assays with the optimised conditions: the first 
two lanes are the enzyme alone, and the next two lanes are gyrase in presence of 50 
µM Mcc17. The bottom band, corresponding to supercoiled DNA, is converted by 
gyrase into the ladder at the top of the gel that correspond to relaxed DNA. The 
inhibitory effect of MccB17 is particularly clear: the ratio of intensity of supercoiled 
DNA (lower band) compared to the sum of all DNA species in the lane is significantly 
higher than what is observed with gyrase alone. 
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5.3 Cleavage 
The great strength of the fluoroquinolone antibacterials is their ability to stabilise a 
DNA-gyrase cleavage complex that leads to the generation of species that are very toxic for the 
cell. The cleavage assay allows us to study in vitro the influence of compounds on the 
formation of DNA-gyrase cleavage complex. To do so, the same conditions as supercoiling are 
used but with a fifteen-fold increase in gyrase concentration, to increase the amount of 
cleavage complex formed. In the presence of compounds that are stabilising this cleavage 
complex there will be a significant enrichment of the population of linear DNA. Microcin B17 
can only efficiently stabilise the cleavage complex in the presence of ATP; this ATP-dependence 
can be shown by running the experiment with versus without ATP. On Figure 79, lane 5 and 6, 
linear DNA is generated in the presence of MccB17 for both conditions, but the amount in the 
absence of ATP is very low. The reactions are run with no drug or 8.5 µM ciprofloxacin as a 
control, ciprofloxacin is able to stabilise the cleavage complex independently of the presence of 
ATP. The assay is conducted as follow: a mixture containing 50 µM MccB17, 5.4 nM relaxed 
pBR322 DNA, 80 nM gyrase and 1 mM ATP is incubated at 37°C for one hour, then 0.2% of SDS 
and 2 µg/µl of proteinase K are added and the reaction is incubated for 30 min at 37°C. The 
sample is treated with one volume of chloroform/isoamyl alcohol (24:1) and one volume of 
STEB before being analysed on a 1% agarose gel. The gel can contain ethidium bromide in 
order to have a better resolution between relaxed DNA topoisomers and linear DNA.  
Figure 79 Gyrase cleavage assays: The top gel corresponds to the cleavage assay run on a standard 
agarose gel; the bottom gel correspond to the same cleavage assay but run on a 1 µg/ml ethidium 
bromide agarose gel. Lanes 5 and 6 highlight the ATP dependence of MccB17 stabilisation of cleavage 
complex. 
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It is important to note the difference between the lanes 5 and 6 in Figure 79, as it 
highlights the ATP-dependence of MccB17 stabilisation of cleavage complex. 
5.4 Comments 
Evidence gathered from supercoiling, relaxation and cleavage assays together give a 
good overview of the potency of an inhibitor and some insight on its mechanism of action. By 
comparing supercoiling and relaxation activity one can infer if ATP hydrolysis is involved in the 
inhibitory mechanism. If a compound inhibits supercoiling but not relaxation, complementary 
evaluation of its influence on ATPase activity should be carried out. Obviously stabilisation of 
cleavage complex and ATP dependence of this event reveal the type of mechanism involved. 
5.5 Resistance to microcin B17 in E. coli gyrase 
The mutation tryptophan 751 to arginine in the GyrB subunit (Y751R) confers gyrase 
immunity to MccB17 (Vizan, Hernandez-Chico et al. 1991). The assays with the mutant gyrase 
are conducted as described above for the wild type in order to determine whether compounds 
related to MccB17 are affected by this mutation, which is the only one conferring resistance to 
MccB17 that has been identified so far; we will describe in the next part our attempt to 
discover others. 
6 In vitro activity on other topoisomerases 
The activity of microcin B17 on gyrase is well documented, but surprisingly the field of 
investigation has not been extended to other topoisomerases. Three topoisomerases have 
been considered here: E. coli topoisomerase IV, which is closely related of gyrase and a well 
known secondary (or sometime primary) target for fluoroquinolones antibacterial drugs, and 
the gyrase from Staphylococcus aureus, which is an important health-threatening bacteria, and 
finally human topo II for its relevance to anti-cancer therapy. 
6.1 Staphylococcus aureus gyrase 
The activity of MccB17 on Staphylococcus aureus gyrase was studied in collaboration 
with Terence Chung. The assays were conducted in the following condition: 200 µM of MccB17 
were added to 2.4 nM SaGyrA, 23 nM SaGyrB, 5.4 nM relaxed pBR322, 2 mM ATP and 3% 
DMSO. Samples were treated with chloroform/isoamyl alcohol (24:1) and STEB before being 
loaded on a 1% agarose gel. No inhibitory activity was observed at this concentration. 
6.2 E. coli topoisomerase IV 
The activity of MccB17 on E. coli topo IV relaxation was assayed using the following 
conditions: 11 nM supercoiled pBR322 DNA and 22 nM topo IV and 1 mM ATP were incubated 
in presence of no inhibitor, 37 µM MccB17 or 17 µM CFX for 30 min at 37°C. Samples were 
treated with chloroform/isoamyl alcohol (24:1) and STEB before being loaded onto a 1% 
agarose gel.  
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There is probably a weak inhibition of the reaction at 40 µM, visible as a shade at the 
level of the supercoiled species, and weaker relaxed bands. Unfortunately, due to time 
constraints we haven’t been able to further validate this preliminary result and determine an 
IC50, but this is an encouraging result to pursue investigation of the inhibition of topo IV by 
MccB17 and particularly evaluating if stabilisation of the cleavage complex can be achieved in 
the presence of MccB17. 
 
6.3 Human topoisomerase II 
The evaluation of the activity of MccB17 on human topo II relaxation was conducted as 
follow: to a mixture 5.4 nM of supercoiled pBR322, 1 U of human topo II, and 1 mM ATP, no 
drug, 100 µM etoposide or 200 µM MccB17 were added. Samples were treated with 
chloroform/isoamyl alcohol (24:1) and STEB before being loaded on a 1% agarose gel. 
Figure 80 Effect of MccB17 on topo IV relaxation reaction: topo IV converts 
supercoiled DNA (bottom band) into relaxed DNA (top ladder of bands). In the 
presence of 17 µM ciprofloxacin an intense bottom band is visible due to its 
inhibitory activity. In the presence of 37 µM, a faint bottom band is visible, 
accounting for some inhibition by MccB17 of topo IV. 
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MccB17 inhibitory activity on topo II relaxation has been observed at 200 µM, which can 
be considered as a high concentration, but this is only twice the concentration of the etoposide 
control we are using. This suggests that MccB17 has some potential as a topo II inhibitor. For 
anti-cancer application, we are less interested in the stabilisation of the cleavage complex, 
however on a mechanistic point of view, and for a better understanding of MccB17 It would be 
useful to ascertain if it is a topo II poison. 
 
7 Selection of new mutants resistant to microcin B17 
We have mentioned in the first chapter that replacement of tryptophan 751 by 
arginine was the only gyrase spontaneous mutation identified that confers resistance to 
MccB17 (Vizan, Hernandez-Chico et al. 1991). Identifying mutated residues that are responsible 
for resistance to the toxin is a good way to have a better understanding of the interaction 
between the enzyme and its inhibitors. Resistance to microcin B17 occurs at an elevated rate 
(10-6) (Lavina, Pugsley et al. 1986); the main resistance mechanism observed is linked with the 
alteration of the uptake system: OmpF in the outer membrane and SbmA in the inner 
membrane (Lavina, Pugsley et al. 1986), this reduces significantly the chance of isolating a 
Figure 81 Evaluation of the inhibitory activity of MccB17 on human topo II: relaxation 
assays with human topo II, the lower band, corresponding to supercoiled DNA, is 
converted by the enzyme into the top ladder of bands, the relaxed DNA species. In 
the presence of an inhibitor such as etoposide, the intensity of the lower band is 
increased and the top ladder decreased. We can observe that MccB17 has an effect 
very similar to etoposide. 
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resistant strain carrying mutations that map to gyrase, as the toxin is not reaching its target. By 
using a permeable strain we aimed to overcome this problem by improving the chances of 
selecting resistance related to this cellular target. 
 
 
 
7.1 NR698 permeable strain  
The permeable train E. coli NR698 was used is this study, it is an MC4100 strain with an 
in frame deletion of 23 amino acids (D330 to D352) in the imp (increased membrane 
permeability) gene (imp4213). Imp encodes for an essential protein involved in the outer 
membrane assembly. This deletion has been reported to increase permeability to drugs like 
Vancomycin (Braun and Silhavy 2002; Ruiz, Falcone et al. 2005). 
7.2 Preliminary study 
During standard halo assays with MG1655 involving MccB17, a few resistant colonies 
inside the inhibition halo were noticed. Following this observation we performed halo assays 
using MccB17 on plates inoculated with MG1655 (wild type) and NR698 (permeable strain), in 
order to evaluate the susceptibility of the permeable strain and the occurrence of resistant 
Figure 82 Comparison of MccB17 on the permeable strain vs standard E. coli 
strain: this is an LB-agar slop plate with a gradient of MccB17 from zero (right) 
to 1 µM (left). The top part is streaked with the standard MG1655 E. coli 
strain, the bottom part with NR698 E. coli permeable strain. 
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colonies. Resistant colonies appeared with NR698 as for MG1655 and 4 of them were collected 
and stored as glycerol stocks. The resistance to MccB17 was confirmed by halo assays with 
MccB17 on LB-amp agar plates inoculated with the collected colonies. 
7.3 Evaluation of microcin B17 MIC on NR698 
MccB17 MIC on NR698 was estimated using an LB-agar slope plates with a gradient of 
MccB17. Slope plates at 5, 2, 1 µM MccB17 where used and lead to the estimated MIC 
MccB17NR698= 0.33 µM and MccB17MG1655= 0.6 µM. These results confirmed the greater 
sensitivity of the permeable strain compared to the wild type and allow us to proceed further 
with the isolation of resistant mutants.  
7.4 Selection of resistant colonies 
Resistant colonies were gathered from an LB-agar plate containing MccB17 inoculated 
with 2 X 109 cells grown overnight in LB. Concentrations up to 2.5 µM of MccB17 (MIC X7.5) 
were used in order to obtain an appropriate number of resistant colonies Around 5000 
colonies were present out of 2X109 cells introduced on the plate initially, giving a frequency of 
one resistant colonies per 4X105 cells. 16 colonies were collected across the plate. Their 
resistance was validated on a “slope plate” containing 0 to 1 µM MccB17.  
7.5 Sequencing of gyrA and gyrB genes of resistant colonies 
To determine if mutations mapped to the gyrA or gyrB genes, a “colony PCR” of the 
resistant colonies was performed. The size of the amplicons was verified by running samples on 
1% agarose gel before submission to sequencing. The resistance to MccB17 could not be 
related to any mutation of the gyrA or gyrB genes.   
7.6 Investigation of resistance mechanism 
As none of the 20 mutants isolated had shown mutation on gyrase we decided to 
investigate further the source of this resistance. 
7.6.1 Loss of permeability  
One of the possibilities that arose to explain these resistances is that the strain had 
reverted to a non-permeable type. In order to discard this eventuality, the sensitivity of the 
resistant strains to bile salts and to vancomycin was evaluated. NR698 have been reported to 
be sensitive to both compounds whereas wild type strain is not. Each mutant was streaked on 
two types of agar plates: MacConkey (bile salts) and LB-Vancomycin (2 µg/ml) and compared 
with MG1655. No mutant colonies grew on either plate during overnight incubation at 37°C 
whereas MG1655 did. This confirms that the resistant strains isolated are still permeable as 
they are still susceptible to these two environments. 
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7.6.2 SbmA alteration 
SbmA impairment has been reported to be the most common source of resistance to 
MccB17. Our strategy that is improving the intake of MccB17 through the outer membrane still 
leaves the possibility for this inner membrane transporter to affect resistance to MccB17. 
SbmA is also involved in the uptake of bleomycin (Yorgey, Lee et al. 1994); in order to check if 
the transporter activity had been modified the sensitivity of the MccB17-resistant mutants to 
bleomycin was assessed. The various mutants were streaked on an LB-plate containing 1 µg/ml 
bleomycin. Unfortunately all the mutants were resistant to bleomycin, this strongly suggest 
that SbmA inactivation is the source of resistance in our isolated resistant strains. Sequencing 
of the sbmA gene should provide evidence for this hypothesis. 
 
7.7 Conclusion 
Isolation of strains that gain resistance to MccB17 through mutation in gyrase has proved 
unsuccessful, mainly because of the underestimation of SbmA alteration occurrence and its 
influence on resistance in our strategy. Enlightened by this fact we can now define a new 
process to address this issue. In this study bleomycin was used to implicate SbmA involvement 
in resistance to MccB17; following this idea, resistance to bleomycin can be used as a criterion 
to discard mutants unlikely to carry a mutation on gyrase. Basically if a mutant is resistant to 
MccB17 because of impairment in SbmA it should be also resistant to bleomycin, by using 
replica plating it will be possible to select only the strains that are resistant to MccB17 and still 
Figure 83 Resistance to bleomycin of MccB17-resistant NR698 mutants: slope plate with a gradient of 0 to 1 µg/ml of 
bleomycin (blue arrows). The black arrows represent the non-permeable strain (MG1655), the green arrows 
represent the wild type permeable strain (NR698), and the others are the isolated MccB17-resistant NR698. Wild type 
NR698 did not grow whereas the MccB17-resistant mutant did grow at a concentration of bleomycin ~0.3 µg/ml. 
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sensitive to bleomycin thus improving the chance of isolating a gyrase mutant. Another 
possibility is to make sure that SbmA will be expressed in the strain by adding a high-copy 
plasmid carrying the wild type SbmA gene; this is an approach similar to what was done to 
isolate the W751K mutant (Vizan, Hernandez-Chico et al. 1991), but it will be applied on the 
permeable strain cumulating the advantage of an increased intake both through the outer and 
inner membranes. 
8 Structural studies: crystallography trial 
The primary structure of MccB17 is well known, but no information has been reported 
about its secondary structure. A way to address a better understanding of MccB17 spatial 
structure is through X-ray crystallography. 
A solution of 1 mg/ml of MccB17 in water with 3% DMSO was used in three common 
crystallisation trials: Classics, JCSG and PACT. Pictures were taken every day for seven days and 
once a week for two more weeks. No positive results were obtained but some small crystal like 
structures were observed. The table below describes the results of these trials. 
Table 2 crystallography screening 
Screen Hit Type Conditions 
Classic C4 Crystal-like structure 5 M lithium sulphate; 0.1 M NaHEPES; pH=7.5  
JCSG D5 Crystal-like structure 10% w/v PEG 1000; 10% PEG 8000. 
  D7 Crystal-like structure 
0.2 M lithium sulphate; 0.1 M Tris pH=8.5;  
1.260 M ammonium sulphate 
  G7 Heavy precipitate 
0.2 M zinc acetate; 0.1 M sodium cacodylate;  
pH=6.5; 10% w/v 2-propanol 
PACT D7 Needles 
0.2 M potassium thiocyanate; 20% w/v PEG 
3350 
 
A round of optimisation was carried out using the C4 and D7 conditions: C4 optimisation 
trial was performed using concentration of lithium sulphate ranging from 1.3 M to 1.8 Min 100 
mM HEPES pH = 7.5. D7 optimisation involved varying the KSCN or the PEG concentrations: 
variation of KSCN ranging from 100 µM to 300 µM, with 50% PEG 3350 were used for the first 
optimisation. The second conditions involved variation of PEG 3350 from 30% to 55%, with 200 
µM lithium sulphate. None of the optimisation condition tested yielded crystals. 
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9  Modified Microcin B17. 
9.1 Chemical conversion of Asn/Gln to Asp/Glu 
Incubation at mild alkaline pH converts MccB17 amide residues to acids residue, as 
reported by Parks et al (Parks, Bottrill et al. 2007); only the two asparagines, Asn53 and Asn59, 
out of three potential residues were modified during the process leaving Gln44 unchanged. 
One of the aims of this study is to evaluate if smaller fragments of MccB17 can be 
topoisomerase inhibitors so this modified MccB17 appeared to be a good template to use with 
endoprotease like endo. Glu-C. This protease will cut specifically after the Asp site potentially 
allowing us to generate fragment in a controlled manner. It was an opportunity as well to 
investigate further the properties of this modified MccB17: it has been reported to be unable 
to stabilize cleavage complex (Parks, Bottrill et al. 2007), but the effect of this compound on 
gyrase supercoiling and relaxation reactions have not been probed.  
9.1.1 Production of the modified MccB17: MccB17(N23D,N27D) 
The modified MccB17 was produced by incubating 12 mg of MccB17 in 500 ml of 100 
mM sodium carbonate buffer pH=10 containing 1% DMSO at 37°C for 24 h. 1 mg of MccB17 in 
100 ml MQ left for 24 h at 37°C was used as a control (Parks, Bottrill et al. 2007). The 
conversion of the two Asn residues was validated by MALDI-ToF MS, the main peak observed 
was m/z = 3096.17 which is an increase of two Da compared to WT MccB17, this corroborates 
the conversion of two amide residues. Fragmentation of the main peak with MALDI-ToF was in 
agreement with the conversion of the two Asn residues to Asp as described by Parks et al 
(Parks, Bottrill et al. 2007). The mixture was purified further by HPLC with the same conditions 
used with MccB17. 
9.1.2 Evaluation of inhibitory activity: 
Our first aim was to evaluate if the change of the asparagine residues to aspartic acid 
was not only removing the capacity to stabilize cleavage complex, but the inhibitory activity on 
supercoiling and relaxation. The MccB17(N53D,N59D) was compared to MccB17 on 
supercoiling and relaxation assays as described above. As MccB17(N53D,N59D) seems to had 
lost only the cleavage complex stabilizer feature of the native MccB17 we decided to 
incorporate it in the assays performed on other topoisomerases. No inhibitory activity was 
observed with Staphylococcus aureus gyrase at 100 µM, however the modified MccB17 was 
able to inhibit human topo II relaxation at this concentration. All assays are summarized in 
Figure 84. 
9.1.3 Proteolysis  
The cleavage of MccB17(N53D,N59D) by endoprotease will be developed in Chapter III 
as this chapter will describe extensively the evaluation of MccB17 fragments. 
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9.2 Evaluation of the importance of C and N terminal residues of 
MccB17 
From previous studies it has been shown that the heterocycles in MccB17 are key 
features for its activity and that their structure is optimised for their purpose. Less is known 
about the other amino acids surrounding them. Alteration of the polyglycine chain in the C-
terminal part of MccB17 has been shown to affect maturation of MccB17. The polyglycine 
appears to be a spacer necessary for MccB17 synthetase to mature MccB17 (Roy, Belshaw et 
al. 1998). Considering that fact, it is legitimate to wonder: from the residues upstream to the 
first heterocycle, which are required for MccB17 activity and which are only present for 
MccB17 maturation? From there it is straightforward to consider the other end of the 
molecule: are the N-terminal residues important for activity or are they there for other reasons 
linked to MccB17 production or transport? We will describe here how we have addressed 
these questions, at first by using exoproteases that allow us to generate mixtures of species 
Figure 84 Evaluation of MccB17(N53D,N59D): top left; supercoiling assay of MccB17(N53D,N59D) noted as 
MccB17(Asp)2, that display a complete inhibition of the reaction at 100 µM. Top right, cleavage assay with 
gyrase, a very weak cleavage band is present (in the middle). Bottom left, relaxation assay, 
MccB17(N53D,N59D) shows an inhibition of relaxation similar to MccB17. Bottom right, relaxation assays 
with human topo II, MccB17(N53D,N59D) shows an inhibitory activity similar to the etoposide control at 
the same concentration. 
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lacking a few terminal residues that can be screened for inhibitory activity and second using 
mutagenesis to generate several single mutants lacking a precise number of residues. 
9.2.1 Enzymatic digestion by exoprotease 
9.2.1.1 N-terminal digest: MccNexo  
The digestion of the N-terminal end of MccB17 was carried out by using leucine 
aminopeptidase in the following conditions: to 300 µM of MccB17 in a 50 mM sodium 
phosphate buffer with 10% DMSO solution was added 0.1 unit of Leu-aminopeptidase, the 
mixture was incubated for 6 h 30 min at 37°C. The mixture was loaded on an Oasis™ (Waters) 
reverse-phase cartridge equilibrated with acetonitrile and water, eluted subsequently with H2O 
and 50% CH3CN/H2O. The last fraction was collected, freeze-dried and redissolved at 1 mM 
concentration in 33% DMSO/H2O solution for further analysis. 
9.2.1.2 C-terminal digest: MccCexo 
Carboxypeptidase A was used to digest the C-terminal end of MccB17: 3.5 units of 
carboxypeptidase A were added to a solution containing 300 µM MccB17, 25 mM Tris.HCl 
buffer pH = 7.5, 10% DMSO. The solution was then incubated for 6 h 30 at 25°C. The mixture 
was then loaded onto an Oasis™ (Waters) reverse-phase cartridge equilibrated with 
acetonitrile and water, eluted subsequently with H2O and 50% CH3CN/H2O.The last fraction 
was collected, freeze dried and redissolved at 1 mM in 33% DMSO/H2O solution for further 
analysis. 
9.2.1.3 MS analysis: 9.2.1.3.1 MccNexo:  
At first glance the spectra show that the proteolysis reaction had not worked, the main 
peaks are m/z = 3094.1, the starting material and m/z = 1394, a degradation product of 
MccB17, and none of the species corresponding to MccB17\(n)N-terminal residues are to be 
seen. In section 3) of this chapter we have described how some fragments of MccB17 are 
generated in experimental conditions including MW=1393. We described as well that usually 
this fragment comes with its complementary sequence with MW=1701. An interesting 
observation is that this fragment is not present at all, even as a trace. It is likely that this 
fragment had been degraded by the Leu-aminopeptidase to generate the following fragments 
than can be observed on the spectra: m/z = 1432 (1701\VGI), m/z = 1376 (1701\VGIG), and 
particularly m/z = 919 which correspond to the fragment 1701 minus all the residues preceding 
the oztz. This experiment didn’t allow us to isolate MccB17 lacking amino acids on the C-
terminal end that we expected. It appears that the enzyme was not able to digest native 
MccB17, although it was active in the conditions used, as fragments of MccB17 seem to have 
been processed. This puts a highlight again on the MccB17 spatial structure: was the enzyme 
not able to access the N-terminal end of the toxin due to its folding, or had the enzyme a 
better affinity for MccB17 fragments? If the second hypothesis is true, we should be able to 
access the products we seek by digesting MccB17 for a longer time in conditions limiting its 
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degradation. If the first hypothesis is true it will prove difficult to change the conditions in 
order to alter the structure of MccB17 while keeping the enzyme active. This investigation was 
not pushed forward as we got some of the answers we were seeking by other approaches that 
will be described in the next chapter. 
 
 9.2.1.3.2 MccCexo: 
The spectra shows beyond any doubt that the digest had been successful, the main 
product observed is MccB17\Ile, other species MccB17\HI (~30% intensity of main peak), 
MccB17\GHI and some residual native MccB17 (~15% int.) are also present.  
Figure 85 MALDI-ToF spectra of MccNexo:  
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9.2.1.4 Evaluation of the inhibitory activity of the exoprotease digests 
Both mixtures were evaluated for inhibitory activity before their content was known. 
MccNexo and MccCexo were assayed at 100 µM final concentration in the standard 
supercoiling reaction conditions. We can see a weak inhibition by MccNexo which was 
probably due to the MccB17 present in this mixture. MccCexo didn’t show any inhibitory 
activity. This is very interesting because the main component of this mixture was the MccB17 
lacking only one amino acid: the C-terminal Isoleucine. This was strong evidence that 
modification of the C-terminal end of the molecule is very detrimental to MccB17. The 
possibility remains that the conditions we have used to produce this modified MccB17 have 
altered it folding thus disrupting its activity. In order to validate our assertion that MccB17 C-
terminal amino acids are key to its inhibitory activity, we decided to produce this shortened 
MccB17 by mutating the mcbA gene and using the standard MccB17 production method 
described earlier in this chapter. We will describe now the method used to produce shortened 
MccB17 by mutagenesis. 
 
Figure 86 MALDI-ToF spectra of MccCexo 
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9.2.2 Mutagenesis of MccB17 
Using carboxypeptidase was a quick way to screen the effect of C-terminal amino acid 
removal on MccB17 inhibitory activity, but it carries inherent limitations: first only mixtures of 
shortened MccB17 can be obtained and second, if the toxin needs to be folded during its 
production to be active, there is no certainty that in the proteolysis conditions used this folding 
was not altered. These limitations can be circumvented by using a mutagenesis approach: by 
replacing the codon of a given amino acid in mcbA by a stop codon and expressing the toxin in 
E. coli as for the WT we should be able to harvest a MccB17 where the modified and all 
subsequent amino acids are missing. The modifications introduced, as they are taking place at 
the end of the peptide, should not alter the processing and export of the toxin. 
Species lacking N-terminal residues can be obtained by a slightly different strategy: a 
lysine residue can be introduced by replacing the codon of one amino acid in the N-terminal 
region by the Lys codon. The mutated toxin can be produced and isolated as usual leading to a 
MccB17 carrying a Lys. A tryptic digest should cleave the peptide after the Lys residue leading 
to a MccB17 where all amino acids preceding the Lys have been removed. This strategy is more 
uncertain, we know that the polyglycine is important for the processing of the enzyme (Roy, 
Belshaw et al. 1998) and the modification is likely to hinder the processing of the heterocycles, 
and this will probably be more true the farther from the N-terminal end the Lys residue will be. 
Additionally, the consequences on MccB17 conformation and export, or on the immunity of 
the host cell, of this Lys introduction, are unknown. 
9.2.2.1 Extraction of pmccb17 
The template pUC19-mccB17 was prepared from the DH5α strain used for MccB17 
production described at the beginning of this chapter. The plasmid was extracted from a 5 
ml overnight culture of DH5α-pUC19-mccB17 in LB-Amp (1 mg/ml) with a QIAprep® 
Miniprep kit (Qiagen) following the supplier’s protocol. The size of the plasmid was 
checked by running a sample digested by EcoRI on a 1% agarose gel. 
9.2.2.2 Mutagenesis of the mcbA gene 
The mcbA gene was mutated by PCR using primers carrying the desired 
modification. The PCR was carried out in a 50 µl reaction mixture containing 200 µM dNTP, 
60 ng of pUC19-mccB17, 10 µM “forward” primer, 10 µM “reverse” primer, 2.5 U of Pfu 
Turbo® DNA polymerase in 1X Pfu supplier buffer. The PCR program and primers are 
described in the Table 1. The amplified mixtures were digested by Dpn1 in order to remove 
the wild type pUC19-mccB17 template as follows: to 25 µl of the previous PCR reaction, 5 
µl of NEBuffer nº4 (10X), 1 µl DpnI (20U) and 18 µl water were added, the mixture was 
incubated for 3 h at 37°C, then 1 µl DpnI (20U) was added and the mixture incubated 
overnight at 37°C. The resulting solution was used for the transformation. 
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9.2.2.3 Transformation of DH5α cells 
MAX efficiency DH5α competent cells were used for the transformation, 2.3 µl of the DpnI-
treated PCR solution were added to 50 µl of competent cell commercial suspension, the 
mixture was left 20 min on ice before being heat shocked for 2 min at 42°C. 500 µl of LB 
was added to the mixture back on ice, and the cells were allowed to grow for 1 h at 37°C 
before being centrifuged at 3000 rpm for 1 min. The supernatant was tipped off and the 
cells carefully resuspended in the remaining supernatant (~20 µl) and used to inoculate an 
LB-Amp-agar plate (0.1 mg/ml). The agar plate was incubated overnight at 37°C. Up to 3 
surviving colonies were gathered and grown overnight in 10 ml LB-Amp (0.1 mg/ml), the 
suspension was used for further sequencing and storage of a glycerol stock.  
9.2.2.4 Sequencing of the mcbA gene in transformed colonies 
The pUC19 plasmid was extracted from 5 ml overnight culture of the transformed colonies 
with a QIAprep® Miniprep kit (Qiagen). Standard 17mer M13 forward primer was used to 
sequence the mcbA gene as a M13 site is present upstream of the mcbA gene. Four 
mutants were successfully isolated G30K, S67Stop, H68Stop, I69Stop. 
9.2.2.5 Production of modified MccB17 
All the mutant MccB17 were produced following the same protocol as for WT MccB17 
leading to the following yields per litre of M63 glucose media: MccB17(G30K) = 0.075 mg/l, 
MccB17(S67Stop) = 2.6 mg/l, MccB17(H68Stop) = 4.2 mg/ml, MccB17(I69Stop) = 2.4 mg/l. As 
expected the yield for the Lys mutant is very low, but the other mutants are in the range of 
usual wild type yield ~6 mg/L. 
Table 3 Primers used for site-directed mutagenesis of MccB17: two types of primers are described, the G(x)toK 
series correspond to the modification of the glycine(x) from the N-terminus of MccB17 to a Lysine, the G-, S-, H-
, ItoStop correspond to the introduction of a STOP codon instead of the designed residue from the C-terminus 
of MccB17. The numbers in green squares are the primers that have lead to the expected mutant. 
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9.2.2.6 Tryptic digest of MccB17(G30K) 
Cleavage of the Lys-Gly bond was performed by incubating a mixture containing 6 µM 
of MccB17(G30K), 20 µg/ml trypsin, 1% DMSO in supplied trypsin buffer for 2 h at 37°C. The 
mixture was left for 5 min at 100°C to inactivate the trypsin. The sample was submitted to 
MALDI-ToF analysis and the successful cleavage was confirmed by the presence of the main 
peak m/z = 2767.83 Da corresponding to the hydrogen adduct of the expected MccB17 minus 
the N-term VGIG. The very weak peak of m/z = 3164.99 Da corresponding to the starting 
material MccB17(G30K) shows that the reaction was virtually complete. 
 
9.2.2.7 Shortened-MccB17 activity on gyrase 
The four mutants were evaluated for activity on gyrase. Both inhibition of supercoiling 
and stabilisation of cleavage complex were evaluated using the standard assays. A moderate 
inhibition of the supercoiling reaction had been observed at 200 μM (4 X MccB17 IC in our 
assays) for the MccB17 derivatives with C-terminal modifications. By comparison the MccB17 
derivative lacking VGIG from the N-terminus completely inhibits the reaction at 50 μM. 
MccB17 derivatives with C-terminal alterations show a definite loss of their ability to stabilize 
cleavage complex: at 100 μM, a moderate cleavage band appears with Mcc\I69, and none is 
visible for the two others; whereas for Mcc\VGIG at 50 μM, a cleavage band slightly weaker 
Figure 87 MALDI-ToF spectra of MccB17(G30K) tryptic digest product. 
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than the MccB17 control is observed. The assays show that the Mcc\VGIG is able to inhibit 
gyrase supercoiling and stabilise cleavage complex efficiently in the same range as MccB17. 
 
 
 
9.2.2.8 Comments 
The assays show that the N-terminus-modified MccB17 is able to inhibit gyrase 
supercoiling and stabilise cleavage complex efficiently in the same range as MccB17, whereas 
any alteration on the other end of the molecule significantly reduces the activity. This evidence 
leads toward a polar model of the toxin where the C-terminal part of the molecule is critical for 
activity on gyrase when the N-terminal part is more involved in the biosynthetic process. The 
main question remaining is how many amino acids can be removed from the N-terminus 
without losing the toxic properties? Considering the C-terminus, we know that removing the 
Figure 88 Evaluation of shortened version of MccB17: top gel, gyrase supercoiling assays of MccB17 derivatives 
lacking 3, 2, or 1 residue from the C-terminus, or 4 residues on the N-terminus Mcc\VGIG. A weak inhibitory 
activity is observed at 200 μM for the C-terminus-modified MccB17, whereas Mcc\VGIG had the same activity 
as what is expected from native MccB17 (strong activity at 50 μM). Bottom gel, gyrase cleavage assays of the 
MccB17 derivative lacking 3, 2, or 1 residue from the C-terminus, the band in the middle correspond to the 
linear DNA, a clear decrease of this band visible as amino acids are removed from the C-terminus, showing the 
loss of stabilisation of cleavage complex ability by these compounds. For Mcc\VGIG the activity is similar to 
native MccB17. 
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end Ile is detrimental to the activity, but what about replacing it by other amino acids? 
Following the same strategy it will be valuable to generate mutation of this residue with non-
polar amino acids like Leucine or Valine. 
10 Conclusion 
This chapter began with the covering a range of experimental tools that are used to obtain 
and characterize MccB17. From this starting point we have shown how these tools could be 
exploited to generate new species, compared them to MccB17 and finally understand more 
about the toxin itself. Improving our understanding of MccB17 mechanism through the 
generation of resistant mutants has proved unsuccessful, but a better insight in the 
development of resistance to MccB17 has led us to develop strategies more likely to bring this 
approach forward.  By altering the N- and C-terminal amino acids of MccB17 we have learned 
that the toxin has a “polar” nature: an N-terminal domain involved in its biosynthesis, and a C-
terminal domain critical for its activity on gyrase. Modification of this N-terminal domain 
should be the starting point to generate lower molecular weight gyrase inhibitors derived from 
MccB17. The best approach will be to remove step by step amino acids from the N-terminus 
until activity is lost, we will have then reached the core of the MccB17 activity. The C-terminal 
isoleucine is another aspect that should be investigated, is this specific amino acid required or 
can it be replaced by any lipophilic residue without altering the activity? The inhibitory activity 
observed with MccB17 on human topo II opens the possibility of generating derivatives of 
MccB17 for this purpose. The fact that the toxin is inhibiting targets other than E. coli gyrase 
confirms the relevance of extending the study of MccB17 and derived compounds to other 
topoisomerases. We have described here that we can shorten the MccB17 molecule while 
keeping the inhibitory activity on gyrase and ability to stabilise the cleavage complex, in the 
next chapter we will bring this approach a step further by assaying the possibility that smaller 
fragments of MccB17 can still retain these characteristics. 
  
111 
 
      CHAPTER III Generation and evaluation of microcin B17 fragments 
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 CHAPTER III Generation and evaluation of microcin B17 fragments 
Despite its formidable antibacterial mechanism as one of the few non-quinolone 
stabilisers of the gyrase-DNA cleavage complex, MccB17 by itself is a poor drug. When 
considering the whole molecule it is important to remember that this structure is not only 
shaped by its antibacterial properties but also by the various enzymatic processes leading to its 
maturation, the necessity of its export, and evolutionary limitations. In order to identify the 
molecular features responsible for the antibacterial properties of MccB17, fragments of the 
toxin were generated and their activity assayed. The following paragraphs will describe two 
different approaches: chemical and enzymatic, that have been used to generate such 
fragments. Finally fragments spontaneously generated during MccB17 preparation will be 
discussed as they are kin to the fragments we are aiming to generate and isolate. 
1 Alkaline hydrolysis  
Preliminary results from previous work have shown that alkaline hydrolysis of MccB17 
leads to a mixture of compounds that shows inhibitory activity on gyrase (Coquin 2005). 
Further investigation of the chemical cleavage of MccB17 will be described here as well as the 
various treatments used to separate the products generated. 
1.1 Reported preliminary results  
(Coquin 2005) 
Hydrolysis carried out over seven days at 110°C with two different concentration of 
sodium hydroxide has been reported previously, respectively using two equivalents and ten 
equivalents of sodium hydroxide per peptide bond.  
The use of a small excess of alkaline agent led to partial hydrolysis, the remaining 
fragment of MccB17 observed corresponds to the final degradation of the polyglycine from 
G6oztzGGQGGGtzGtz to oztzGGQGtzGtz, a small amount of MW= 1700 can still be observed. 
The fact that the MW= 1701 fragment was the last large fragment to disappear, and that the 
main remaining fragments are the core fragment oztzGGQGtzGtz and its derivatives with 
various number of extra glycine, tend to prove that oztzGGQGtzGtz is the most stable part of 
MccB17, at least in alkaline conditions. This interesting observation makes one wonder if this 
resilience to alkaline condition is due to the chemical stability of the fragment or due to 
secondary structure. It would have been valuable to have information about the inhibitory 
activity of these fragments, but unfortunately none have been reported.  
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A higher excess of sodium hydroxide leads to complete destruction of MccB17 where only 
low molecular weight compounds can be observed, they correspond to tz, oz, tzoz or oztz, 
tzozG or oztz+G, and Dtzoz. Inhibition of supercoiling was observed with this hydrolysis 
mixture at 33 µM. The formulated hypothesis was that small molecules related to the 
heterocycles contained in MccB17 were responsible for the activity observed. As these results 
were preliminary and study of single MccB17 heterocyclic amino acids described in Chapter IV 
did not show strong inhibitory activity, the hydrolysis experiment was repeated with the 
purpose of first validating these observations and possibly identifying the novel compound(s) 
responsible for the activity in the mixture. 
1.2 Validation of preliminary results 
1.2.1 Hydrolysis reaction 
The cleavage of the toxin was achieved by the action of ten equivalent/peptide bond of 
sodium hydroxide in water with 50% DMSO on 0.45 mM MccB17.  The mixture was stirred at 
120°C for seven days, afterwards the reaction mixture was neutralized with a hydrochloride 
solution 1 M before being freeze fried. The solid residue was triturated with a mixture of 10% 
methanol in ethyl acetate, the solution was filtered, evaporated and the residue was 
solubilised in DMSO in order to evaluate its effect on the E. coli gyrase supercoiling reaction. 
1.2.2  Evaluation of inhibitory activity on gyrase 
The solution used for this assay results from 7 mg of initial MccB17 that have been 
hydrolysed and gathered by trituration of the dry reaction mixture with 1 ml DMSO. As the real 
content of the mixture is unknown, the concentration will be given in equivalents of initial 
MccB17. The influence of the mixture on the three different reactions involving gyrase has 
been tested: supercoiling, relaxation and cleavage. The inhibitory activity on the supercoiling 
reaction of the gyrase resistant to MccB17 was tested as well. 
The mixture of compounds resulting from the alkaline hydrolysis shows a strong 
inhibitory activity on supercoiling and relaxation by gyrase. No stabilisation of the cleavage 
complex could be observed and the gyrase A2B(W751R)2 is susceptible to inhibition by the 
hydrolysate. This suggests that the active compound of this mixture is acting by a different 
mechanism than MccB17. Having validated the potency of the alkaline digest, the next step 
was to identify the active component of this mixture. 
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1.3 Identification of active fragments 
1.3.1 HPLC-MS analysis of hydrolysis mixture 
The mixture was analysed on a 250x2 mm, 4 µ Polar RP column (reverse phase, pi-pi 
aromatic specificity) with a methanol gradient in water from 2 to 80%. Unfortunately the 
results showed mainly signals corresponding to very hydrophobic compounds that are very 
unlikely to be related to MccB17 and only a weak signal corresponding to oz+G, tzozG or 
oztz+G, and to the single heterocyclic amino acid could be observed. It is possible that the 
compounds we were looking for were present in too low amounts to be identified, as the 
trituration of the solid residue is probably not a very efficient extraction method considering 
the large amount of sodium chloride present. The hydrolysis was repeated in an increased 
scale in order to introduce liquid phase separation steps.  
Figure 89 Evaluation of MccB17 alkaline hydrolysate activity on E. coli gyrase: the strong inhibitory effect of the 
MccB17 alkaline hydrolysate mixture on gyrase supercoiling (top left) and relaxation (top right); as well as on 
MccB17-resistant gyrase supercoiling (bottom right) is shown. The inability of the mixture to stabilise gyrase-DNA 
cleavage complex (bottom left) is also displayed. The ciprofloxacin control (CFX) is at 15 µM concentration. 
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1.3.2 Separation methods 
The treatment of MccB17 alkaline hydrolysis product has been improved over several 
experiments. We had to take in account that the species we are looking for can spread over a 
wide range of lipophilicity. Preparation of MccB17 described in Chapter II involved a 
preliminary purification step with a Sep-Pak® reverse phase column eluted with acetonitrile 
and water, first with 12% CH3CN/H2O to remove contaminants, then with 50% CH3CN/H2O to 
collect the MccB17 species. We considered using a similar method to fractionate the hydrolysis 
mixture; this way the sample will be desalted in the process and the fraction generated will be 
a less complex mixture, these two improvements should facilitate subsequent analysis. The 
logical next improvement was to use a gradient of acetonitrile to fractionate the mixture and 
identify which ones display inhibitory activity, and finally the refinement of this approach was 
to use a gradient of acetonitrile in water but on a preparative HPLC column. Each method was 
developed on a different batch of hydrolysate. The different purification methods will be 
described below, as well as the assays performed on the isolates from each methods, which 
consist of standard gyrase supercoiling assays as described in Materials & Methods. The results 
of the mass spectrometry analysis for all the techniques will be summarized in the final section. 
1.3.2.1 MccB17 purification method  
The dry hydrolysate residue was extracted with AcOEt/MeOH 9/1 as before. The organic 
extract was concentrated under vacuum and redissolved in DMSO for assays. The remaining 
solid was triturated with ethanol before being resuspended in water with 10% DMSO and 
filtered. The ethanol extract, after being concentrated, and the filtrate were kept for further 
analysis. The filtrate was purified on a Sep-pak® column following the standard MccB17 
purification protocol described in Chapter II: both 12% and 50% fractions were collected, 
named respectively hyd2_12% and hyd2_50%, concentrated under vacuum, freeze dried, and 
redissolved in DMSO for the assays. 
 
 
Figure 90 Supercoiling assays of the fractions from MccB17 alkaline hydrolysate: the activity of the fractions obtained 
from MccB17 alkaline hydrolysis is shown here, the extract from the initial solid residue with EtOH (EtOH extract), and 
the fraction separated on a sep-pak® with 12% or 50% CH3CN in H2O. The 50% CH3CN fraction has a strong inhibitory 
activity, and the ethanol extract has a moderate inhibitory activity. 
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Two fractions having inhibitory properties with gyrase supercoiling, were isolated: the first 
was the ethanol extract from the dried reaction mixture, the second the 50% 
acetonitrile/water elution fraction from the sep-pak® column purification. Analysis of this last 
fraction shows that it contains species with MW around 1000 Da, this led us to further 
investigate separation on the reverse phase column as a method to isolate medium sized 
fragment of MccB17 with inhibitory activity. 
1.3.2.2 Reverse phase column eluted with a gradient of acetonitrile in water 
The hydrolysate after neutralization was directly loaded onto a Sep-Pak® column 
equilibrated with acetonitrile and water. The column was eluted with steps of 10% acetonitrile 
in water with 0.1% TFA from 0 to 90%, each fraction was collected, concentrated under 
vacuum and freeze dried. The solid residues were redissolved in DMSO in order to assay the 
activity on gyrase. 
 
 
 
The separation was not very efficient as compounds were found in multiple fractions, but 
inhibitory activity was observed in the fractions 40, 50, 60, and 90%. The resort to an HPLC 
approach was a way of improving the separation while keeping track of what was eluting 
through the column.   
1.3.2.3 HPLC with a gradient of acetonitrile in water 
As the Sep-pak® column purification did not prove sufficient to isolate the active 
components of the mixture, we relied on the HPLC method to achieve this. HPLC has two 
advantages over the Sep-Pak® column: the resolution of HPLC column is far better, and the UV 
Figure 91 Activity of MccB17 alkaline hydrolysis fraction isolated from an acetonitrile gradient on a reverse 
phase column: this is the validation assay of the active fraction isolated from the separation by an acetonitrile 
gradient on a Sep-Pak® column. Only weak inhibition by MccB17 can be observed, however, ciprofloxacin (17 
µM) show a strong inhibition as well as the hydrolysate fractions.  
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absorbance can be followed during the elution. Following the UV absorbance is particularly 
advantageous as the active compounds are likely to carry heterocyclic moieties that are 
absorbing, specifically at 254 nm. The purification was performed on a Dionex Ultimate 3000 
HPLC system with a preparative reverse phase column ACE 5 C18-300 250x21.2mm (ACE-221-
2520). The elution system was acetonitrile in water with 0.1% TFA with a 4.5 ml/min flow. A 
gradient of 2% CH3CN/min from 0 to 80% allows a rough separation of different fractions that 
would have been followed by a second run specifically adapted to the acetonitrile gradient 
elution window of each fraction. Unfortunately for technical reasons this experiment was not 
completed, and as other approaches gave promising results, this strategy was abandoned. 
1.3.2.4 Results 
Over the several experiments that have been conducted inhibitory activity has been 
consistently observed in the hydrolysis mixtures, and in some fractions, confirming that in 
alkaline conditions molecules with inhibitory properties on gyrase can be generated. Table 4 
summarize the different the species observed with the various separation methods. 
 
 
Over the different experiments the heterocyclic amino acids contained in MccB17 have 
been consistently observed as single molecules or linked with a glycine residue; the evaluation 
of the heterocyclic amino acids is described in Chapter IV which will cover MccB17-related 
small molecules. Another set of species that was always present was the fragments with MW = 
Table 4 Summary of the species observed in the various active fractions isolated from MccB17 alkaline hydrolysate 
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856 and MW = 857 Da, but they correspond probably to respectively VGIG9NHCH2CONH2 and 
VGIG9NHCH2COOH, molecules that have been found as inactive MccB17 by-products. 
Unfortunately the data gathered did not lead to the identification of the active compound as 
no specific species were consistently observed in the active fractions. Part of the difficulty 
came from the fact that, in the harsh conditions being used, a wide variety of reactions can 
occur thus producing a very complex and variable system. Another issue was that molecules 
with molecular weights comprised between 75 and 3093 Da are potentially generated so we 
had to cross ESI and MALDI-ToF mass spectrometry analysis to cover this range. The 
compounds studied, similar to MccB17, showed different ionisation behaviour depending on 
the MS technique used for the analysis and led to different results for the same sample 
depending on the technique. Finally, technical issues with our HPLC column prevented us from 
completing our study on HPLC separation of the hydrolysis products. This strategy was not 
pushed forward for two reasons: first the MccB17 heterocyclic amino acids that are described 
in Chapter IV, have all displayed levels of activity around 400 µM apart from oxazole that 
shows none. This level of activity can’t explain the strong inhibition observed, however it is 
possible that an additional glycine to one or multiple heterocyclic amino acids, increases the 
overall activity, but this seems unlikely to us. Therefore these derivatives have not been 
evaluated further, even if they might worth further studying. The second point was that the 
mixture generated, contrary to what had been reported in the preliminary study, did not 
stabilise the DNA-gyrase cleavage complex, which is the major feature of MccB17 we are 
interested in. Taking this into account, this strategy was abandoned in favour of a more 
selective way of cleaving MccB17 that gave promising preliminary results. This approach, 
involving enzymatic digestion, will be described in the following section. 
2 Cleavage with endoprotease: 
  A good way to selectively cleave a peptide is to use an endoprotease that will cut the 
peptide bond specifically before or after a particular residue defined by the enzyme type. 
MccB17 aside from its specific heterocyclic moieties, does not possess a large diversity of 
amino acids, it is composed of 20 glycines and 9 other amino acids. With a closer look at the 
sequence of the toxin we can notice that amide residues are nicely distributed in the middle 
part of the molecule and are therefore sites of choice for selective cleavage. Two different 
possibilities have been considered: first the modification of asparagine and glutamine residues 
in MccB17 into their acid counterpart and the subsequent cleavage using endoproteinase Glu-C 
which is able to cut at the carboxyl of aspartic or glutamic acids residues. The second approach 
considered is the digestion of the native MccB17 by subtilisin, a less selective enzyme that will 
cut at the carboxyl of asparagine and glutamine residues but also at lipophilic residues such as 
isoleucine and valine thus generating more fragments in the process. Actually the difference of 
selectivity of the enzymes can be turned to our advantage, making it possible to compare 
activities of closely related fragment from the two enzyme digests. The fragments that can be 
theoretically generated with their respective molecular weight are described in Figure 92.  
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2.1 Proteolysis reactions 
2.1.1 Digestion of MccB17(N53D;N59D) by endoproteinase Glu-C 
The production of MccB17(N53D; N59D) has been described in Chapter II and is 
available in more detail in the Materials & Methods chapter. One equivalent (w/w) of 
endoproteinase Glu-C was added to MccB17(N53D; N59D) in a 100 mM ammonium 
bicarbonate buffer (pH = 7, 10 % DMSO). The mixture was stirred at 37°C for 48 h. The solution 
was loaded on a Strata C18-EC QSPE reverse-phase column equilibrated with 
acetonitrile/water, the column was eluted respectively with water and with 50% CH3CN in 
water, this second fraction was collected, concentrated under vacuum and freeze dried. The 
residue dissolved in DMSO was submitted to MALDI-ToF MS analysis. 
2.1.2 Digestion of native MccB17 by subtilisin 
Subtilisin was added to a solution containing 20 eq. of MccB17 in a 10 mM sodium 
acetate, 5 mM calcium acetate buffer pH = 7.5 with 10% DMSO. The mixture was incubated for 
48 h at 37°C with stirring. The reaction mixture was loaded on a Strata C18-EC QSPE reverse 
phase column equilibrated with acetonitrile/water, the column was eluted first with water and 
Figure 92 Potential cleavage products from MccB17 endoproteolytic digest: the top part of the figure shows the 
sequence of MccB17 with the cleavage site residues in red, predicted fragments from the proteolysis by subtilisin 
are show as coloured boxes with the corresponding MW displayed inside. Colouring is for readability only. The 
bottom part corresponds to the predicted fragment from endoprotease Glu-C proteolysis, using the same display. 
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with 50% CH3CN in water, the last fraction being collected, concentrated under vacuum and 
freeze dried. The residue dissolved in DMSO was and submitted to MS analysis. 
2.2 Analysis of endoproteolytic mixtures 
2.2.1 Endo Glu-C  
The mass spectrometry spectra below (Figure 93) shows that MccB17 has not been 
completely digested by Endo Glu-C; there is still a significant starting material remaining (MW = 
3093). Some expected fragments are present but in a very low proportion as shown in Figure 
93. Fragmentations of the most intense peaks that are observed have shown that they are not 
related to MccB17, they are probably degradation products from the protease. 
 
 
 
Figure 93 MALDI-ToF spectra of the endoprotease Glu-C digest mixture: fragments resulting from endo Glu-C 
cleavage are shown in green, their intensity is very weak. Major fragments not resulting from endo Glu-C 
cleavage are shown in red. 
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2.2.2 Subtilisin 
The MALDI-ToF analysis of the purified fraction reveals that the reaction is complete, as 
the signal from initial MccB17 is negligible. Five of the expected fragments can be identified on 
the spectra: MW = 981; 1106; 1210.5 ; 1632.5; and 1863; however the most intense signal 
observed comes from the MccB17 degradation product Mw = 1393 (Figure 95). The peak at 
923 can result from a loss of a glycine residue by the fragment of Mw = 980. The fragment 
corresponding to these molecular weights are summarized in Figure 96. 
Figure 94 Fragments present in the endo Glu-C digest: the MccB17 sequence is shown in orange with the cleavage 
sites in red. All the potential fragments are shown in the figure as boxes with the corresponding MW written inside, 
the fragments present in the digest are shown in green, whereas the fragments in grey are not present. Only small 
amount of the expected fragments were present in the digest. 
Figure 95 MALDI-ToF spectra of the subtilisin digest mixture: fragments resulting from subtilisin cleavage are shown in 
green. Major fragments not resulting from subtilisin cleavage are shown in red. 
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2.2.3 Evaluation of digests activity on gyrase 
Solutions of the two proteolysis mixtures in DMSO were used to assay the activity on 
gyrase. The mixture obtained from proteolysis with subtilisin showed inhibitory activity on 
supercoiling at a minimal concentration of 33 µM. 
 
 
Figure 96 Fragments present in the subtilisin digest: the MccB17 sequence is shown in orange with the cleavage sites in 
red. All the potential fragments are shown in the figure as boxes with the corresponding MW written inside, the 
fragments present in the digest are shown in green, with the brightness of the colour corresponding to the intensity of 
the peak in the MS spectra. In grey, are the expected fragments that are absent. In yellow are fragments of MccB17 
present in the digest but not resulting from subtilisin cleavage. 
Figure 97 Supercoiling assays of the proteolytic digests of MccB17: the mixtures 
obtained by digesting MccB17 with subtilisin (Subt. digest) and endo Glu-C (endo 
digest) were evaluated for their inhibitory activity on gyrase supercoiling. Only the 
subtilisin digest inhibits the supercoiling reaction. 
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2.2.4 HPLC analysis of the mixture 
The proteolysate was analysed on a Primesphere 5µ/300 Å/4.8 mm X 250 mm 
analytical HPLC column. 0.86 mg of the proteolysis residue was diluted in 200 µl of 10% 
CH3CN/H2O and used as a stock solution. The conditions were optimised to separate the 
components of the mixture using a 1/300 dilution of the stock solution in 5% CH3CN/H2O/0.1% 
TFA. A gradient of 0.66 % acetonitrile/min gave a good resolution of the peaks. A dilution of 
1/30 the stock solution in 5% CH3CN/H2O/0.1% TFA was used for the purification, fractions 
were collected every minute from 10 to 60 min, and concentrated under vacuum. Fractions 
that were evaluated for inhibitory activity on gyrase supercoiling were named A to Q and are 
shown on Figure 98. Unfortunately not enough material was available to assess the activity on 
gyrase. The experiment was repeated on a bigger scale. 
 
Figure 98 Purification of the subtilisin digest of MccB17: the top figure is the trace from the HPLC purification, 
letters A to Q have been associated to each fraction collected. The bottom table shows the MW observed with 
MALDI-ToF MS for each fraction. The MW in red represents fragments expected from subtilisin cleavage. In green 
are fragments related to MccB17 which have been identified, but which are not resulting from cleavage by 
subtilisin. 
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2.3 Identification of the active component of Subtilisin digest 
2.3.1 Scaling up the digest 
As the first results were encouraging, the same 
reaction was planned on a bigger scale in order to 
separate and evaluates the components from the 
mixture. Unfortunately the experimental conditions at 
this stage led to a large amount of precipitate that 
hindered the reaction and reduced dramatically the 
yield. Subtilisin is used as a catalyst in organic solvents, 
it can retain some its activity in such conditions, a 
certain tolerance to DMSO has been reported: at 50% 
DMSO concentration, the enzyme retains half of its protease activity (Flynne 2008). Therefore, 
the DMSO concentration was increased to 50% in order to circumvent this solubility problem. 
2.3.2 Proteolysis in 50% DMSO: MccSub50% 
2.3.2.1 Proteolysis reaction 
MccB17 at 180 µM in a buffer containing 42 mM potassium phosphate, 1.7 mM 
sodium acetate, 0.8 mM calcium acetate and 50% DMSO at pH=7.5. 1.1 mg of subtilisin in the 
same buffer without DMSO was added to the mixture.  The reaction mixture was incubated for 
48 h at 37°C. The sample was diluted 1/5 in water before being loaded on a 20 ml Oasis® HLB 
reverse-phase column equilibrated with 50 ml water and 50 ml acetonitrile. The column was 
eluted with 60 ml water and 75 ml 50% CH3CN/H2O and this last fraction was collected, 
concentrated under vacuum and freeze dried. The residue was diluted in DMSO. The activity of 
the solution was validated using a gyrase supercoiling 
assay, its composition was checked with MALDI-ToF 
MS. 
2.3.2.2 Characterisation of MccSub50% 
The activity of the MccSub50% on gyrase 
supercoiling was assayed using the standard assay 
method, strong inhibitory activity was observed at 
100 µM (equivalent MccB17). 
The MALDI-ToF analysis of the MccSub50% 
shows that the mixtures generated in 10% and 50% 
DMSO are significantly different; Figure 100 show a 
comparison of both spectra with the expected 
fragments highlighted. In the 10% DMSO reaction, the 
most intense peak was the expected fragment Mw = 
1861.5 and nothing was present at a higher molecular 
weight. At 50% DMSO, new fragments corresponding 
Figure 99 Activity of the MccSub50% mixture: the 
inhibitory activity of the mixture resulting from 
the subtilisin digest of MccB17 in a 50% DSMSO 
environment is shown on the gel. Ciprofloxacin 
control (CFX) is at 8 µM concentration. 
Table 5 HPLC program for the purification of 
the subtilisin digest. 
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to Mw = 2767.81 and Mw = 2258.61 appeared as the main fragments, Mw = 1862.5 and 
MccB17 (Mw = 3093.03) were also observed as before, but with a lower intensity. An 
improvement brought by the new conditions is that the level of MccB17 degradation by 
products around 1400 Da had significantly decreased compared to the first experiment where 
they were the strongest peaks. The compounds with Mw = 2767.81; Mw = 2258.61 seems to 
be MccB17 degradation products as they are not resulting from any expected specific cleavage 
by the protease. As the mixture contained MccB17 fragments of interest and displayed 
inhibitory activity on gyrase, we proceeded to the HPLC purification. 
 
 
 
  
Figure 100 Comparison of MccB17 subtilisin digest in presence of 10% and 50% DMSO: Maldi-Tof spectra of MccB17 
subtilisin digest in 10% DMSO (top) and 50% DMSO (bottom) are aligned for comparison. The increase of DMSO 
percentage leads to a decrease of the enzyme activity (reaction not complete, MccB17 present) and the appearance 
of new species unrelated to subtilisin cleavage. However the production of MW=1375, and 1394.5, which do not 
result from subtilisin cleavage is diminished. 
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Table 6 HPLC program for subtilisin digest separation 
 
2.3.2.3 HPLC separation: 
 Mass spectrometry analysis shows that the mixture generated in higher DMSO 
concentration was slightly different from the first experiment and, as a consequence, displayed 
a different HPLC profile. The same HPLC column 
was used with the conditions described in 2.2.4 
modified to improve the profile of the new 
subtilisin digest. A gradient of 0.5% CH3CN/min 
yielded a better resolution and thus was selected 
for the purification; the conditions are detailed in 
Table 6 on the right. As some MccB17 was 
present the sample, a MccB17 control was run 
beforehand to evaluate in which fraction it should 
be expected; Figure 102 shows the HPLC profile of 
the proteolysis mixture as well as MccB17’s for 
comparison. 
 
 
Figure 101 Fragments present in the digest of MccB17 by subtilisin in 50% DMSO (MccSub50%): in orange at the top 
and bottom, the sequence of MccB17 with the cleavage site in red. The fragments present in the proteolysate 
resulting from subtilisin cleavage are shown in green boxes with the related MW inside. In grey the expected 
fragments that are absent in the proteolysate. In yellow the fragment unrelated to subtilisin cleavage but present in 
the mixture. 
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Fractions were collected every minute from t = 18 to 48 min, and concentrated under vacuum. 
Figure 103 below shows a zoom of the HPLC trace with the fraction numbers and the amount 
of material isolated. 
  
Figure 102 Separation of the MccB17 digest by subtilisin in 50% DMSO: the HPLC trace at 254 nm is shown at the 
bottom in red. For comparison, the HPLC trace of MccB17 in the same HPLC conditions is shown in blue at the top. 
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As the quantity of the different fractions collected was very low, the residues were redissolved 
in 10 µl DMSO, the minimum volume allowing the recovery of the residues. The activity on 
gyrase was therefore assayed on solutions with concentrations ranging from 0.3 to 6 mM. 
  
Figure 103 Quantification of the MccSub50% fraction isolated: the HPLC trace of MccB17 proteolysis by subtilisin in 50% 
DMSO is shown with the amount of material isolated from each fraction overlaid as blue bars. The weight of the fraction is 
shown at the top of the blue bar in mg. 
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2.3.2.4 Analysis and evaluation of MccSub_50% HPLC fraction   
The HPLC fractions were assayed using both E. coli gyrase supercoiling and cleavage 
assays. The assays were conducted as described in Materials & Methods with the following 
changes: 2 µl of the tested HPLC fraction solution was added instead of 1 µl leading to a final 
DMSO concentration of 6.6 %, and the reaction time was extended to 2.5 h to compensate the 
slowing down effect of increased DMSO concentration in the reaction. The gels assays are 
detailed in Figure 104 and the quantification of the gel is shown in Figure 105. Inhibitory 
activity on gyrase supercoiling over 30% was observed for fractions 17, 18, 19, 21, 22, 24, 
among them only 18, 21 and 22 were stabilizing the DNA-gyrase cleavage complex.  
 
 
Fraction 5 to 24 were submitted to MALDI-ToF MS analysis, the fragments observed in each 
fraction linked to the activity on supercoiling displayed by the fraction are detailed in Table 7, 
the fragments expected from the proteolysis are in bold, and the intensity of the 
corresponding peak compared to the main peak of the fraction are in blue. 
  
Figure 104 Evaluation of HPLC fractions from MccSub50%: supercoiling and cleavage assays. The numbers displayed 
on the gel correspond to the fraction as shown on Figure 15. The effect on supercoiling by gyrase, is shown on the 
left side, and the stabilization of the gyrase-DNA cleavage complex on the right side. Fraction 18 is of particular 
interest due to its activity on both supercoiling and cleavage. It is also important to note that fraction 21 and 22 
contains MccB17. 
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We can see from Table 7 that fractions 21 and 22 contained mainly MccB17 which is a good 
blind internal control for our method. Fraction 18 contains mainly two species MW = 950 and 
2768; 950 is found as well as the main component of fraction 19 which display a lower inhibitory 
activity and no cleavage stabilization, so this suggest MW = 2768 as the active species. This 
fragment corresponds to MccB17 lacking the first four amino acids: MccB17\VGIG, the MS 
fragmentation of the structure was in agreement with this hypothesis. In the context of isolating 
a new antibacterial structure this result was disappointing as the fragment isolated is very close 
to MccB17 and thus will probably display physical properties very similar to MccB17 and so be 
unsuitable for therapeutical purpose. On the other hand the fact that the lost of these N-
terminal amino acids still leads to a compound displaying inhibitory activity on gyrase 
supercoiling and stabilisation is significant information about MccB17 itself, indeed most of the 
modifications carried out on MccB17 in the literature tend to diminish significantly its activity on 
gyrase, the stabilisation of cleavage complex being the most sensitive property. This discovery 
inspired the mutagenesis work on MccB17 N- and C-termini that is described in Chapter II. 
 
 
Figure 105 Quantification of the inhibitory activity of the HPLC fraction of MccB17 subtilisin digest in 50% DMSO: 
this is a bar chart showing the percentage of inhibition of gyrase supercoiling by the various fractions isolated by 
HPLC from the MccB17 subtilisin digest. The quantification was done using Genetools from Syngene. “DMSO” point 
correspond to the gyrase alone control, CFX is the ciprofloxacin control, and the numbers correspond to the 
associated HPLC fraction. 
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In the first subtilisin digest experiment this MccB17\VGIG fragment was not present and so 
could not account for the activity observed, this means that there was in the initial mixture a 
different active compound. The assays on MccSub50% fraction have shown some weak 
inhibitory activity that could not be validated and some of the fractions isolated contained a 
really small amount of material. So we considered repeating the experiment under conditions 
closer to what has been used initially; the purification process developed for MccSub50% will 
be used on the new proteolytic digest as it has proved successful. Carrying out the HPLC 
purification on two different mixtures had improved our understanding of the elution 
properties of the different fragments. Figure 106 shows the comparison of MccSub1 and 
MccSub50% HPLC purification traces with the species identified that will be useful markers for 
future purification.  
 
Table 7 Content of HPLC fractions isolated from MccSub50%: for each fraction, are shown the main species observed 
by MALDI-ToF MS (in black). The fragments expected from subtilisin cleavage are shown in bold. The intensity of the 
corresponding species is shown in blue, the main peak is use as a reference (value = 1), others are shown as a 
fraction of the main peak (i.e. 0.4 is 40% of the main peak intensity). 
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2.3.3 Proteolysis in 20% DMSO: MccSub20% 
2.3.3.1 Proteolysis reaction 
The reaction was carried out by incubating at 37°C for 48 h 2 mg/ml MccB17 and 0.1 
mg/ml subtilisin in a buffer pH = 7.5 containing 40 mM sodium phosphate, 1.7 mM sodium 
acetate, 0.8 mM calcium acetate and 20% DMSO. The solution was loaded on a Sep-Pak ® 
reverse phase column eluted with acetonitrile and water, first with H2O to remove salts and 
enzyme, the proteolysis fragments were collected by elution with 50% CH3CN/H2O. The 
collected fraction was concentrated under vacuum and freeze dried. The inhibitory activity of 
the mixture on gyrase supercoiling was validated as described before. 
  
Figure 106 Comparison of HPLC purification of MccB17 proteolysis by subtilisin in 10% and 50% DMSO: traces from 
the HPLC purification of the digest of MccB17 by subtilisin, in black is the trace of the first digest in 10% DMSO 
(MccSub1); in red is the trace of the digest in 50% DMSO (MccSub50%). 
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2.3.3.2 HPLC separation 
The HPLC purification was scaled up to accommodate the increased amount of 
material used in this experiment. A Jupiter 5aC18 300 Å 10x250 mm HPLC column was chosen, 
the dimensions of the new column corresponded to a 4.3-fold volume increase. A new method 
was extrapolated from the previous conditions on this basis: basically the same gradient was 
used but with a flow of 2 ml/min instead of 0.5 ml/min. The column was fed with a 5 mg/ml 
solution of the proteolysis residue in 50% DMSO/ H2O, 0.1% TFA. Figure 107 shows the elution 
profile. 
 
As before a lot of different peaks can be observed from the gradient; we decided to 
use a first rough separation, evaluate the mixtures and then run again the active fraction with 
conditions optimised for the gradient window where the compounds elute. Five fractions were 
isolated as shown in Figure 107 and assayed for inhibition of gyrase supercoiling using the 
standard method. The results are shown in Figure 108. 
 
Figure 107 Collected fractions from the HPLC separation of MccSub20%: The blue boxes are showing the time 
window of each collected fraction with its numbering. 
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All the fractions display some background activity, but 3 and 4 are the most active; all 
were analysed by MALDI-ToF MS and the results are summarized in Figure 108. Fraction 4, the 
most active, contains only one main species with a Mw = 1402.86, but MS fragmentation did 
not link it to any MccB17 substructure. Fraction 3 however contains four main components 
some being expected proteolysis fragments. The next step was to separate the components of 
Fraction 4. Unfortunately this fraction consists of only 0.5 mg of material which would probably 
not yield enough material from a second purification to perform the assays. The solution was 
to produce new material and proceed the HPLC purification with conditions improving the 
separation in the elution window of fraction 3. 
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Figure 108 Evaluation and identification of MccSub20% collected HPLC fractions: top left, supercoiling assays of the 
different fractions; all fractions show a background inhibitory activity, but fraction 3 and 4 are the most active. 
Bottom left, bar-chart of the quantification of the inhibition observed in the supercoiling assay gel (Genetools from 
Syngene).The column on the right shows the MW of the species observed in each fraction by MALDI-ToF MS (in 
black), and the intensity of the related species in blue, the main peak is use as a reference (value = 1), others are 
shown as a fraction of the main peak (i.e 0.3 is 30% of the main peak intensity). 
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2.3.3.3 Second Proteolysis reaction MccSub20%_2 
The proteolysis experimental conditions were modified to address two different 
concerns:  first we wondered if the presence of calcium ions could promote the production of 
MccB17 degradation product during our experiment, as we realised that the sodium and 
calcium acetate were not required in the subtilisin reaction buffer we decided to use a 
phosphate buffer. The second modification involved the purification on a sep-pak® column, we 
noticed that a fair amount of material seemed to be lost during this step, so we decided to 
omit it for this experiment. The reaction was carried out using 2 mg/ml MccB17 and 0.1 mg/ml 
subtilisin in a 40 mM sodium phosphate buffer pH = 7.5 containing 20% DMSO. The reaction 
mixture was incubated at 37°C for 48h. Some precipitate had appeared during the reaction, the 
mixture was centrifuged 10 min at 13000 rpm and the supernatant stored at -20°C. The solid 
residue was resuspended in 50% DMSO/water, vortexed and centrifuged again, the second 
supernatant stored as well to be tested on HPLC.  
2.3.3.4 Mass spectrometry analysis of the proteolysis reaction product 
 
 
Figure 109 MALDI-ToF spectra of MccSub20%_2: MALDI-ToF spectra from the MccB17 digest by subtilisin in a 
phosphate buffer with 20% DMSO mixture. The side products that have been reduced by the new experimental 
conditions are shown by the blue arrows with their MW on the top. 
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Carrying out the proteolysis in just a phosphate buffer seemed to have reduced the 
amount of MccB17 degradation products MW = 1393 and 1700 generated (blue arrows in 
Figure 109). The various expected fragments are present, so we proceeded to the HPLC 
purification.  
2.3.3.5 HPLC Purification 
In the previous HPLC purification fraction 3 was collected between RT = 40 and 49 min, 
considering that the void volume correspond to 8 min and that the following formula gives the 
percentage of acetonitrile as a function of time for the window [5; 80] min in the previous 
program: %CH3CN = 5 + (RT - 8 - 5) X 0.33. Applying the retention time in that formula led to 
the following acetonitrile gradient window for the elution of fraction 3: 13.9 < %CH3CN Fraction 
3 < 16.8%. A gradient of 0.24 % CH3CN/min was used between t = 5 min and 80 min in order to 
improve the separation in this range. Figure 110 below shows the HPLC trace of the new 
method. 
  
The change in the gradient improved the separation, unfortunately it seems not to 
have particularly improved the resolution in the fraction 2 elution window and the separation 
between fraction 2 and 3, we decided nonetheless to isolate the peaks generated by this 
method, as displayed below on the zoomed trace. 
 
Figure 110 Separation of MccSub20%_2 components by HPLC. 
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2.3.3.6 Evaluation of the activity for the different fractions 
In the previous digest, inhibitory activity has been observed for fractions at the end of 
the gradient, so in this experiment factions G to K, that correspond to the window where 
activity has been observed previously, were assayed in priority with supercoiling and cleavage 
assays. Fraction J and K were pooled together as they contains the same species (MALDI-ToF 
analysis not shown). Fraction I and (J+K) shows strong inhibitory activity on gyrase supercoiling 
at 200 µM. Fraction I was not assayed on the cleavage reaction because it contains MW=2767, 
and we had shown (in paragraph 2.3.2) that it stabilises the cleavage complex. No strong 
stabilisation of cleavage complex had been observed for the others fractions, however a faint 
band is visible for fraction H that will require further investigation. 
 
Figure 111 Collected fractions of the HPLC separation of MccSub20%_2: The blue boxes are showing 
the time window of each collected fraction with its reference letter. 
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2.4 Summary of proteolysis experiments and conclusion  
An initial experiment had shown that the complete digestion of MccB17 by subtilisin 
generates a mixture containing products resulting from MccB17 specific cleavage and 
degradation. This mixture was able to inhibit DNA supercoiling by gyrase at a concentration of 
33 µM. Following this encouraging result we decided to isolate the active species from the 
mixture. Precipitation issues arose as we scaled up the reaction, so we increased the DMSO 
concentration to 50% (MccSub50%), and still observed the same results concerning the activity 
on gyrase. The reaction mixture was separated with an HPLC apparatus building up on our 
experience with the hydrolysate. Among the different fractions isolated one was able to inhibit 
gyrase supercoiling as well as stabilize the cleavage complex. The fragment with MW=2767 was 
identified as the active compound of this fraction. Unfortunately this compound was 
corresponding to MccB17 lacking the four N-terminal amino acids. Interestingly this fragment 
Figure 112 Evaluation and identification of MccSub20%_2 collected HPLC fraction: top left, 
supercoiling assays of the different fractions; fraction I and J+K are the most active. Bottom 
left, gyrase cleavage assays, no strong stabilization of cleavage complex is shown, however a 
weak cleavage band might be present for G and H. The column on the right shows the MW of 
the species observed in each fraction by MALDI-ToF MS (in black), and the intensity of the 
related species in blue, the main peak is use as a reference (value = 1), others are shown as a 
fraction of the main peak (i.e 0.6 is 60% of the main peak intensity). 
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was not present in the initial reaction mixture, and appeared to be a side product favoured by 
the reaction with 50% DMSO. We repeated the same strategy with a lower concentration of 
20% DMSO, and two fractions, having strong inhibitory activity on gyrase supercoiling at 100 
µM, were isolated. The first one contained a mixture of compounds: MW = 1862; 1393; 1747; 
and 1700. The second, the most active, contained mainly one species MW = 1403, but this 
compound seemed not to be related to MccB17. Not enough material was available to try to 
separate further the components of first fraction. The proteolysis experiment was repeated to 
produce more material. It was carried out with 20% DMSO as before but without sodium 
acetate and calcium acetate in the buffer. In these conditions we observed a reduction of 
MccB17 degradation products. The HPLC conditions were modified to improve the separation 
in the window of elution where active compounds in the previous proteolysis were observed. 
Unfortunately only mixtures were still isolated. Two fractions active against gyrase 
supercoiling, the first contained fragments of MW = 1863; 1884; 1749; 2767; and the second 
contained MW: 1395.5; 1843.5; 1728. Annoyingly there is not a strong enough correlation 
between the two experiments to draw sound conclusion about the active compound, we had 
isolated similar structures over the two experiments but not exactly the same. Another 
concern is that some of the compounds present in the active fractions are related to the 
MccB17 degradation compound; this suggests that they may be responsible for the inhibitory 
properties observed. The activity of MccB17 degradation product will be discussed in the next 
section. 
3 Isolation and evaluation of MccB17 by products 
We have described in Chapter II how some compounds related to MccB17 were eluting 
ahead of MccB17 species during its purification. The determination of their structure by MS is 
described in Chapter II. Figure 113 and Figure 114 show the collected fraction from MccB17 
purification containing this species and their structure. The compounds identified described in 
Figure 114, although unlikely to be active species, were included in our supercoiling assays 
trials. Our attention was further brought to these fragments as similar compounds were 
generated as by-products during the proteolysis experiments, and were also observed in the 
fraction showing inhibitory activity on gyrase. 
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3.1 Evaluation of activity of the mixture isolated from MccB17 prep 
The standard supercoiling and cleavage assay were performed as described in Materials & 
Methods to evaluate the activity of the mixture. During the various preparation of MccB17 and 
others experiments fractions containing the fragments of interest as their main component 
have been isolated. The compound with MW = 857 Da has been found as the main component 
of several inactive fractions during the work on alkaline hydrolysis of MccB17, so we focused 
on the two others compounds observed: MW = 1393.4 Da, and MW = 1700.6 Da. 
 
Figure 113 MccB17 HPLC purification trace. 
Figure 114 Fragments of MccB17 isolated from MccB17 preparation: the sequence of MccB17 is shown in orange, the 
coloured boxes correspond to MccB17 fragments with their corresponding MW, in bold are the fragments isolated, 
in italic are related fragment for information. 
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3.1.1 Initial validation of activity:  
A fraction isolated from the purification of MccB17 by HPLC during its production, and 
eluting ahead of the expected MccB17 peaks appeared to have inhibitory activity on gyrase 
supercoiling as shown in Figure 115. MALDI-ToF analysis of this fraction revealed that it did not 
contain any MccB17 species, but smaller molecules related MccB17, as described in Chapter II-
4. 
The analysis of the sample using MALDI-ToF MS spectrometry shows that it contains MW = 
1700.6 and MW = 1393.4. In later experiments special attention was paid to fractions that 
contain this species alone. 
3.1.2 MW = 1700.6 Da 
In later purification of MccB17 we managed to isolate the compound with MW = 
1700.6 alone. It was assayed both on E. coli gyrase supercoiling and human topo II relaxation.  
Figure 115 Evaluation of the fraction preceding MccB17 in 
HPLC: gyrase supercoiling assay of the fraction eluting before 
MccB17 species during its HPLC purification 
Figure 116 Evaluation of the inhibitory activity of MW = 1700.6 Da on gyrase supercoiling and topo II relaxation. 
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Inhibition of gyrase supercoiling had been observed at a concentration of 122 µM. The 
compound shows a complete inhibition of human topo II at a concentration of 100 µM. 
Interestingly, MW = 1700.6Da was more active on topo II than the native MccB17. This is 
encouraging in considering MccB17 substructures as inhibitors for topoisomerases other than 
gyrase.  
3.1.3 MW= 1393.4 Da 
Isolating this compound had proved more challenging, and we were not able to obtain 
it singular. The initial characterisation of the mixture containing MW = 1700.6 Da and MW = 
1393.4 Da, exhibited a strong inhibition of the supercoiling reaction at 100 µM, by comparison, 
MW=1700.6 Da alone exhibited a weak inhibition at 122 µM (Figure 115 and 116), suggesting 
that MW = 1393.4 Da increases the inhibition in this reaction. Fractions containing MW = 
1393.4 were pooled together and submitted to HPLC purification using the same method as for 
the proteolysis mixtures in 2.3.3.5. Unfortunately the compound co-eluted with another 
compound, MW = 2937 Da corresponding to Mcc\VG, known to be active. The intensities 
observed for the two peaks on the MALDI-ToF MS spectra, are 1 for MW=1393.4 and 0.3 for 
Mcc\VG, a rough estimation of the concentrations of each component in the mixture from 
these proportion, led to a Mcc\VG having a concentration close to our MccB17 control. In the 
supercoiling assays the fraction containing MW = 1393.4 and Mcc\VG display a stronger 
inhibitory activity than the MccB17 control Figure 117. 
Figure 117 gyrase supercoiling assays of the HPLC fraction containing MW = 1393.4. 
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Finally a fraction containing MW = 1393.4 (50%), 1374.5 (25%), and 1410.5 (25%) has 
been isolated from the subtilisin digest experiments. This fraction was shown to inhibit gyrase 
supercoiling (Figure 118). 
 
We were not able to have direct evidence for the MW = 1393.4 inhibitory activity on 
gyrase. However, we gathered a body of information that suggests that this compound is active 
in the 100 µM range. Isolation of the pure compound and evaluation of its activity will be 
necessary to consolidate this hypothesis. 
3.2 Summary of MccB17 fragments from MccB17 degradation and 
proteolytic cleavage 
We have shown in the last paragraph that fragments of MccB17 spontaneously produced 
during MccB17 preparation possessed inhibitory activity on gyrase supercoiling. As they were 
also present in some active fractions isolated from proteolysis mixture they could be 
responsible for the inhibitory activity observed. Fortunately, we have reduced the amount of 
these compound produced in our last proteolysis experiment, and it was still active, suggesting 
that other species are involved in the inhibitory effect, probably compounds derived from MW 
= 1861.5. Our final list of active candidates contains MW = 1393.5; 1700.6; 1862.5.  
 
 
Figure 118 Gyrase supercoiling assay of a mixture containing MW = 1393.4: the 
inhibitory activity on gyrase supercoiling of a mixture containing (MW (relative 
MS intensity)): 1393.4 (1), 1374.5 (0.5) and 1410.5 (0.5) is shown. A weak 
ladder of relaxed species is visible (top), the control without drug is completely 
supercoiled which is not ideal to characterize MccB17-type inhibitors. 
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It will be required to isolate each of them as single compounds to ascertain that there are 
indeed active species and quantify their activity. This will require an improvement of the 
separation technique by using different type of columns, with aromatic selectivity for example. 
The interesting preliminary results obtained on topo II with the MccB17 “natural” fragments 
suggest that extension of the investigation of the proteolytic cleavage species to human topo II 
might yield good results as well. 
4 Conclusion 
This chapter had described the various approaches we had used to generate fragments of 
MccB17. An alkaline hydrolysis strategy initially produced complex mixtures which did not 
permit us to identify any active component, followed by a more moderate method involving 
enzymatic proteolysis which was more fruitful. The inhibition of gyrase that was consistently 
observed independently of the cleavage method used, probably caused by different structures, 
highlights the fact that fragments of MccB17 have the potential for being topoisomerase 
inhibitors. Two major difficulties were inherent to this approach: first the physical properties of 
the starting material MccB17 made it particularly hard to work with as it tended to precipitate 
with its by-products after some time in a very stable form. Secondly MccB17 is not a very 
diverse molecule apart from the presence of heterocyclic residues and possesses some sort of 
symmetry which causes the fragments generated to have very similar physicochemical 
properties and makes their separation very difficult. We have isolated and identified fragments 
of half the size of MccB17 with inhibitory activity on gyrase in the same range as their parent 
molecule, but unfortunately not with a strong ability to stabilize the DNA-gyrase cleavage 
complex. These structures where isolated as the main component of mixtures with other 
MccB17 fragments, to evaluate accurately their inhibitory activity and validate these results it 
will be necessary to isolate them as pure compounds. This can be achieved by improving the 
HPLC condition with a different solvent system, and a column with different selectivity. An 
alternative method will be to use site-directed mutagenesis to introduce specific cleavage sites, 
this method will ensure that only one compound is produced but the yields and post 
translational modifications might be altered. If we consider the coverage of the native MccB17 
structure by our active candidates, and other fragments that are not active we can start to 
draw a picture of the structural requirement. The fact that MW = 1209.4 is the main product of 
Figure 119 Fragments of MccB17 found in active fractions. 
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the inactive fraction G of the second proteolysis, and MW = 1393.5 had been shown to be 
active, suggest that either MW = 1393.5 is close to a minimal required structure or that the 
Ser-Asn residues that differentiate the two compounds are vital for the activity. This finding 
gave additional information on MccB17 mechanism and these structures can be the starting 
point to define what is really required in MccB17 to stabilize the cleavage complex. Even if they 
are not stabilizing the cleavage complex, these compounds are E. coli gyrase inhibitors, and in 
some case human topo II inhibitors, this would make the systematic investigation of their 
potency against gyrase and topo IV from pathogenic bacteria, or human topo II the next logical 
step in a drug discovery approach. 
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CHAPTER IV Small molecules related to microcin B17 
The previous chapters covered initially MccB17 as a whole molecule, its activity on various 
topoisomerases and some key elements required for its activity. It was followed by the 
investigation of fragmentation of MccB17 to diverse degrees that revealed that some parts of 
the molecule alone have inherent inhibitory activity. The most significant feature of MccB17 
and its fragments, is the presence of heterocyclic amino acids that result from post-translation 
modification, some of these residues have been reported to be essential for MccB17 activity on 
gyrase (Sinha Roy, Kelleher et al. 1999). The alkaline hydrolysis of MccB17, outlined in Chapter 
III and described in a previous study (Coquin 2005), showed that heterocyclic amino acids 
specific to MccB17, as well as these same amino acids associated with a glycine or an aspartic 
acid residue were present in the resulting mixture, which was able to inhibit gyrase. It is 
legitimate to wonder what the activity of these heterocyclic amino acids molecule on gyrase is. 
Preliminary studies of these compounds have shown an inhibitory effect under 100 µM on 
gyrase supercoiling and no stabilization of the cleavage complex for the tzoz, and tz amino 
acids. As these heterocyclic residues were the necessary building blocks to synthesize the 
MccB17 fragments we planned to study, we decided to generate these compounds and 
validate these preliminary results. In the first part will be described how these compounds 
have been synthesised and their activity on topoisomerases evaluated. A second part will deal 
with the evaluation of small molecules that are not present in MccB17 but possessed 
similarities with MccB17’s heterocyclic amino acids. A general overview of the results obtained 
with these small molecules will conclude this chapter.  
1 Heterocyclic amino acids from microcin B17 
The full synthesis of MccB17 has been reported by Videnov et al (Videnov, Kaiser et al. 
1996) and has been described in chapter I. The part involving the synthesis of MccB17 
heterocyclic moieties (Videnov, Kaiser et al. 1996), H-oz-OH: 2-aminomethyl oxazole-4-
carboxylic acid, H-tz-OH: 2-aminomethyl thiazole-4-carboxylic, H-oztz-OH: 2-(2'-
aminomethyloxazole-4'-yl)thiazole-4-carboxylic acid, and H-tzoz-OH: 2-(2'-
aminomethylthiazole-4'-yl)oxazole-4-carboxylic acid, is of particular interest here, as it was our 
reference method to generate these residues. Recent innovation in the synthetic chemistry of 
oxazole rings has been included in our synthetic strategy as it provides some improvements to 
our method. The Hantzsch method described by Videnov was used to generate the thiazole 
rings, whereas oxazole rings were synthesized by using a one-pot method involving a Gly-Ser 
motif (Phillips, Uto et al. 2000). 
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1.1 A novel method to generate oxazole rings for MccB17 heterocyclic 
amino acids 
An efficient method to convert β-hydroxy amides to oxazoline, which can be further 
oxidized into an oxazole in a one-pot reaction, has been developed by Phillips et al (Phillips, 
Uto et al. 2000), it is shown in the top part of figure 120 below. We decided to use this method 
to generate our oxazole species because it possesses two advantages: first, the cyclisation 
reaction and further oxidation of the oxazoline can be performed via a one-pot method which 
makes it a simpler route compared to the modified Hantzsch method employed by Videnov et 
al (Figure 120). Second, the fact that this method involves β-hydroxy amides means that it is a 
more flexible method potentially applicable to a variety of peptide templates containing a 
serine residue. This is particularly interesting in the context of this study as this route involves a 
mechanism closer to MccB17 biosynthesis where a X-Gly-Ser-X, or X-Gly-Ser-Cys-X and X-Gly-
Cys-Ser-X motifs are converted respectively into oz, oztz, and tzoz. Once this method is 
validated on generating MccB17 oxazole-containing building blocks, it open the possibility of 
synthesizing peptides derived from MccB17 containing oxazole rings from the corresponding 
Gly-Ser- or tz-Ser-containing peptide. 
 
 
 
Figure 120 Comparison of oxazole synthetic routes: the top part of the figure describes the one-pot method 
involving deoxofluor. The lower part concerns the more classic approach with the modified Hantzsch method. 
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1.2 Synthesis of oxazole amino acid (H-oz-OH): 2-aminomethyl 
oxazole-4-carboxylic acid  
 
1.2.1 Boc-Gly-Ser-OMe:  
Methyl 2-(2-(N-tert-butoxycarbonyl)aminoacetamido)-3-hydroxypropanoate 
The reaction was carried out at 0˚C and under anhydrous conditions. Boc-Gly-Ser was 
mixed with equimolar amount of N-(tert-butoxycarbonyl)glycine), O-methyl serine 
chlorhydrate, N,N′-dicyclohexylcarbodiimide (DCC), and triethylamine (Et3N,) in 
dichloromethane. The reaction proceeded overnight at 0°C. After removal of the solvent in 
vacuo; trituration with ethyl acetate, and removal of the solid residue, the filtrate was 
concentrated under vacuum. The isolated residue was triturated with a small amount of 
tetrahydrofuran and filtered, the filtrate was concentrated in vacuo. The isolated residue was 
purified by silica gel column chromatography with AcOEt, 5% MeOH as eluent. 
1.2.2 Boc-oz-OMe: Methyl 2-(N-tert-butoxycarbonyl)aminomethyloxazole-4-
carboxylate 
The reaction was carried out at -20°C under anhydrous conditions. To a solution of N-
Boc-Gly-Ser-OMe in anhydrous dichloromethane, 1.15 equivalent (eq) of bis(2-
methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor®) was added. After 30 min stirring, 3.75 eq 
of bromotrichloromethane were added to the mixture, followed by 3.75 eq of DBU. The 
reaction mixture was stirred at T= 2-3°C for 8 h before being quenched with a saturated 
solution of sodium bicarbonate. The mixture was extracted with ethyl acetate, the organic 
phase dried and concentrated under vacuum. The residue was purified on silica gel column 
chromatography with n-hexane/AcOEt (1/1) as eluent. 
1.2.3 Boc-oz-OH: 2-(N-tert-butoxycarbonyl)aminomethyloxazole-4-carboxylic acid 
The Boc-oz-OMe residue was resuspended in a solution of dioxane/water (3/1) 
containing 1 eq NaOH, and the mixture was stirred for 1 h at RT. The solution was neutralized 
Figure 121 synthetic route of 2-aminomethyl oxazole-4-carboxylic acid (H-oz-OH)  
 
150 
 
and extracted with dichloromethane. The organic phase was dried; the removal of the solvent 
in vacuo led to Boc-oz-OH. 
1.2.4 H-oz-OH: 2- aminomethyloxazole-4-carboxylic acid 
Boc-oz-OH was dissolved in TFA/CH2Cl2 (1/1) and stirred for 2 h. The mixture was 
concentrated in vacuo to lead to the final product. 
 
1.3 Synthesis of thiazole amino acid (H-tz-OH): 
 2-aminomethyl thiazole-4-carboxylic acid  
The method used to generate this compound is directly inspired from the synthesis 
described by Videnov et al.  
 
1.3.1 Boc-glycine amide: N-tert-butoxycarbonylglycine amide 
Di-tert-butylcarbonate was added to a solution of 0.9 eq of glycylamide and TEA in 
THF/H2O (4/1). The mixture was stirred for 5 h at RT. The mixture was extracted with ethyl 
acetate. The organic phase was washed respectively with 1 M sodium hydrogencarbonate 
solution and brine before being dried and concentrated in vacuo to yield to the Boc-protected 
glycylamide. 
1.3.2 Boc-glycylthioamide: N-tert-butoxycarbonylglycine thioamide 
Lawesson’s reagent (0.75 eq) was added to a solution of Boc-protected glycylamide in 
dimethoxyethane (DME), the solution was stirred overnight at RT. The solvent was removed 
under vacuum. Ethyl acetate and 1 M sodium hydrogencarbonate were added to the residues 
and stirred for 10 min. The organic phase was recovered and the aqueous phase was washed 
Figure 122 Synthetic route of 2-aminomethyl thiazole-4-carboxylic acid (H-tz-OH) 
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with ethyl acetate. The combined organic phases were washed with brine, dried, and 
concentrated in vacuo. The solid residue was recrystallised in EtOAc/n-hexane. 
1.3.3 Boc-tz-OH: 2-(N-tert-butoxycarbonyl)aminomethylthiazole-4-carboxylic acid 
Under anhydrous conditions, N-Boc-2-glycylethioamide, and 4 eq of potassium 
carbonate were introduced in ethanol. 1.5 eq of 3-bromo-2-oxopropanoic acid in anhydrous 
ethanol was added dropwise. The reaction mixture was stirred for 4 h at RT, before being 
filtered, the filtrate was concentrated under vacuum. The residue isolated was recrystallised in 
AcOEt/n-hexane and led to the pure expected product. 
1.3.4 H-tz-OH 
N-Boc-tz-OH was dissolved in TFA/CH2Cl2 (1/1) and stirred for 2 h at RT. The mixture 
was concentrated in vacuo to lead to the TFA salt of H-tz-OH. 
1.4 Synthesis of H-oztz-OH:  
2-(2’-aminomethyloxazole-4’-yl)-thiazole-4-carboxylic acid 
The synthesis of this bis-heterocyclic compound use the Boc-oz-OMe described in 1.2.2 
as the starting material using the same method described to produce H-tz-OH.  
 
1.4.1 Boc-oz-NH2: 2-(N-tert-butoxycarbonyl)aminomethyloxazole-4-amide 
35% aqueous ammonia were added to a solution of Boc-oz-OMe in methanol, the 
mixture was stirred overnight at RT. After concentration in vacuo, a solution of NaHCO3 was 
added. The solid residue was filtered and washed with water. 
1.4.2 Boc-oz(CS)-NH2: 2-(N-tert-butoxycarbonyl)aminomethyloxazole-4-thioamide 
0.75 eq of Lawesson’s reagent was added to a solution of Boc-oz-NH2 in DME, the 
solution was stirred overnight at RT. The solvent was removed and ethyl acetate and 1 M 
Figure 123 Synthetic route of 2-(2’-aminomethyloxazole-4’-yl)-thiazole-4-carboxylic acid (H-oztz-OH) 
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sodium hydrogencarbonate were added to the residues and stirred for 10 min. The organic 
phase was recovered and washed with brine, dried, and concentrated in vacuo. The solid 
residue was recrystalized in EtOAc/n-hexane. 
1.4.3 Boc-oztz-OEt:  
Ethyl-2-((N-tert-butoxycarbonyl)-2’-aminomethyloxazole-4’-yl)-thiazole-4-
carboxylate 
Under anhydrous conditions, Boc-oz(CS)-NH2 and 6 eq potassium hydrogencarbonate 
suspended in anhydrous DME were stirred for 10 min before the addition of 3.5 eq of 
ethylbromopyruvate. The reaction mixture was left stirring overnight at RT. The mixture was 
filtered, washed with brine, dried, and concentrated. The residue was purified by silica gel 
column chromatography with EtOAc/n-hexane (2/1) as eluent. 
1.4.4 Boc-oztz-OH: 
2-((N-tert-butoxycarbonyl)-2’-aminomethyloxazole-4’-yl)-thiazole-4-carboxylic acid 
A mixture of Boc-oztz-OEt dissolved in dioxane/water (3/1) with 2 eq of sodium 
hydroxide (0.52 mmol) was stirred for 1 h at RT. The solution was set to pH = 6. The dioxane 
was removed under vacuum, the pH of the solution further set to pH = 3 before being 
extracted with ethyl acetate. The organic phase was dried and the solvent removed in vacuo to 
lead to Boc-oztz-OH. 
1.4.5 H-oztz-OH 
Boc-oztz-OH was dissolved in TFA/CH2Cl2 (1/1) and stirred for 1 h at RT. The mixture 
was concentrated in vacuo to lead to the TFA salt of H-oztz-OH. 
1.5 Synthesis of H-tzoz-OH: 
2-(2’-aminomethylthiazole-4’-yl)-oxazole-4-carboxylic acid 
The synthesis of this bis-heterocyclic compound use the Boc-tz-OH described in 1.3.3 as 
starting material with a method similar to the synthesis of H-oz-OH (Figure 124).  
1.5.1 Boc-tz-Ser-OMe: 
N-(2-(N’-tert-butoxycarbonyl)aminomethylthiazole-4-carbonyl)-Serine methyl ester 
Under anhydrous conditions at 0˚C, Boc-tz-OH was dissolved in dichloromethane, 2 eq 
of TEA, 2 eq serine hydrochloride and 2 eq of DCC were added to the mixture. The reaction 
mixture was stirred overnight at 0°C. The solvent was removed in vacuo and the residue 
resuspended in ethyl acetate. The dicyclohexylurea (DCU) was removed by filtration, and the 
filtrate concentrated under vacuum. A small amount of THF was added and the ammonium 
chloride precipitate was removed The filtrate was concentrated before being purified by silica 
gel column chromatography with AcOEt/ 5% MeOH as eluent. 
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1.5.2 Boc-tzoz-OMe: 
Methyl-2-((N-tert-butoxycarbonyl)-2’-aminomethylthiazole-4’-yl)-oxazole-4-
carboxylate 
At -20°C, under anhydrous conditions, 1.1 eq of DeoxoFluor® was added to Boc-tz-Ser-
OMe in dichloromethane. After 30 min, 3.6 eq of bromotrichloromethane DBU were added, 
the reaction mixture was stirred for 8 h at 0˚ C . The mixture was quenched with a saturated 
solution of sodium hydrogencarbonate, the dichloromethane was removed under vacuum and 
the remaining aqueous phase was extracted with ethyl acetate. The organic extract was dried 
and concentrated in vacuo. The residue was purified by silica gel column chromatography with 
ethyl acetate as solvent.  
1.5.3 Boc-tzoz-OH: 
2-((N-tert-butoxycarbonyl)-2’-aminomethylthiazole-4’-yl)-oxazole-4-carboxylic acid 
Boc-tzoz-OMe was dissolved in a dioxane/water (3/1) containing 1 eq of sodium 
hydroxide. After being stirred at RT for 1 h, the dioxane was removed from the mixture and the 
Figure 124 Synthetic route of 2-(2’-aminomethylthiazole-4’-yl)-oxazole-4-carboxylic acid (H-tzoz-OH). 
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pH was adjusted to 3. The solution was extracted with ethyl acetate, and the organic phase 
was dried and concentrated in vacuo.  
1.5.4 H-tzoz-OH 
Boc-tzoz-OH was dissolved TFA/CH2Cl2 (1/1) and stirred for 1 h at RT. The mixture was 
concentrated under vacuum and led to the TFA salt of H-tzoz-OH. 
1.6 In vitro assays of synthesized compounds 
1.6.1 E. coli gyrase 
The heterocyclic amino acids found in MccB17 as well as synthetic intermediates were 
assayed for activity on gyrase supercoiling using the standard method described in Chapter II. 
Initial results show inhibitory activity for some of the compounds at the millimolar range. The 
determination of precise IC50 was not successful due to the low level of activity of the studied 
compounds and the variability of the assays. Examples of supercoiling assays are available in 
Figure 125. The results obtained with the various heterocyclic amino acids are summarized in 
Table 8. 
Figure 125 Evaluation of the inhibitory concentration of Mcc17 heterocyclic compounds on gyrase 
supercoiling (example): Gel electrophoresis of the product of standard supercoiling assays in the presence of 
no drug, 25 µM ciprofloxacin, 40 µM MccB17, or 5/50/500 µM of tested heterocyclic compound. The upper 
bands represent the starting relaxed DNA, the lower band represents the produced supercoiled DNA. In the 
presence of inhibitor, the lower band loses in intensity in favour of the upper band.  
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Further characterization of this series was performed by submitting Boc-tz-OH and Boc-
tzoz-OMe to relaxation assays: a difference of inhibitory activity toward relaxation and 
supercoiling would suggest an involvement of the inhibitors with the ATPase activity of the 
enzyme. Additionally, difference of susceptibility to these compounds between gyrase wild 
type and gyrase carrying the MccB17 resistance mutation Y751R was evaluated. Finally 
stabilization of gyrase-DNA cleavage complex was assayed on Boc-tz-OH, H-tz-OH, H-tzoz-OH, 
Boc-oztz-OEt. Examples of the extra experiments carried out on this series are provided in 
Figures 126 and 127. 
The compounds displayed the same activity on gyrase supercoiling and relaxation. The 
compounds had approximately the same level of inhibitory activity on supercoiling by WT 
gyrase and MccB17-resistant gyrase, suggesting that their mechanism of action differs from 
MccB17’s. It should be noted that MccB17 control for the relaxation reaction failed, however 
the two compounds assayed showed clearly inhibition of relaxation. The compounds tested 
were not able to stabilize the cleavage complex at 1 mM concentration. 
 
 
Table 8 Summary of inhibitory concentration of MccB17’s natural and chemically protected heterocyclic 
compounds on the E. coli gyrase supercoiling reaction 
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These results were disappointing considering the level of inhibition observed. The results 
were similar to what had been previously reported: no effect of protecting groups on activity, 
the oxazole amino acid had no activity, the thiazole and the bis-heterocycle amino acids 
displayed inhibitory activity, with the bis-heterocycles being the best (tz < oztz < tzoz). 
However the activity we observed was ten-fold lower than what was expected from the 
Figure 126 Relaxation and cleavage assays of 
MccB17’s heterocyclic compounds (example): 
Relaxation: gel electrophoresis of standard 
relaxation assays performed in presence of 25 
µM ciprofloxacin, 40 µM MccB17, or 1 mM of 
tested MccB17 heterocyclic compounds. The 
lower band represent the starting supercoiled 
DNA, the upper bands represent the produced 
relaxed DNA. In the presence of an inhibitor, 
the upper bands lose in intensity in favor of the 
lower band. The ladder observed in between 
corresponds to various topoisomer 
intermediates.  
Cleavage: gel electrophoresis of standard 
cleavage assays performed in presence of 25 
µM ciprofloxacin, 40 µM MccB17, or 1 mM of 
MccB17 heterocyclic compounds. The upper 
band represents the starting relaxed DNA, the 
lower band represents the produced 
supercoiled DNA. In presence of a cleavage 
complex stabilizing agent a new band 
corresponding to linear DNA appears between 
the two others. None of the compounds tested 
stabilized the cleavage complex. 
 Figure 127 comparison of inhibition by 
MccB17’s heterocyclic compounds of wild type 
and MccB17-resistant gyrase (example): gel 
electrophoresis of standard supercoiling assays 
using either wild type gyrase or 
gyrA+gyrB(W751R), in the presence of 25 µM 
ciprofloxacin, 40 µM MccB17, or 1 mM of 
tested MccB17’s heterocyclic compound. The 
upper bands represent the starting relaxed 
DNA, the lower band represents the produced 
supercoiled DNA. In the presence of an 
inhibitor, the lower bands loses in intensity in 
favor of the upper bands. The upper part of the 
figure shows the inhibition of wild-type gyrase 
by various agents, and the lower part of the 
figure shows the same experiment with 
MccB17-resistant gyrase. In this last part, 
MccB17 displays no inhibitory activity whereas 
the heterocyclic compounds tested show the 
same inhibitory activity in both experiments.  
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preliminary study (Coquin 2005). Interestingly the compounds retain their activity on the 
MccB17-resistant mutant, and as no stabilization of cleavage complex was observed, it 
suggests that the mode of action of these small molecules is different from MccB17’s.  
1.6.2 Human topo II 
Four representative compounds from the series were tested with topo II: H-oz-OH, Boc-
tz-OH, H-tzoz-OH, H-oztz-OH using the standard procedure. 
 
Very weak inhibition of relaxation was observed at 300 µM for Boc-tz-OH and H-tzoz-OH, 
at 500 µM H-oz-OH had no activity whereas H-oztz-OH showed complete inhibition. 
1.7 Conclusion 
All the compounds we desired to obtain have been successfully synthesized; the method 
described by Phillips et al (Phillips, Uto et al. 2000) to generate oxazole has been successfully 
integrated into our synthetic pathway and yielded the expected heterocycles. In the context of 
this synthesis, the use of a one-pot cyclization/oxidation step simplifies the production of 
oxazole-containing compounds, but more importantly the glycylserine substrate used in this 
reaction introduces more flexibility into the method: for example, peptides bearing multiple 
glycylserine sites can be generated and multiple cyclization can be achieved in a single step; 
another possibility is to use already existing natural peptides containing the Gly-Ser motif as a 
substrate to introduce new oxazole ring in the structure. We have considered this last 
possibility to efficiently generate the MccB17 derivatives carrying an extra oxazole ring 
observed as a side-product during MccB17 preparation; this is a compound of interest as it had 
been reported to have superior inhibitory activity compared to MccB17. Inhibitory activity has 
been observed on gyrase supercoiling and relaxation and on topo II relaxation at 
concentrations around 500 µM for the thiazole and the bis-heterocycles. The few inhibitors 
that were tested did not produce any stabilization of gyrase-DNA cleavage complex.  
Figure 128 Inhibition of human topo II by MccB17 heterocyclic compounds: the inhibitory activity was evaluated 
using standard topo II relaxation assays in the presence of either no drug, 100 µM etoposide, 150 µM MccB17, 300 
µM of Boc-tz-OH or H-tzoz-OH  or 500 µM of H-oz-OH or H-oztz-OH. The lower band represents the starting 
supercoiled DNA, in the presence of topo II the lower band is converted to the ladder of upper bands that represent 
the relaxed DNA species. . In the presence of an inhibitor, the upper bands lose intensity in favor of the lower bands. 
A very faint lower band is visible in the presence of some of our inhibitors: MccB17, Boc-tz-OH, and H-tz-OH. H-oztz-
OH on the other hand did fully inhibit the reaction at 500 µM. 
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2 Compounds related to microcin B17 
2.1 Pyrrole 
The first class of compounds related to MccB17 heterocyclic amino acids we have 
considered were pyrrole amino acids, that as pentaheterocyclic amino acids can be considered 
as bioisosters of our thiazole and oxazole compounds. These compounds were available 
through the courtesy of our collaborator Christian Greeff (Chris Pickett lab, CAP department, 
UEA, Norwich). 
Three different compounds have been tested:  
• Boc-2,5pyr-OH: 5-((tert-butoxycarbonyl)aminomethyl)-1H-pyrrole-2-carboxylic acid. 
• Fmoc-2,5pyr-OMe: methyl 5-(fluorenylmethoxy)carbonyl)aminomethyl)-1H-pyrrole-2-
carboxylate. 
• Fmoc-2,4pyr-OH: 4-(fluorenylmethoxy)carbonyl)aminomethyl)-1H-pyrrole-2-carboxylic 
acid. 
This set was interesting as the effect of two different protecting groups Boc and Fmoc can be 
compared as well as two different substitutions of the pyrrole ring. The compounds were 
analysed using standard gyrase supercoiling assays. 
Figure 129 Pyrrole compounds 
Figure 130 Evaluation of the inhibitory concentration of pyrrole compounds on gyrase supercoiling: Gel 
electrophoresis of the product of standard supercoiling assays in the presence of no drug, 25 µM ciprofloxacin, 50 
µM MccB17, or 1000/500/250 µM of the tested pyrrole compound. The upper bands represent the starting relaxed 
DNA, the lower band represents the produced supercoiled DNA species. In the presence of inhibitor the lower band 
loses intensity in favor of the upper bands. Fmoc-2,5pyr-OH and Fmoc-2,4pyr-OH show inhibition for all 
concentrations tested whereas Boc-2,5pyr-OMe did not show any inhibition. 
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It appears from the assays that Fmoc-2,5pyr-OH and Fmoc-2,4pyr-OH can completely 
inhibit supercoiling down to 250 µM, while Boc-2,5pyr-OMe shows no activity. We wondered if 
this difference came from the difference in protecting group or from the esterification of the 
acid group. To address this question we used two different experiments. First we removed the 
Fmoc protecting group from Fmoc-pyr-OH in order to evaluate the activity of the non 
protected pyrrole amino acid. And second, we decided to introduce a Fmoc protecting group 
on one of the MccB17 heterocyclic amino acids. We chose to use H-tzoz-OH for this experiment 
as it was one of the most active heterocycles. Using this compound has both the advantage of 
evaluating the influence of the Fmoc group and of isolating a potentially potent compound.   
2.1.1 H-2, 5pyr-OH 
Fmoc-2,5pyr-OH (0.07 mmol) was dissolved in 2 ml DMF, 1 ml of 0.1 sodium hydroxide 
solution was added and the mixture was stirred for 10 min. The reaction mixture was set to pH 
= 7 by addition of 1 M hydrochloric acid solution, 10 ml water were added and the solution was 
extracted with ethyl acetate. The organic phase was dried and concentrated under vacuum. 
2.1.2 Fmoc-tzoz-OH: 
H-tz-OH (0.09 mmol) and sodium carbonate (0.18) were added to 0.265 ml water. A 
solution of 0.11 mmol Fmoc-OSu (N-(9-Fluorenylmethoxycarbonyloxy) succinimide) in 0.53 ml 
THF was added to the mixture. The reaction mixture was stirred overnight at RT. Water was 
added to quench the mixture, and it was acidified to pH = 3. The precipitate was filtered, 
washed with water and dried. 
2.1.3 Evaluation of H-2,5pyr-OH and Fmoc -tzoz-OH effect on gyrase 
The two compounds isolated H-2,5pyr-OH and Fmoc -tzoz-OH were assayed on gyrase 
supercoiling, and compared with the respective starting material Fmoc-2,5pyr-OH  and H -tzoz-
OH. In the assay displayed in Figure 131 a lower activity than what was observed initially for 
the reference compounds was observed, this was probably due to greater supercoiling activity 
by gyrase. Nonetheless we can notice that the removal of the Fmoc group from the pyrrole 
compounds disrupts its activity, whereas its addition to the tzoz compound increases the 
inhibitory effect. 
The study of these compounds was not pushed forward as even if addition of a Fmoc 
group increases the activity of our heterocyclic compounds, it is still in the range of 100 µM 
and without any stabilization of gyrase-DNA cleavage complex (data not shown). Another issue 
was that the introduction of the Fluorenyl group is significantly increasing the lipophilicity of 
the compound, which is something we want to avoid in a drug design approach. 
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2.2 Peptides related to MccB17 
Two series of peptides were studied here, the first were two heptapeptides described 
previously that we considered as potential starting templates for variation of amino acids to 
establish structure-activity relationship and potentially generate new lead compounds. This 
series will be referred as HeptX. The second series was inspired by the MccB17 alkaline 
hydrolysis experiment. In several fractions with inhibitory activity on gyrase, a compound with 
MW = 857 was observed, this compound could be related to the MccB17 fragment G43toN53 
(MW = 856). This fragment contain two tz residues, and two amide residues, which are 
important MccB17 features and make this compound a plausible candidate for a gyrase 
inhibitor. The fragment corresponding exactly to this MW would be MccB17(G43toN53) where 
only one of the amide groups has been converted to an acidic residue in the alkaline 
conditions. The possibility that one of the amide residues, likely the glutamine, could have 
been unaffected by the hydrolysis seems a possibility as we have observed in Chapter I that the 
glutamine residue remained untouched during the conversion of MccB17 amide residue to acid 
in mild alkaline condition. We extended our field of investigation to all the possible variations 
of this fragment that are described in Figure 132 in order to identify the optimal inhibitor. All 
these peptides were ordered from EMC-microcollections (Tübingen). This series of compounds 
will be referred as PeptXX. 
 
 
Figure 131 Evaluation of the effect of protecting groups variation on pyrrole and tzoz compounds on gyrase 
supercoiling: gel electrophoresis of the reaction mixture of standard supercoiling assays in presence of no drug, 
17 µM ciprofloxacin, or 1 mM of the tested compound. The results for Fmoc-tzoz-OH are not very clear but there 
is definitely an improvement of inhibition compared to the related unprotected amino acid. Additionally 
removal of the protecting group from Fmoc-2,5-pyr-OH led to a compound without any inhibitory activity at 1 
mM concentration. 
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2.2.1 Evaluation of the peptides: 
2.2.1.1 Heptapeptides 2.2.1.1.1 E. coli gyrase 
Preliminary studies have shown that these peptides have inhibitory activity on 
supercoiling at 20 µM for Hept-tz, and 70 µM for Hept-pyr (Coquin 2005). The two peptides 
were evaluated using standard supercoiling assays. As the activity observed was below what 
we expected, we decided to follow the inhibitory activity over a time course, as described for 
MccB17 in Chapter II. The supercoiling time courses are shown below in Figure 133. The time 
courses show a weak activity at 1 mM, and Hept-pyr appear to be more active than Hept-tz. 
Figure 132 Structures and references of the Heptapetides and PeptXX compounds series 
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Figure 133 Inhibition of gyrase supercoiling by Hept-tz and Hept-pyr over time: gel 
electrophoresis from samples of a standard supercoiling assay in the presence of no 
drug, MccB17 40 µM, or Heptapeptide at 1 mM, taken at 15 min, 30 min, 1 h, 1 h 30, 
2 h, 3 h, and 4 h. The upper ladder corresponds to the starting relaxed DNA species, 
the lower band corresponds to the supercoiled DNA products. Inhibition of 
supercoiling reaction by MccB17 shows an increase of relaxed species, i.e. brighter 
top bands. Only Hept-pyr displays a weak inhibitory activity at 1 mM.  
Figure 134 Evaluation of Hept-pyr and Hept-tz on E. coli topo IV: gel 
electrophoresis of standard topo IV relaxation assay in presence of 17 µM of 
ciprofloxacin, or 1 mM of heptapetide. The lower bands represent the starting 
supercoiled DNA, the upper band represents the produced relaxed DNA. In 
the presence of an inhibitor (ciprofloxacin) the upper bands loses in intensity 
in favor of the lower band. Some activity is observed for both tested 
compounds. 
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2.2.1.1.2 E. coli topo IV 
The compounds were reported to be active on topo IV as well so assays on E. coli topo 
IV were performed to complement our observations. As with gyrase, weak inhibitory activity 
on topo IV was observed for both peptides at 1 mM concentration (Figure 134).  
2.2.1.2 PeptXX 2.2.1.2.1 E. coli gyrase 
PeptXX compounds were assayed for activity on gyrase supercoiling and cleavage using 
the standard method. The results are shown in Figures 135 and 136. Inhibition of gyrase 
supercoiling activity was observed at 500 µM concentration for all compounds. 
Figure 135 Activity of the PeptXX compounds on E. coli gyrase supercoiling: gel electrophoresis from samples of a 
standard supercoiling assay in the presence of no drug, MccB17 40 µM, or peptXX at 500 µM. The upper band 
corresponds to the starting relaxed DNA species, the lower band corresponds to the supercoiled DNA products. 
In the presence of an inhibitor (ciprofloxacin) the lower band loses intensity in favor of the upper band. PeptED, 
PeptEN and PeptQN inhibit the reaction at 500 µM, PeptQN being the most potent. 
Figure 136 Evaluation of the stabilisation of cleavage complex by PeptXX: gel electrophoresis of standard 
cleavage assays performed in presence of 40 µM MccB17 or 500 µM of PeptXX. The upper band represents the 
starting relaxed DNA, the lower band represent the produced supercoiled DNA. In the presence of a cleavage 
complex stabilizer (MccB17) a new band corresponding to linear DNA appears between the two others. None of 
the compounds tested stabilised the cleavage complex. 
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2.2.2 Heptapetides and PeptXX on human Topo II 
The inhibitory activity displayed by the Heptapeptides and PeptXX series encouraged 
us to evaluate them on other topoisomerases, even if their activity was weak on gyrase they 
might have a increased potency on another target. Inhibitory activity on human topo II 
relaxation was assayed using standard method. The compounds were initially tested at 333 µM 
for the heptapepides and 250 µM for PeptXX series. As no inhibitory activity was observed, no 
further studies were performed on these compounds. 
2.2.3 Conclusion 
The low level of activity that we observed for both heptapeptides discouraged us from 
using them as models to develop peptide topoisomerase inhibitors as was planned initially. The 
PeptXX series was not much more successful, the level of activity displayed could not account 
for the activity of the alkaline hydrolysis mixture observed in Chapter III-1. In the light of our 
present knowledge this is not surprising: the initial observation of a species with a MW = 857 in 
the hydrolysate was very likely to be related to the inactive MccB17 by-product described in 
Chapter II-3. Interestingly the most active of our PeptXX compounds was the MccB17 “natural” 
fragment, the one containing two amide residues, the inhibitory activity seems to weaken with 
the replacement of amide residues by acid residues. None of the compounds were able to 
stabilise the gyrase-DNA cleavage complex. This was an additional clue showing the 
importance of these residues for MccB17 interaction with gyrase and the fact that the toxin is 
an “optimised” structure. Even if these results were disappointing, we had achieved inhibition 
of gyrase supercoiling with a small fragment of MccB17 at ten times the MccB17 inhibitory 
concentration, this is encouraging evidence that sub structures of MccB17 have the potential 
to produce good topoisomerase inhibitors. 
2.3 Benzothiazole 
This series of compounds derived from benzothiazole were reported as Staphylococcus 
aureus (S. aureus) inhibitors with an unknown target. All the benzothiazole series displayed in 
Figure 137 was kindly provided by our collaborator Marco Antonio Florio (Dipartimento 
Farmaco-Chimico, Università degli Studi di Bari). 
Figure 137 Structures and references of the benzothiazole series compounds 
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2.3.1 Evaluation of activity on E. coli gyrase   
The activity of BZ compounds was first evaluated on E. coli gyrase using standard 
supercoiling assays. Preliminary results displayed strong inhibitory activity so concentrations 
ranging from 1 mM to 1 µM were used to obtain an approximate IC50. The values were 
extrapolated by a linear regression of the percentage of inhibition observed on the gel as a 
function of the concentration for the point corresponding to 50% inhibition. The IC50s values 
obtained, structure, and the in vivo activity on S. aureus (personal communication M. A. Florio 
(Dipartimento Farmaco-Chimico, Università degli Studi di Bari)) of the BZ compounds are 
summarized in Figure 138 
 
 
 
The BZ series had shown some interesting inhibitory activity on E. coli gyrase, 
surprisingly the most active compounds on E. coli gyrase are different from those that are 
active on S. aureus. This suggests that gyrase is unlikely to be the main target of the 
Figure 138 Supercoiling assays of the benzothiazole compounds and summary of evaluated IC50 and MIC values 
reported for S. aureus: In this table can be seen the gel electrophoresis results of standard supercoiling assay 
reaction in the presence of 16 µM ciprofloxacin, or 1/10/100/1000 µM of the benzothiazole compound tested. 
The upper bands correspond to the starting relaxed DNA species, the lower band corresponds to the supercoiled 
DNA products. In the presence of an inhibitor (ciprofloxacin) the lower band loses in intensity in favor of the 
upper band. In the bottom left corner are summarised the IC50s extrapolated from this gel by linear regression of 
percentage of the inhibition observed for the two points surrounding 50% inhibition; the reported MIC on S. 
aureus is present for information as well. 
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benzothiazole series, but until these compounds are evaluated on the S. aureus gyrase this 
cannot be certain. To further characterize these active species, BZ16 and BZ17 were assessed 
in cleavage assays, but no stabilization of the gyrase-DNA cleavage complex was observed 
(data not shown). 
2.3.2 Evaluation of activity on Staphylococcus aureus gyrase 
Supercoiling assays were carried out with the BZ compounds on S. aureus gyrase as 
described in Chapter II. These assays were performed with the collaboration of Terence Chung 
(Dept Biological Chemistry, John Innes Centre).  
 
 
 
Some inhibition of S. aureus gyrse supercoiling has been observed at 500 µM for the 
following compounds BZ17, BZ12, BZ5 in order of increasing inhibitory activity.  
2.3.3 Evaluation of activity on human topo II 
As the BZ compounds appeared to have a topoisomerase inhibitor profile, we decided 
to extend our study to human topo II. Relaxation assays were performed as described in 
Chapter I. Three compounds show inhibitory properties on topo II at 200 µM: BZ 12, BZ 16 and 
BZ17, the last being the most active and further assays placing its IC50 between 100 and 200 µM 
(Figure 140). 
Figure 139 Evaluation of Inhibitory activity of benzothiazole on S. aureus gyrase supercoiling: gel electrophoresis 
from samples of S. aureus supercoiling assay as described in Chap II in the presence of no drug, ciprofloxacin 17 
µM, novobiocin 1 µM, or benzothiazole compound at 500 µM. The upper bands correspond to the starting 
relaxed DNA species, the lower band corresponds to the supercoiled DNA products. In presence of an inhibitor 
(ciprofloxacin) the lower band loses intensity in favor of the upper band. BZ5, BZ12 and BZ17 inhibit weakly the 
reaction at 500 µM. 
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2.3.4 Conclusion 
The benzothiazole compounds have proved to be successful inhibitors on human topo II 
(BZ17 particularly) and E. coli gyrase (BZ16), but were not cleavage gyrase-DNA complex 
stabilizer for E. coli. The assays on S. aureus gyrase did not show a sufficient level of inhibitory 
activity to explain the antibacterial properties of the BZ series on S. aureus. It would be 
interesting to evaluate these compounds on S. aureus topo IV as weak inhibition was displayed 
on gyrase. This family of compounds might worth further investigation on human topo II as the 
inhibitory concentration of BZ17 not far from what we use for the etoposide control. 
 
Figure 140 Evaluation of Inhibitory activity of benzothiazole on human topo II relaxation: gel electrophoresis from 
samples of standard topo II supercoiling assay as described in Chap II) in the presence of no drug, etoposide at 
100 µM, or benzothiazole compound at 200 µM. The lower band corresponds to the starting supercoiled DNA 
species, the upper band correspond to the relaxed DNA products. In presence of an inhibitor (etoposide) the 
upper band lose in intensity in favor of the lower band. BZ12 and BZ16 inhibit the reaction at 200 µM at a lower 
level than the etoposide control. 
Table 9 Summary of benzothiazole compound activity on topoisomerases. 
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2.4 Prodiginines (SWH) 
Prodiginines are pigmented tripyrrolic antibacterial compounds produced by 
actinomycetes and eubacteria. They have been shown to have a wide range of other 
therapeutic potential, immunosuppressant and antitumour agent for example. A series of 
compounds produced by the modification of the undecylprodiginine biosynthetic pathway 
have been provided by our collaborator Stuart Haynes (Greg Challis lab, Department of 
Chemistry, University of Warwick). As some of these compounds share some similarities with 
MccB17 heterocyclic residues we included them in this study and evaluated their inhibitory 
activity on a set of topoisomerases. The compounds are described in Figure 141 with the 
references allocated. 
 
2.4.1 Evaluation on E. coli gyrase  
The activity of prodiginines was evaluated in the gyrase supercoiling reaction. The 
inhibitory activity observed at 200, 66, 22 and 7 µM concentrations, were used to obtain 
approximate IC50 values as shown on Figure 142. Following this observation of a good 
inhibitory activity, the compounds were evaluated for their ability to stabilise the gyrase-DNA 
cleavage complex using standard cleavage assays (Figure 143). 
Figure 141 Structures and references of the prodiginines series compounds (SWH) 
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Figure 143 Evaluation of the stabilisation of 
the gyrase-DNA cleavage complex by 
prodiginines: gel electrophoresis of standard 
cleavage assays performed in presence of 40 
µM MccB17 or 500 µM of SWH compound. 
The upper band represents the starting 
relaxed DNA, the lower band represents the 
produced supercoiled DNA. In presence of a 
cleavage complex stabilizer (MccB17) a new 
band corresponding to linear DNA appears 
between the two others. None of the 
compounds tested shows an increased level 
of linear DNA compared to the gyrase alone 
control. 
 
Figure 142 Supercoiling assays of the prodiginine series and summary of evaluated IC50s : In this table can be seen 
the gel electrophoresis results of standard supercoiling assays in the presence of 17 µM ciprofloxacin, or 
200/66/22/7 µM of the SWH compound tested. The upper bands correspond to the starting relaxed DNA species, 
the lower band corresponds to the supercoiled DNA products. In the presence of an inhibitor, the lower band loses 
intensity in favor of the upper bands (MccB17) or disappears if the inhibition is total (ciprofloxacin). In the lower 
right corner are summarized the IC50 approximated from the plotted the percentage of inhibition observed on this 
gel versus the concentration of inhibitor. 
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2.4.2 Evaluation on human topo II 
Following the success on E. coli gyrase, the prodiginine trial was extended to human 
topo II, all the compounds were tested at 200, and 100 µM. The results obtained at 100 µM are 
shown in Figure 144 (left). Compounds showing activity at 100 µM were subsequently assayed 
at 50 µM where only SWH84 was still active Figure 144 (right). 
 
2.4.3 Conclusion 
The prodiginine derivatives displayed some promising properties as topoisomerase 
inhibitors both with E. coli gyrase and human topo II; these results are summarised in Table 10. 
SWH79 and SWH86 where the best inhibitors of E. coli gyrase with IC50s = 7 µM; this is 
comparable to the level of activity shown by ciprofloxacin in our assays. SWH84 was the best 
inhibitor of human topo II, with 100% inhibition at 50 µM, whereas etoposide had an IC50 of 
100 µM in our assays. Interestingly the higher level of inhibition of E. coli gyrase and human 
topo II was achieved by different compounds in the series. This suggests that different features 
of the prodiginines are involved in the interaction with E. coli gyrase or human topo II, 
therefore prodiginine-inhibitors specific to E. coli gyrase or human topo II could be designed. 
Unfortunately in spite of these promising results, due to lack of time, no additional 
experiments were conducted on these compounds, although further investigation of this series 
will be planned in concert with our collaborators. 
 
 
 
 
Figure 144 Evaluation of the Inhibitory activity of prodiginines on human topo II relaxation: gel electrophoresis 
from samples of standard topo II supercoiling assay in presence of no drug, etoposide at 100 µM, or SWH 
compound at 100 µM and 50 µM for SWH84 and SWH86. The lower band corresponds to the starting supercoiled 
DNA species, the upper bands correspond to the relaxed DNA products. In presence of an inhibitor (etoposide) the 
upper band lose in intensity in favor of the lower band. All prodiginines inhibit the reaction at 100 µM some of 
them at a higher level than the etoposide control. SWH84 displayed complete inhibition of relaxation at 50 µM. 
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2.5 Methylenomycin 
Methylenomycins are antibacterial compounds produced by Streptomyces coelicolor. 
Two of these cyclopentanoid compounds have been studied here: methylenomycin A (MetA), 
methylenomycin C (MetC), their structures are described below in Figure 145. These 
compounds were kindly provided by our collaborator Christophe Corre (Greg Challis lab, 
Department of Chemistry, University of Warwick, Coventry).  
Figure 145 Methylenomycin A and C structures and references. 
Table 10 Summary of the prodiginines activity on topoisomerases. 
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2.5.1 Evaluation of inhibitory activity on E. coli gyrase 
The activity of the two compounds was assayed using standard supercoiling, relaxation 
and cleavage protocols. The various assays are shown in Figure 146. Gyrase supercoiling was 
inhibited by concentrations as low as 90 µM for MetA and 20 µM for MetC. The relaxation 
experiment was not so conclusive, very weak inhibition was observed. None of the compounds 
was able to stabilize the gyrase-DNA cleavage complex. 
Figure 146 Supercoiling, relaxation and cleavage assays of methylenomycin A and C on gyrase:  
Supercoiling: gel electrophoresis results of standard supercoiling assay reaction in presence of 17 µM 
ciprofloxacin, 40 µM MccB17 or 90 µM MetA or 20 µM MetC. The upper bands correspond to the starting relaxed 
DNA species, the lower band corresponds to the supercoiled DNA products. In the presence of an inhibitor the 
lower band loses intensity in favor of the upper band (MccB17) or disappears if the inhibition is total 
(ciprofloxacin). MetA shows a weak inhibition at 90 µM, MetC seems to give 50% inhibition of supercoiling at 20 
µM. 
Relaxation: gel electrophoresis results of standard relaxation assay reaction in presence of 17 µM ciprofloxacin, 
40 µM MccB17 or 90 µM MetA or 20 µM MetC. The lower band corresponds to the starting supercoiled DNA, the 
upper band correspond to the relaxed DNA products. In the presence of an inhibitor the lower band loses 
intensity in favor of the upper band (ciprofloxacin). A very weak inhibitory effect is observed for the two 
compounds at their respective concentration, similarly to the MccB17 control in this experiment (the ladder of 
relaxed species is larger for MccB17, MetA and MetC compared to gyrase alone). 
Cleavage: gel electrophoresis of standard cleavage assays performed in presence of 40 µM MccB17, 100 µM 
MetA or 25 µM MetC. The upper band represent the starting relaxed DNA, the lower band represent the 
produced supercoiled DNA. In presence of a cleavage complex stabilizer (MccB17) a new band corresponding to 
linear DNA appears between the two others. None of the compounds tested increased the level of linear DNA 
compared to the gyrase alone control. 
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2.5.2 Evaluation of inhibitory activity on human topo II 
As the two methylenomycins show activity on E. coli gyrase their evaluation was 
extended to human topo II. Their inhibitory activity was evaluated using standard topo II 
relaxation assays with concentration of compounds of 100 µM and 200 µM. MetA did not show 
any inhibitory activity at 200 µM. MetC displayed complete inhibition of relaxation at 100 µM, 
which is a stronger effect than the etoposide control (Figure 147). 
 
2.5.3 Conclusion 
From the two methylenomycin compounds MetC was the most active on both E. coli 
gyrase (20 µM) and on human topo II (<100 µM), MetA was fifty times less active on gyrase and 
not active on topo II. The significant difference of activity between the two compounds is quite 
surprising as they only differ by the presence of an epoxide function in MetA where MetC has a 
double bond. This difference of activity might indicate that the “flatness” of MetC in this region 
of the molecule is important for its activity, and thus should be conserved if derivatives are 
generated. Although these results are promising, they were preliminary and will require 
validation before the series can be further investigated.  
 
 
Figure 147 Evaluation of Inhibitory activity of Methylenomycin A and C on 
human topo II relaxation: gel electrophoresis from samples of standard topo 
II supercoiling assay in the presence of no drug, etoposide at 100 µM, or 
methylenomycin at 200 µM or 100 µM. The lower band corresponds to the 
starting supercoiled DNA species, the upper band corresponds to the relaxed 
DNA products. In the presence of an inhibitor (etoposide) the upper bands 
lose intensity in favor of the lower band. MetC inhibit the reaction at 100 
µM at a higher level than the etoposide control. 
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3 Activity of compounds related to MccB17 on E. coli cells 
The heterocycles from MccB17, the pyrroles compounds and the heptapeptides 
described above were submitted to in vitro test on E. coli colonies. Two different strains were 
used for the halo assays: MG1655 a standard E. coli strain and NR698, an E. coli drug-
permeable strain that has been described in chapter II. The halo assays were performed using 
the following method: 200 µl of overnight culture of either MG1655 or NR698 were added to 3 
ml of molten LSS agar, after gentle mixing the mixture was poured onto a LB agar plate to form 
a homogeneous layer. Drops of 2 µl of DMSO containing the drug tested were laid down on the 
surface of the agar plate. The plate was incubated overnight at 37°C before being read. The 
table below summarizes the level of inhibitory activity observed for the various compounds on 
the two strains, a custom reference system that was created to classify the level of inhibition 
observed is detailed as well. The inhibitory activity on in vivo growth of MG1655 and NR698 
observed with the different compounds were in no case comparable to the MccB17 control, 
inhibition was lower than MccB17’s with concentrations at least fifty times higher. The best 
inhibitors were the two Fmoc-pyrrole compounds. The overall low inhibitory activity displayed 
can be explained by a low uptake of the compounds used: MccB17 benefit from an active 
transport system, OmpF in the outer membrane and SbmA in the inner membrane to reach its 
target; probably no transport system is available to bring the compounds assayed to their 
target. The increased inhibition of growth observed on NR698 compared to MG1655 supports 
this hypothesis, as the outer membrane is permeable to the compounds it removes one of the 
barriers on the way to their potential target, but the inner membrane still remains to be 
crossed. 
Table 11 Summary of methylenomycins activity on topoisomerases. 
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Strong: visible 
on a black 
background, 
nearly 100% 
cells killed. 
Medium: 
visible on a 
black 
background, 
not all cells 
killed. 
Weak: can only 
be seen with a 
white lighting 
from behind. 
V. weak: can 
only be seen 
with raking 
light 
illumination. 
Table 12 Summary of in vivo activity of the MccB17’s heterocyclic compounds, pyrroles, and heptapeptides series 
on wild type and permeable E. coli strains: the table details the size of the halo created by a 2 µl drop of DMSO 
containing the concentration described in the table under Conc. on an agar plate layered either with the wild type 
strain MG1655 or the drug-permeable strain NR698. Only the Fmoc-pyr compounds displayed inhibitory activity 
equivalent to MccB17 but at higher concentration. On the right side is defined the reference system used to 
characterize the level of inhibition. 
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4 Summary 
The in vitro assays results obtained in this chapter are summarized in Table 13. The 
various compounds are colour-coded by family, written in red are the reference compounds 
used in the assays. 
Table 13 Summary of the inhibitory activity observed on various topoisomerases with the series of compounds 
described in this chapter 
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5 Conclusion 
The Investigation of the activity of small molecules containing heterocyclic moieties on 
various topoisomerases was described in this chapter. We started with the heterocyclic amino 
acids found in MccB17 both in their natural or chemically protected form. Although inhibitory 
activity displayed by these compounds was observed around 500 µM at best, it implies that 
some of these structures are interacting with gyrase with a low affinity and might prove a good 
starting point to build up series of topoisomerase inhibitors. This is supported by the results 
obtained with the alkaline hydrolysate described in Chapter III, where even if no precise 
compound has been identified, there are strong hints that the mixture contains such 
heterocyclic derivatives. The evaluation of compounds directly related to MccB17 was followed 
by the study of compounds more remotely related to these structures. In the three series of 
molecules provided by our collaborators we have found promising hits that inhibits E. coli 
gyrase in the same range as MccB17 or ciprofloxacin, and topo II at the same range as 
etoposide. Although the results gathered were preliminary and will require further validation, 
they will be pushed forward with our collaborators in the near future. The results obtained 
with benzothiazoles, prodiginines, and methylenomycins compounds once validated will open 
these chemical families for the design of potential new topoisomerase inhibitors. 
Unfortunately, none of the compounds studied in this chapter was able to stabilize the gyrase-
DNA cleavage complex which would be the real breakthrough in antibacterial drug discovery 
we were aiming at. Although it is still possible that such property can be attained by building 
more complex structures based on MccB17’s heterocycles. 
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CHAPTER V Discussion 
Over the previous chapters we have described the various approaches carried out on 
MccB17 to understand its mechanism and use it as a template to generate topoisomerase 
inhibitors. After describing the various antibacterial agents and their mechanism, we had put a 
special focus on topoisomerases. We mentioned the successful exploitation by the 
fluoroquinolone drugs of two topoisomerases, gyrase and topo IV, through a mechanism called 
topoisomerase poisoning. Placing MccB17 in the context of the present antibacterial agent 
crisis, we highlighted its importance as one of the rare non-quinolone structures able to poison 
gyrase. We had described how we planned to explore MccB17 activity and its structure as a 
potential source for small molecule topoisomerase inhibitors over three aspects: the first 
focusing on the mechanistic aspect of MccB17 action, the second involving the fragmentation 
of the toxin and evaluation of the resulting species, and finally the evaluation of the 
heterocyclic moieties that characterise MccB17 and some related species. We will cover this 
last part first as it stand aside from the other results.  
Previous studies suggested that some of the heterocyclic amino acids found in MccB17 
had some inhibitory activity on gyrase by themselves. As we were planning to build on such 
structures to generate new topoisomerase inhibitors, we evaluated the activity of the various 
heterocyclic residues found in MccB17, and incorporated as well various protected 
intermediates in the study. The level of activity we observed was weaker than what we 
expected, thiazole, bis-heterocyclic amino acids and their protected counterparts showed 
inhibition of gyrase at ~ 500 µM at best. The compounds were not able to poison gyrase, and 
were affecting MccB17-resistant gyrase at the same concentration as the wild type. This 
evidence suggested that their mechanism of inhibition was unrelated to MccB17’s; this, added 
to their weak activity observed, discouraged us from performing further investigation. 
However, three families of related compounds were investigated as well: benzothiazoles, 
prodiginines and methylenomycins. Interestingly in each family were found compounds able to 
inhibit gyrase to some degree, the best were: BZ16 at 30 µM for the benzothiazole, SWH79 and 
SWH86 at 7 µM for the prodiginines, and methylenomycin C at 20 µM for the 
methylenomycins; none of them were able to stabilize the gyrase-DNA cleavage complex. 
These preliminary data are encouraging to investigate further these chemical families. It will be 
important first to clarify the compound’s mechanism of action, knowing if it involves the 
ATPase activity of the enzyme for example; this can be done by using relaxation assays or 
ATPase assays. Another possibility is the generation of spontaneous mutations of gyrase in vivo 
that confer resistance to the best compound identified; the location of these mutations will 
give insight into the mode of action of these different compounds. Finally the structure-activity 
relationship for each group can be built by assaying a set of compounds covering a range of 
chemical variations for each family. The prodiginine family seems the most promising, as all its 
members have their inhibitory activity below 40 µM, with the best at 7 µM, which is close to 
the ciprofloxacin IC50 in our assays. The only downside of the prodiginines is their high 
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lipophilicity (calculated LogP SWH86 = 5.3 and LogPSWH79 = 5.5, Lipinski rule advise LogP < 5), which 
limits their solubility and will probably hinder their uptake.  
One aspect we wanted to tackle here was the molecular basis of MccB17 interaction 
with gyrase. To address this we relied on isolating spontaneous mutations mapping to gyrase 
and conferring resistance to MccB17 in vivo. As previous studies reported that most resistance 
to MccB17 were due to uptake impairment, we considered using a strain with an increased 
permeability to chemicals. Unfortunately none of the MccB17-resistant mutants isolated 
carried mutations on gyrase. It appeared that the resistance observed were caused by 
mutation of the MccB17 transporter SbmA in the inner membrane; this was confirmed by the 
fact that strain resistant to MccB17 were also resistant to bleomycin, which uses the same 
transporter. The only spontaneous mutation leading to resistance to MccB17 reported so far in 
the literature is GyrB W751R (Vizan, Hernandez-Chico et al. 1991; del Castillo, del Castillo et al. 
2001). The mutant was isolated from strains modified to overexpress SbmA, after discarding 
colonies where resistances were caused by outer membrane mutations, which were 
representing the majority of resistant colonies. By modifying our permeable strain NR698 to 
overexpress SbmA, we will avoid all possible resistance linked with the uptake of the toxin, 
thus increasing the possibility that resistance will arise by mutation of the MccB17’s target, 
gyrase. Even if this part of the work did not yield the information we were expecting, we found 
a way to address this problem in the future, with confidence about a positive outcome. Dealing 
with the in vivo resistance mechanism to MccB17, we became aware of the critical role of the 
uptake system for MccB17 action, and how easily bacteria can acquire a way to protect 
themselves against the toxin. Taking that into account, we should aim at new antibacterials 
derived from MccB17 that are not dependent on this uptake system. In future work, early 
tracking of the emergence of resistant colonies to a given MccB17 derivative should be kept in 
mind. 
The central question in this study was: which features of MccB17 are responsible for its 
activity, and can they be copied to produce new antibacterial agents? Elements from both the 
study of the whole MccB17 molecule in Chapter II and the generation and evaluation of 
MccB17 fragments in Chapter III led to convergent evidence regarding these aspects. The first 
major discovery was the fact that removal of terminal amino acids affects differently the 
activity of the toxin depending if they belong to N- or C-terminus of the peptide. This was first 
hinted by a MccB17 species, present as the main component of a fraction isolated from the 
digest of MccB17 by subtilisin: the MccB17 derivative, even if it was lacking the four N-terminal 
amino acids, seems to have its activity unaltered. To complement this information, the effect 
of shortening the C-terminus on MccB17 activity was studied by digesting the peptide with the 
exoprotease Carboxypeptidase A. The resulting mixture contained mainly a species 
corresponding to MccB17 lacking the last C-terminal residue, an isoleucine. Other species 
observed in lower amounts were corresponding to species lacking two and three C-terminal 
amino acids. The mixture did not show any inhibitory activity on gyrase supercoiling at twice 
the usual MccB17 concentration. These two experiments suggested that modification of the N-
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terminus of MccB17 did not alter its activity whereas alteration of the C-terminus was highly 
detrimental to its activity. To validate this hypothesis we produced the species observed in the 
two experiments as pure compounds, by site-directed mutagenesis of the mcbA gene coding 
for MccB17 sequence in the pmcb17 plasmid, and transformation of E. coli DH5α. A stop codon 
was used to remove up to 4 C-terminal amino acids, whereas the substitution of a glycine by a 
lysine followed by a tryptic digest removed the substituted and upstream amino acids from the 
N-terminus. Evaluation of the MccB17 species lacking C-terminal amino acids shows a 
significant decrease of activity directly linked with the number of amino acids removed. An 
even more drastic loss of the ability to stabilize the cleavage complex was observed with the 
removal of the amino acid. The species lacking four N-terminal amino acids retain, as observed 
before, its full inhibitory activity on gyrase and its ability to stabilize the cleavage complex. The 
tolerance of the N-terminus of MccB17 to modification confirms what was earlier hypothesised 
in the literature about MccB17 synthetase: the N-terminus residues are mainly involved in the 
maturation of the peptide as a spacer necessary for synthetase activity. The sensitivity of the C-
terminus on the other hand suggests a more critical role in MccB17 antibacterial activity. This 
finding opens some interesting perspectives to produce a “minimal MccB17” as a working 
template, which will be a MccB17 where all the N-terminal residues unnecessary for the 
stabilisation of the cleavage complex have been removed. We had demonstrated that a 
derivative with eight glycine residue upstream of the A site is as active as MccB17, but how 
many glycines are really required to maintain the gyrase-poisoning activity. If this area of 
MccB17 is only a spacer required for processing the toxin, as we think it is, it is possible that a 
MccB17 derivative starting at the A site or with only a few glycines upstream will still be active. 
Let us imagine that a compound corresponding to MccB17 where the first 10 N-terminal 
residues have been removed leaving only two glycines upstream of the A site is active. This 
compound would have a MW =2425 which is a ~20% decrease in MW compared to MccB17, 
and two less lipophilic residues, Val and Ile; these modifications represent a significant 
improvement toward drugability. 
 
Figure 148 MccB17 modification area: the green box shows the amino acids that have been successfully removed 
without altering the peptide activity. The yellow box shows residues that can be removed by proteolytic or chemical 
methods to evaluate their importance. The blue box shows the variation we consider to characterise the essential C-
terminal Ile. 
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Once the “minimal MccB17” template is identified, the next step will be to evaluate if 
the remaining glycines upstream of the A-site can be substituted by other residues to increase 
the affinity of the peptide for the cleavage complex. Concerning the C-terminus, we revealed 
that removing the terminal isoleucine is detrimental to the toxin activity, and further removal 
of residues kills completely the activity. But what is the cause of the loss of activity observed 
when the Ile is removed, is it due to the loss of specific interaction of this residue with a 
lipophilic pocket? In that case replacement of the Ile by another lipophilic residue of similar 
size should not be too detrimental for the activity of the resulting compound. Another possible 
reason for the loss of activity is that removing the Ile residue causes the shift of the negatively 
charged carboxylate group from the Ile end to the His end, this can have a destabilizing effect 
on the DNA-gyrase-peptide complex if repulsive electrostatic interactions take place at the new 
position of the carboxylate group. In this case, the substitution of the C-terminal Ile by a Gly 
should restore the position of the carboxylate and lead to an active compound. Answering 
these questions will be a real breakthrough in the understanding of MccB17 structure-activity 
relationships. To investigate further the modification of the N-terminus of MccB17, the 
application of site directed mutagenesis techniques seems the obvious choice to address this 
issue. The only limitation is that the introduction of a Lys residue in the vicinity of the A site 
may prevent its processing, and generally hinder the toxin production. An alternative will be to 
consider again the exopeptidase digest strategy; it will probably worth optimising the 
conditions we have used with the Leu-aminopeptidase, as only one unsuccessful attempt was 
made and  was not studied further as we obtained what we wanted from a different method. It 
might be sensible to consider different aminopeptidases as well. These two methods have their 
advantage and drawbacks: if similar results to what we obtained with the Carboxypeptidase A 
can be achieved with an aminopeptidase, then the aminopeptidase digest of MccB17 can be 
set up to remove the required N-terminal amino acid from MccB17. The exoprotease digest 
reactions are straightforward once the optimisation is done, and usually give very good yield, 
the downside of the method being that we had only a relative control over the species 
produced, and the final product is likely to be the expected compound as the main component 
in mixture with other species with one more or one less amino-acid. The site-directed 
mutagenesis on the other hand produces a single compound with good purity, but there is no 
certainty that it will be processed, and the yield is unpredictable. Site-directed mutagenesis is 
the method of choice to generate MccB17 C-terminal mutants as there is no problem with the 
processing due to the position of the change. An alternative method for the N-terminal 
modification we have considered lately, but had not tried, is Edman degradation. This method 
is usually applied for peptide sequencing, but it is applicable in our case to remove the N-
terminal residues of MccB17. By reacting an amino group with phenylisothiocyanate, this 
method transforms the N-terminal residue of a peptide into a phenylthiocarbamyl in moderate 
alkaline conditions (pH = 8). The shift to acidic conditions causes the phenylcarbamyl-N-
terminal residue to cyclise into a thiazolinone, thus releasing the peptide minus one residue. 
The thiazolinone is recovered to be analysed; heating it in acidic conditions converts it into a 
phenylthiohydantoin, which is a better analyte for electrophoresis or chromatography. In our 
case, by only using the two first steps, and removing the thiazolinone with an organic 
extraction with solvent where MccB17 is not soluble, we should be able to remove one N-
terminal amino acid from MccB17. Repeating this process over a defined number of cycles will 
produce MccB17 lacking the desired number of residues on its N-terminus. Such a method will 
require some experimental set up, but it is routinely applied to peptides for sequencing and 
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the solvent system is compatible with MccB17, we are confident that it will yield the expected 
results. 
More drastic alteration of MccB17 has been explored by cutting it into fragments. The 
initial means used to fragment MccB17 was the non-selective hydrolysis of its peptide bonds 
by sodium hydroxide. It had been reported in previous work that such treatment led to a 
mixture of small fragments that can inhibit gyrase activity. We followed the same approach 
with the intent of using purification methods to isolate the different components of the 
mixture and identify the inhibitor(s). We observed as well the effect of the hydrolysate mixture 
on gyrase supercoiling, but no stabilization of cleavage complex. Our efforts to isolate the 
active component(s) were unfruitful. We decided to use a more selective method involving the 
proteolytic cleavage of MccB17 to generate large fragment as potential gyrase inhibitors or 
poisons. During the production of MccB17 we observed that some by-products turned out to 
be fragments of MccB17; these “spontaneous” fragments were integrated into our set of 
evaluated MccB17 fragments. Initially we were wondering if these fragments were resulting 
from the degradation of MccB17 in the conditions used to extract the toxin from the producing 
cells, or if they were by products from the biosynthesis in the cell. Interestingly these 
“spontaneous” fragments were observed repeatedly in the proteolysis experiments as well, 
suggesting that they are likely to be spontaneous products from MccB17 degradation in the 
experimental conditions. Lately we realized that some of these “spontaneous” fragments were, 
to our surprise, active. This was both good and bad news, on one hand we had substructures of 
MccB17 that can be easily generated and that possess interesting inhibitory properties. On the 
other hand, in the meantime, the digest of MccB17 by subtilisin had successfully yielded 
mixtures active on gyrase, but they were containing as well some of these “spontaneous” 
fragments,  making us worried that the observed inhibition was only due to these compounds, 
and not from any specific subtilisin cleavage. Fortunately, as we have used different conditions 
in the course of our proteolysis experiments, these “spontaneous” fragments were produced in 
various amounts depending on the experiment, whereas the level of activity observed was 
nearly constant. This was confirmed by some of the fractions isolated from the HPLC 
purification from MccB17 digest by subtilisin were active and did not contain any 
“spontaneous” fragment.  
 
 
In spite of our effort to separate the components of the various active mixtures, we 
were not able to isolate and identify the active entities. The species observed in the active 
fraction over our different experiments narrowed the possibilities to a list of a few candidate 
compounds. Interestingly, these compounds are related to two main area of MccB17 as shown 
Figure 149 Summary of MccB17 fragmentation results: the top part of the table shows fragments that are present in 
the active fractions as the main components. The lower part shows identified inactive proteolytic fragments. 
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in Figure 149, this list is completed with a few other compounds that were present as the main 
component in fractions with no inhibitory activity on gyrase. By comparing the active and 
inactive fragments we can start to formulate a hypothesis about the requirements to have a 
gyrase inhibitor. 
The most significant information we can get from Figure 149 is the comparison of Mw 
= 1393.4 and 1410.6 which are active at ~100 µM, with MW = 1209.4 which is not. MW = 
1410.6 and 1209.4 differ only by two amino acids on the N-terminus, Ser-Asn, whereas MW = 
1393.6 is a derivative from MW= 1410.6 by loss of ammonia. This suggests that these two 
amino acids are of some importance in the interaction with the gyrase-DNA complex. 
Furthermore supporting the importance of this Asn residue, is the fact that when Asn residues 
in MccB17 were converted to Asps, we observed a loss of the ability to stabilize the cleavage 
complex, and at least a two-fold decrease in the inhibition of gyrase supercoiling. This evidence 
implies that the MW=1410.6 fragment might be one of the minimal structures necessary to 
duplicate MccB17 inhibition of gyrase. Unfortunately we have only preliminary data, but they 
suggest that these compounds are not able to stabilize the cleavage complex. Slightly 
contradictory is the fact that MW = 1700.6, which is the complementary part of MccB17 to 
MW = 1410.6, has some inhibitory activity on gyrase supercoiling between 100 and 300 µM 
(and no cleavage complex stabilisation), and MW = 1374.4 is among our active candidates. On 
the other hand if we compare the structure it appears that they share a common pattern of 
residues distribution: bisheterocycle, amide, heterocycle, heterocycle, each feature separated 
by a glycine spacer. This arrangement of residues can be interpreted as a scaffold that can bind 
to the gyrase-DNA complex. In the case of MW=1410.6 there is the Ser-Asn that is missing in 
the inactive MW = 1209.4 at one end, and the Ser-His-Ile that is critical to the whole MccB17 
on the other end, these two fragments adding favourable interaction with gyrase whereas they 
are absent in MW=1700.6, explaining the difference of activity. The long glycine tail in 
MW=1700.6 can be an additional source of destabilisation.  
 
The question arising is what these structures are lacking to be able to stabilize the 
cleavage complex? It may be that they need an extra interaction with the gyrase cleavage 
complex to have the proper fit, and that can be achieved by the addition of a hydrogen bond 
donor/acceptor or a lipophilic/aromatic residue in the right place. The other possibility is that 
the whole two sequences are required to stabilize the gyrase-DNA complex. A partial answer 
can be given by testing if an equimolar mixture of MW = 1700.6 plus MW = 1393.6 is able to 
stabilize the cleavage complex, unfortunately that experiment would require us to isolate each 
compound alone, and separation of MccB17 fragments was one of the major issues in this 
Figure 150 Comparison of the two halves of MccB17: alignment of fragment 1700.6 and 1393.6 display their 
similarities in the distribution of their heterocyclic and amide residues. 
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work. If the whole sequence of heterocycles is required, it seems difficult to reproduce the 
effect of such a large molecule, but this not certain until we know exactly what the mechanism 
of MccB17 action is.  
As a summary, we can say that the heterocyclic amino acids found in MccB17 do not 
have a strong activity by themselves, and the weak effect observed was probably not related to 
the MccB17 mode of action. Substructures of MccB17, about half the size of the toxin, have 
inhibitory activity on gyrase between one to five times the MccB17 concentration; we did not 
get precise inhibitory concentration because the different species couldn’t be isolated as pure 
products. Preliminary experiments suggest that these fragments are not able to stabilise the 
cleavage complex, but further study should validate this fact. Considering the variation 
observed during the assays over various mixtures it is possible that different fragments can act 
synergistically mimicking the effect of the whole MccB17, but this will require better 
purification techniques to be addressed. The two main fragments of MccB17 that have shown 
activity have a common arrangement of heterocyclic and amide residues, this pattern (Figure 
151), and can be viewed as a potential template to design a synthetic chemical library of 
potential gyrase inhibitors. 
 
Considering the whole MccB17, we demonstrated that the removal of residues from 
the N- and C- terminus of the native MccB17 had different effects on its activity: the 
modification of the C-terminus is very detrimental to the toxin activity whereas the N-terminus 
can tolerate the loss of at least four amino acids without any alteration of activity. Based on 
these data, we suggest that N-terminal amino acids can be removed further to identify at 
which point a loss of activity can be monitored and thus define a “minimal” MccB17 structure 
able to poison gyrase. Such a structure would not only be useful to define the structural 
requirements for the activity, but would be a formidable tool for further structural studies. 
Peptide toxins have proved that they can adopt unusual structures and modes of action. CcdB 
and MccJ25, that have been mentioned before, illustrate perfectly how structural information 
can be critical with such compounds: CcdB’s mode of action was only really understood when 
the crystal structure of a fragment of GyrA and CcdB was solved, and shows how the CcdB 
dimer was filling a space created by gyrase conformational change during its cycle in the GyrA 
dimer and creating a dead end in the cycle, preventing gyrase from closing back its DNA gate, 
and thus stabilising the cleavage complex. Before these structural data were released, 
biochemical evidence was not able to give a coherent picture of the mechanism of CcdB.  
Figure 151 Schematic of the template inspired by MccB17 fragments for new synthetic topoisomerase inhibitors. 
186 
 
 
As for MccJ25, this 21 amino acids peptide was thought to be a head to tail cyclic 
peptide, as there was an 18 Da difference compared to the translation product. The 
biochemical evidence was understood when the 3-dimensional structure of MccJ25 was solved 
by extensive NMR and MS studies, and appears to adopt an unusual lassoed tail fold (Figure 
153). Its is not unlikely for MccB17 to have such an unusual structural twist, we already know 
that there is two different MccB17 species observed during the HPLC purification, and that 
their population varies depending on the pH. The problem encountered with MccB17 solubility 
in our experiments, suggest that it can agglomerate in a very stable form. 
Direct evidence about MccB17 interaction with gyrase is scarce: only one mutation 
conferring resistance to MccB17 have been identified on gyrase (B subunit) and no structural 
data are available. Finding news mutations conferring resistance to MccB17 will help define its 
binding site, but this work had shown the inherent difficulties of this approach, even if we had 
defined a strategy likely to be successful in the future. But the major progress will be to have 
information about the 3-dimensional structure of MccB17, this can be achieved by 
crystallography using the toxin alone, or better with gyrase and DNA; or by using protein NMR 
techniques on MccB17 in the presence and absence of gyrase and DNA. One of the features of 
Figure 152 Complex of CcdB and GyrA14 and models: (a) Gyr-A14: CcdB complex viewed along its 2-fold axis. 
The two CcdB monomers are drawn in orange and red and the two GyrA14 monomers in two shades of blue. 
(b) Same as (a), but rotated 90°. (c) Model of closed GyrA59 (blue) with CcdB (green) docked onto it by 
superposition of the  GyrA14:CcdB complex on the crystal structure of GyrA59 (Reece and Maxwell 1989). 
Residues Arg462 of both monomers of GyrA59 are highlighted. Strong steric overlaps (red) with the CAP 
domains are observed. (d) Model of the GyrA59: CcdB complex with GyrA59 in its open conformation. The 
open conformation of GyrA59 was modelled according to the corresponding yeast topoisomerase II structure 
(PDB entry 1BGW (Berger, Gamblin et al. 1996)). In this model, there is no steric overlap between CcdB and 
GyrA59. Reproduced from Dhao Thi & Van Melderen (Dao-Thi, Van Melderen et al. 2005). 
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MccB17, which was detrimental to such approaches, is the presence of the polyglycine tail, this 
disordered area is unfavourable for crystallography experiments, and creates unassignable 
signals in NMR analysis. The “minimal” MccB17 we mentioned above, once identified, may 
improve the output of these techniques, as a significant amount of the problematic residues 
might be removed. Until spectroscopic techniques generate such a structural breakthrough, 
the mode of action of MccB17 will probably remain a black box. We have the conviction that 
this is where future work on this subject should primarily focus.  
 
The reader may have the feeling from this summary that the stabilisation of the 
cleavage complex, which is the key feature of MccB17, requires most of the peptide structure. 
Even if all the residues upstream of the site A can be removed, the resulting compound might 
seem of limited interest as it still will be a large 31-residue peptide with properties close to 
MccB17’s. Two arguments can be propounded in favour of MccB17 derivatives: first, until the 
mode of action is precisely defined, the possibility of reproducing it by different means can not 
be dismissed. Second, once the smallest MccB17 fragment able to poison gyrase is isolated, the 
areas of the peptide that can tolerate modifications can be investigated and modified in order 
Figure 153 NMR-based structural model of MccJ25. In each view, the peptide chain is colored in a ramp (red-
orange-yellow-green-blue) from the N-terminal Gly1 (red) to the C-terminal Gly21 (blue), with the isopeptide 
bond linking the R-amino group of Gly1 with the γ-carboxyl of Glu8 coloured magenta. (a) Ensemble of 20 
models resulting from distance geometry simulated annealing calculations. The side chains of E8, F19, and Y20 
are shown and labeled. (b) Representative structure, shown in the same view as part a. The side-chains of V6, 
P7, E8, F19, and Y20 are shown. (c) The lariat ring (G1-E8) and the C-terminal tail (S18-G21) are shown as CPK 
atoms, with the C-terminal tail rendered transparent so the backbone is visible. Selected side-chains are 
labeled. (d) Stereoview with selected side-chains shown and labeled. Reproduced from Wilson et al (Wilson, 
Kalkum et al. 2003).  
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to improve the drugability of the molecule. The stabilisation of the cleavage complex has 
proved to be such an efficient way of killing cells that it will be a shame to miss the opportunity 
of identifying a new mechanism favouring it. Simple inhibition of gyrase, is not as lethal as 
poisoning, but is valuable if the inhibitors have a high affinity for the enzyme and can block 
efficiently its activity, as demonstrated by the aminocoumarins. We have focused here on 
MccB17 for its mode of action, and the potential of compounds duplicating it, as new 
antibacterial drugs. But other natural products, able to stabilize the gyrase-DNA cleavage 
complex have the same potential. Three other compounds seem to share that potential with 
MccB17: we had already mentioned CcdB, and albicidin as well as the toxin ParE are two other 
compounds that arouse our interest. We have described the mode of action of CcdB, and it 
seems hard to reproduce it with small molecule for therapeutic application, however some 
synthetic peptide (Figure 154) copying some feature of CcdB were shown to have inhibitory 
activity on gyrase and topo IV, but no stabilization of cleavage complex (Trovatti, Cotrim et al. 
2008). 
 
Albicidin is a toxin produce by Xanthomonas albilineans, the agent that causes the 
sugarcane leaf scald. The toxin had been shown to have attractive antibacterial properties 
(Birch and Patil 1985) as an ATP-dependent gyrase cleavage complex stabilizer (Hashimi, Wall 
et al. 2007). Albicidin’s primary structure is still under investigation: a gene required for it 
synthesis have been identified, and is encoding for a hybrid polyketide-peptide synthetase, this 
added to the NMR data reporting several aromatic ring and around 38 carbon atoms and, and 
the MS data giving an approximate MW = 842, give some indication about its chemical 
structure (Royer, Costet et al. 2004). The study of the toxin have been made difficult by the 
slow growth of the producing bacterium, fortunately heterologous production of albicidin has 
been reported  recently and open perspectives for the identification of its chemical structure 
Figure 154 CcdB and derived peptides: the various peptides evaluated by Trovatti et al, the green box highlight 
the peptide that shows a complete inhibition of on gyrase at 10 µM and of topo IV at 5 µM (Trovatti, Cotrim et al. 
2008).  
189 
 
and application in drug discovery (Vivien, Pitorre et al. 2007). If we consider its activity, and 
reasonable molecular weight, it is a promising compound. The ParE toxin is very similar to 
CcdB. ParE is a part of a toxin-antitoxin system with ParD that are included in the addiction 
plasmid RK2, whereas CcdB and the antitoxin CcdA are included in the F plasmid. ParE is a 12 
kDa protein that has been shown, like CcdB to stabilise the cleavage complex. The 
crystallographic structure of the ParE-ParD complex has been solved recently (Dalton and 
Crosson 2010). 
 
Looking at the toxin anti-toxin complex in comparison with the gyrA dimer, it is easy to 
imagine a mode of action similar to CcdB, even if the structures are quite different. It is very 
likely that the successful generation of peptide inhibitors from CcdB, can be applied with the 
toxin ParE. And if CcdB and ParE have similarities in their interaction with gyrase, features of 
both structures can be combined to design new gyrase inhibitors. A more remote approach to 
identify new compounds is related to MccB17 biosynthesis. MccB17 synthetase is an unusual 
enzyme that is converting specific sequence of, Gly, Ser, Cys into heterocycles. There are a 
multitude of bio-active molecules carrying oxazole and thiazole heterocycle that have been 
reported, some close to MccB17 are referred as TOMM (thiazole/oxazole-modified microcin) 
like the recently discovered plantazocilin (Scholz, Molohon et al.), others have a more remote 
structure like bleomycin, microcyclamides (Raveh, Moshe et al.), thiocillin (Wieland Brown, 
Acker et al. 2009), nostocyclamides, telomestatine, micrococcin P1 (Hughes and Moody 2007), 
tioseptron or pathelamides (Nolan and Walsh 2009). Tracking genes coding for protein similar 
to MccB17 synthetase, is a potential way of using the MccB17 biosynthetic pathway to discover 
new heterocyclic bioactive compounds. This approach is supported by the recent study of the 
streptolysin S biosynthesis from Streptococcus pyogenes. This toxin is produced by the sag 
gene cluster, sagA encodes the protoxin, and following sagB, sagC, sagD gene, have around 
20% identity with respectively mcbC, mcbB, and mcbD, and convert SagA to a cytolysin by 
heterocyclisation of peptide sequences (Lee, Mitchell et al. 2008). There is a close relation 
between these two pathways, and the fact that the biosynthetic operon, responsible for the 
Figure 155 Illustration of CcdB, ParE, their antitoxin and GyrA crystal structures: from left to right, GyrA59 dimer 
(yellow and orange) from Edwards et al (Edwards, Flatman et al. 2009); CcdB dimer (blue and green) and gyrA14 
dimer (yellow and orange) from Dao-Thi et al (Dao-Thi, Van Melderen et al. 2005), CcdB dimer (blue and green) 
and two CcdA (C-terminal domain; pink and magenta) from De Jonge et al; ParE dimer (turquoise and violet) and 
two ParD (red and yellow) from Dalton and Crosson (Dalton and Crosson 2010).  
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production of oxazole- and thiazole-containing toxins, is widely distributed is very encouraging 
to adopt such approach. Similarly, tracking proteins related to the immunity peptide McbG can 
be a way of finding in the related toxin, a compound with biological relevance. 
Our principal interest in this study was to isolate new topoisomerase inhibitor 
antibacterials, and we had principally being involved with gyrase. But occasionally we had 
widened our target scope to topo IV, a logical choice, as it is the sister target of gyrase for 
quinolones, and topo II for its relevance in cancer therapy. This digression had proved valuable 
as we have identified that MccB17 and some of its fragments were able to inhibit human topo 
II at ~100 µM, this opens a completely new prospect for MccB17 derivatives applications. This 
is as well an encouraging example of the relevance of evaluating families of topoisomerase 
inhibitors on various other topoisomerases. This can be further illustrated by the successful 
example of the transfer of quinolone structures from application in antibacterial therapy to 
anti-cancer therapy (Hawtin, Stockett et al. ; Sissi and Palumbo 2003). It makes perfect sense in 
the context of topoisomerase poisons if we consider them globally. Topoisomerase poisons are 
structures that interact with the cleavage complex, and generally, apart from CcdB, by 
stabilizing it through direct interaction with DNA and the protein at or close to, the cleavage 
site. This means that if we have compounds with the features to interact both with DNA and a 
topoisomerase, and possibly with the architecture of a cleavage site, its derivatives are likely to 
still have a topoisomerase inhibitor profile, but maybe fitting better with a different 
topoisomerase cleavage complex. We think it is worth keeping that in mind: not restricting 
studies on only one topoisomerase, and evaluating the potential on other topoisomerases of 
both successful and failed inhibitors. 
We hope we had convinced the reader of the great potential of natural products and 
their application on validated drug targets through new mechanisms. We chose to study the 
gyrase poison MccB17, and we have opened perspectives in using MccB17 derivatives to create 
new topoisomerase inhibitors. We had discussed the possible limitations of future work on this 
subject, as well as the potential for a significant breakthrough. Regardless of the outcome of 
MccB17 uses for new topoisomerase inhibitors, we have mentioned the vast pool of related 
compounds available from natural sources. Microorganisms have, through their evolution, 
explored multiple possibilities to kill the competition, we have just to observe, understand, and 
duplicate or improve the means they have developed and make them ours. Synthesis by 
Nature has a set of limitations, it works in aqueous environment and at a limited range of 
temperature, but it has evolved a gigantic range of catalytic tools to widen its synthetic 
capacity. A few of these tools are at our disposition as well, and we have an extra advantage 
with the chemistry we have developed that allows us to work in various solvents, with 
anhydrous condition, and very reactive species that cannot exist in aqueous environments. A 
wide range of temperature and pressure are available as well to us. However Nature inside its 
limitation is able to construct far more complex structure and more efficiently that we are, it 
has tested and refined its tools over millions of years. We have developed wonderful methods, 
but they are in a limited number and what we produce is biased most of the time by what is 
available from our suppliers. This means that we have through pure synthesis a restricted 
chemical space to explore, and that fact can account for the plateau we reached in drug 
discovery. We should benefit from the two sources, identifying unusual structures and 
mechanisms present in nature, which are not available through chemical synthesis, and 
improve them so they would not be sensitive to defence mechanism like proteolysis of 
peptides. Other improvement can be gained through exploration of chemistry unusual in 
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nature like halogenation and particularly fluorination, or the use of retropeptide and 
bioisostere to optimise activity and stability. We hope that this work and its future perspective 
illustrate fully this approach, and have given hope in our ability to restore the antibacterial Era. 
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CHAPTER VI Materials and Methods 
1 Materials 
1.1 Softwares 
Chemical structure drawing: MarvinSketch (ChemAxon). 
DNA sequence analysis: Sequencher (Gene Codes). 
Gel picture analysis: Genetools (SynGene). 
1.2 Chemicals 
All chemicals were purchased from Sigma-Aldrich. 
1.3 Buffers and gels 
TAE: 40 mM Tris.acetate, 2 mM Na2EDTA, pH = 8.5.  
TE: 10 ml Tris.HCl pH = 8.0, 1 mM EDTA. 
LB (amp): 10 g/l bacto-tryptone, 5 g/l yeast extract, 10 g/l NaCl, pH = 7.5. 
M63 glucose media (amp): 3 g/l KH2PO4, 7 g/l K2HPO4, 2 g/l (NH4)SO4, 1 mM MgSO4, 1 µg/ml 
thiamine, 0.2% glucose (0.1 mg/ml ampicillin added just before use). 
Mac Conkey Agar: peptone 17.0 g/l, proteose peptone 3.0 g/l, lactose 10.0 g/l, bile salts nº3 
1.5 g/l, sodium chloride 5.0 g/l, agar 13.5 g/l, neutral red 0.03 g, crystal violet, 0.001 g/l. 
1.4 Enzymes 
DpnI: was purchased from Biolab (RO176S). 
Subtilisin: was purchased from Sigma-Aldrich (P5380). 
Endoprotease Glu-C: was purchased from Sigma-Aldrich (P2922). 
Carboxypeptidase A: was purchase from Sigma-Aldrich (C9268). 
Taq DNA polymerase: was purchased from Invitrogen. 
Pfu-turbo DNA polymerase: was purchased from Stratagen (600250). 
Trypsin: was purchased from Promega (V5111). 
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1.5 Primers 
 
1.6 Apparatus 
1.6.1 High pressure liquid chromatography 
A Dionex Ultimate 3000 HPLC system was used for most of the purifications. Two 
different columns were used in conjunction with this system. The first was a preparative 
reverse phase column ACE 5 C18-300 250 X 21.2mm (ACE-221-2520). The second, was a semi-
preparative column Phenomenex Jupiter 300 5µ C18, 10 mm X 250 mm. The initial separation 
of the subtilisin digest of MccB17 was performed with an analytical column Phenomenex 
primesphere 5µ C18MC 300 Å, 4.6 mm X 250 mm adapted on a Waters™ system: a Waters 626 
pump was associated with a Waters 600S controller, the detection was performed with a 
photodiode array detector 996, and the collection was done using a 717plus Autosampler. 
 
Table 14 List of primers 
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1.6.2 Nuclear magnetic resonance 
NMR data was recorded at 300 K, on a Bruker Avance II 600 MHz NMR spectrometer 
with Bruker TCI cryoprobe (1H and 13C). 1H and 13C NMR chemical shifts (δ) are referenced 
with respect to the DMSO-d6 solvent: (DMSO: delta 1H 2.49 ppm and delta 13C 39.5 ppm). 
1.6.3 Mass spectrometry 
Mass spectrometry analysis were performed on either on a Bruker Ultraflex™ MALDI-
ToF/ToF (referred as MALDI-ToF), or a Thermo-Fisher LCQ DecaXPplus (EI). 
2 Methods 
2.1 Production and purification of Microcin B17 (MccB17) 
2.1.1 Expression in E. coli 
The toxin was produced using a protocol similar to the one describe by Roy et al (Sinha 
Roy, Kelleher et al. 1999). The E. coli strain used had been designed and reported by Milne et al 
(Milne, Eliot et al. 1998) is a DH5α carrying a pUC-19-plasmid containing the MccB17 operon 
mcbABCDEFG. DH5α-pmccB17 from the glycerol stock was grown overnight at 37°C in 12x5 ml 
of LB-amp media (10 g/l bacto-tryptone, 5 g/l yeast extract, 10 g/l NaCl, 0.1 mg/ml ampicillin). 
The culture were used to inoculate 12 X 1l of M63 glucose Ap media (3 g/l KH2PO4, 7g/l K2HPO4, 
2 g/l (NH4)2SO4, 1 mM MgSO4, 1 mg/ml thiamine, 0.2% glucose and 0.1 mg/ml ampicillin) in 2 l 
baffled flasks, which were incubated overnight at 37°C with stirring at 220 rpm. The cells where 
centrifuged for 15 min at 4250 g and the pellets collected. The pellets where resuspended in 
500 ml of a boiling solution containing 1 mM EDTA and 100 mM acetic acid solution and stirred 
for 10 min. The solution was allowed to cool to ~40°C before centrifugation at 4500 rpm for 10 
min. The warm supernatant was then divided in four fractions and loaded separately on a 35cc 
(10 g) Sep-Pak® column (Waters WAT043345) equilibrated beforehand with 300 ml of 
acetonitrile and 300 ml water. Elution with 250 ml water followed by 250 ml 12.5% acetonitrile 
in water removed contaminants, then the MccB17-containing fraction was collected by elution 
with 250 ml of 50% acetonitrile in water. Acetonitrile was removed from the collected fraction 
under vacuum, and the remaining solution was freeze dried to lead to solid raw MccB17. The 
solid was dissolved in DMSO at a mM concentration and stored at -20ºC. 
2.1.2 Purification of raw microcin by HPLC: 
The raw microcin solution was purified on a Dionex Ultimate 3000 HPLC system with a 
preparative reverse phase column ACE 5 C18-300 250 X 21.2mm (ACE-221-2520). The solution 
of raw MccB17 in DMSO (mM concentration) was loaded onto the HPLC via a 5 ml loop. The 
elution program was a linear gradient from 13% to 23% CH3CN in water, with 0.1% TFA, over 40 
min. The peaks highlighted on Figure 156 were collected manually. The difference fractions 
collected were concentrated under vacuum before being freeze-dried. The solid residues were 
dissolved in DMSO and stored at -20°C. The various fractions collected were concentrated 
under vacuum before being freeze dried. 
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2.1.3 Methanol-water alternative system 
Due to the global shortage of acetonitrile in 2008-2009 the HPLC purification of 
microcin was shifted from a water-acetonitrile system to a water-methanol (relative polarities 
H2O = 1; MeOH = 0.762; CH3CN = 0.460) (Reichardt 2003). 
 
 
Figure 156 Trace at 254 nm of the HPLC purification of raw MccB17  
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As before, the purification was performed on a Dionex Ultimate 3000 HPLC system with 
a preparative reverse phase column ACE 5 C18-300 250x21.2mm (ACE-221-2520). The solution 
of raw MccB17 in DMSO (mM concentration) was loaded onto the HPLC via a 5 ml loop. The 
elution program was a linear gradient from 20% to 35% over 40 min. 
2.1.4 Isolation of microcin B17 by-products 
The chromatogram of MccB17 purification shows a few peaks coming out of the column 
before MccB17. The fraction with 25 min<RT< 31 min was collected for further analysis. In later 
purifications individual peaks were collected. The fractions collected were concentrated under 
vacuum, freeze-dried and redissolved in DMSO. 
2.2 In vitro assays on topoisomerases: 
2.2.1 E. coli Gyrase 
In the cell, gyrase is an enzyme that introduces negative supercoils in DNA at the 
expense of ATP in order to remove topological stress. This property can be reproduced in vitro 
and the influence of inhibitors recorded. It is possible as well in vitro for the enzyme to relax 
supercoiled DNA in the absence of ATP; this is not a reaction the enzyme is designed for and so 
its activity is a lot lower than a relaxing enzyme like topo IV. By comparing supercoiling and 
relaxation reactions for a given inhibitor it is possible to trace its involvement in the ATPase 
activity of the enzyme; an ATPase inhibitor will hinder the supercoiling reaction but will have 
little effect on relaxation. The last in vitro assay used to characterise inhibitor of gyrase is the 
cleavage assay that relies on the formation of the DNA-gyrase cleavage complex. This complex 
is a transient intermediate of the supercoiling and relaxation reactions, by using an increased 
amount of enzyme the equilibrium is pushed toward its formation. Cleavage assays are used to 
characterize inhibitors like fluoroquinolones, drugs that are cleavage-complex stabilizers and so 
increase its formation in this assay.  
Figure 157 HPLC system solvent equivalence (http://www.discoverysciences.com/product.aspx?id=6306)  
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2.2.1.1  Supercoiling 
  The supercoiling reaction was carried out in the 
following conditions: for a 30 µl reaction, 6 µl of 
reaction buffer 5X (175 mM Tris.HCl pH = 7.5, 120 mM 
KCl, 20 mM MgCl2, 10 mM DTT, 9 mM spermidine, 1 
mM ATP, 32.5% v/w glycerol, 0.5 g/l BSA), 16.5 µl MQ 
water, and 0.5 µl of 1 mg/ml relaxed pBR322 were 
mixed on ice. Solutions of GyrA, GyrB, and the gyrase 
dilution buffer (50 mM Tris.HCl pH = 7.5, 100 mM KCl, 2 
mM DTT, 1 mM EDTA, 10% w/v glycerol) were mixed to 
lead to 27 nM GyrA and 27 nM GyrB solution and left 
for 5 min on ice. 6 µl of the gyrase mixture was added 
to the reaction mixture. Finally 1 µl of DMSO or drug in 
DMSO were added. Special attention was paid to make 
sure the DMSO solutions didn’t freeze in the pipette 
tips during the addition. To avoid such trouble, when 
possible, to a reaction mixture containing only 12.5 µl of MQ water were added to 5 µl of the 
drug in 20% DMSO solution in the last step. The table on the right shows the final 
concentrations in the reaction mixture. The mixture was incubated for 2 h at 25°C. Then 30 µl 
of chloroform/isoamyl alcohol (24:1) and 30 µl of STEB were added to stop the reaction. The 
mixture was vortexed for 10 s and centrifuged 2 min at 13000 rpm. The aqueous layer was 
loaded on a 1% w/v agarose gel and run either overnight at 17 V or 3 h at 70 V. 
2.2.1.2 Relaxation 
  The relaxation reaction was carried out in the 
following conditions: for a 30 µl reaction, 6 µl of 
reaction buffer 5X (175 mM Tris.HCl pH = 7.5, 120 mM 
KCl, 20 mM MgCl2, 10 mM DTT, 32.5% v/w glycerol, 0.5 
g/l BSA), 16.5 µl MQ water, and 0.5 µl of 1 mg/ml 
supercoiled pBR322 were mixed on ice. Solutions of 
GyrA, GyrB, and the gyrase dilution buffer (50 mM 
Tris.HCl pH = 7.5, 100 mM KCl, 2 mM DTT, 1 mM EDTA, 
10% w/v glycerol) were mixed to lead to 200 nM GyrA 
and 200 nM GyrB solution and left for 5 min on ice. 6 µl 
of the gyrase mixture was added to the reaction 
mixture. Finally 1 µl of DMSO or drug in DMSO were 
added. The same method described for supercoiling 
assays was used to make sure the DMSO solutions 
didn’t freeze: to a reaction mixture containing only 12.5 µl of MQ water was added 5 µl of the 
drug in 20% DMSO solution in the last step. The final concentrations in the reaction mixture are 
shown in the table on the right. The mixture was incubated for 2 h at 37°C. Then 30 µl of 
chloroform/isoamyl alcohol (24:1) and 30 µl of STEB were added to stop the reaction. The 
Gyrase supercoiling assay mixture 
Compound Conc. 
Gyrase 2.7 nM 
Relaxed pBR322 5.4 nM 
DMSO  3.3 % V/V 
compound (in DMSO) variable 
ATP 1 mM 
MgCl2 4 mM 
Tris.HCl pH = 7.5 45 mM 
KCl 44 mM 
DTT 2.4 mM 
spermidine 1.8 mM 
glycerol 8.5 % w/V 
BSA 0.1 mg/ml 
Gyrase relaxation assay mixture 
Compound Conc. 
Gyrase 20 nM 
supercoiled pBR322 5.4 nM 
DMSO  3.3 % V/V 
compound (in DMSO) variable 
MgCl2 4 mM 
Tris.HCl pH = 7.5 45 mM 
KCl 44 mM 
DTT 2.4 mM 
glycerol 8.5 % w/V 
BSA 0.1 mg/ml 
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mixture was vortexed for 10 s and centrifuged 2 min at 13000 rpm The aqueous layer was 
loaded on a 1% w/v agarose gel and run either overnight at 17 V or 3 h at 70 V. 
2.2.1.3 Cleavage 
 The cleavage reaction was carried out as described above but with a 79.5 nM gyrase 
final concentration, using supercoiling conditions, if the reaction was studied in presence of 
ATP or relaxation condition if the reaction was studied in its absence. The mixture was 
incubated for 1 h at 37°C. 6 µl of 1% w/v SDS and 3 µl of proteinase K (20 mg/ml) were added 
and the reaction was incubated for 30 min at 37°C. 30 µl of chloroform/isoamyl alcohol (24:1) 
and 30 µl of STEB were added, the mixture was vortexed for 10 s and centrifuged 2 min at 
13000 rpm. The aqueous layer was loaded on a 1% w/v agarose gel and run either overnight at 
17 V or 3 h at 70 V. The gel may contain 1 µg/ml ethidium bromide in order to discriminate 
linear DNA, relaxed species and nicked DNA Figure 158. 
 
 
  
Figure 158 Examples of supercoiling, relaxation and cleavage assays: Top left, supercoiling assay, relaxed DNA (upper 
ladder) is converted into supercoiled DNA by gyrase (bottom band). In the presence of an inhibitor the bottom band 
intensity is reduced in favour of the top bands. Bottom left, relaxation assay, supercoiled DNA (lower band) is 
converted into relaxed DNA (upper ladder) by gyrase; the presence of an inhibitor induces a decrease of the upper 
bands in favour of the lower band. Right side, cleavage assays, during a supercoiling or relaxation reaction with 
increased amount of enzyme, linear DNA is produced. Unfavourable in normal conditions, this reaction is favoured by 
the presence of a cleavage complex stabilizer like ciprofloxacin or MccB17 (with ATP) and leads to the appearance of a 
band in the middle. 
200 
 
2.2.2 E. coli topo IV relaxation 
Topo IV is a topoisomerase specialized in 
relaxation and decatenation. Both activities can be 
reproduced in vitro, but only relaxation has been 
carried out in this study. The reaction was carried out 
in the following conditions: for a 30 µl reaction, 6 µl 
of reaction buffer 5X (200 mM HEPES.KOH pH = 7.6, 
500 mM KCl, 50 mM MgCl2, 50 mM DTT, 0.25 g/l 
BSA), 16.5 µl MQ water, and 0.5 µl of 1 mg/ml 
supercoiled pBR322 were mixed on ice. 6 µl of 0.11 
µM topo IV in dilution buffer (40 mM HEPES.KOH, pH 
= 7.6, 100 mM KCl, 1 mM DTT, 1 mM EDTA, 40% w/v 
glycerol) and 1 µl of 30 mM ATP were added. Finally 1 
µl of DMSO or drug in DMSO were added to the 
mixture. Ciprofloxacin at 17 µM was used as a 
positive control. The table on the right shows the 
final concentrations in the reaction mixture. The mixture was incubated for 30 min at 37°C. 
Then 30 µl of chloroform/isoamyl alcohol (24:1) and 30 µl of STEB were added to stop the 
reaction. The mixture was vortexed for 10 s and centrifuged 2 min at 13000 rpm. The aqueous 
layer was loaded on a 1% w/v agarose gel and run either overnight at 17 V or 3 h at 70 V. 
2.2.3 Human topoisomerase II relaxation 
The reaction was carried out in the following 
conditions: for a 30 µl reaction, 3 µl of reaction buffer 
10X (500 mM Tris.HCl pH = 7.5, 1.25 M NaCl, 100 mM 
MgCl2, 50 mM DTT, 1 g/l BSA), 24.5 µl MQ water, and 0.5 
µl of 1 mg/ml supercoiled pBR322 were mixed on ice. 
0.1 µl of topo II (1 Unit) in (50 mM Tris.HCl, pH = 7.5, 100 
mM NaCl, 1 mM DTT, 0.5 mM EDTA, 50% w/v glycerol, 
50 µg/ml BSA ) and 1 µl of 30 mM ATP were added. 
Finally 1 µl of DMSO or drug in DMSO were added to the 
mixture. Etoposide at 100 µM was used as a positive 
control.  The table on the right shows the final 
concentrations in the reaction mixture. The mixture was 
incubated for 30 min at 37°C. 30 µl of chloroform/isoamyl alcohol (24:1) and 30 µl of STEB 
were added to stop the reaction. The mixture was vortexed for 10 s and centrifuged 2 min at 
13000rpm. The aqueous layer was loaded on a 1% w/v agarose gel and run either overnight at 
17 V or 3 h at 70 V. 
 
Topo IV 22 nM 
supercoiled pBR322 5.4 nM 
ATP 1 mM 
HEPES.KOH (pH = 7.6) 48 mM 
KCl 120 mM 
MgCl2 10 mM 
DTT 10.2 mM 
EDTA 0.2 mM 
Glycerol 8% 
BSA 50 μg/ml 
Topo II 22 nM 
supercoiled pBR322 5.4 nM 
ATP 1 mM 
Tris.HCl (pH = 7.5) 50 mM 
NaCl 125 mM 
MgCl2 10 mM 
DTT 5 mM 
BSA 100 μg/ml 
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2.2.4 Staphylococcus aureus gyrase supercoiling 
The reaction was carried out in the following 
conditions: for a 30 µl reaction, 6 µl of reaction buffer 
5X (200 mM HEPES.KOH pH = 7.6, 50 mM Mg(OAc)2, 50 
mM DTT, 0.25 g/l BSA, 10 mM ATP), 17.5 µl MQ water, 
0.5 µl of 1 mg/ml of relaxed pBR322, and 5 µl of 6X 
KGlu (3 M) were mixed on ice. 6 µl of 72 nM SaGyrA 
and 720 nM SaGyrB in dilution buffer (50 mM Tris.HCl, 
pH = 8.0, 1 mM DTT, 1 mM EDTA, 10% w/v glycerol). 
Finally 1 µl of DMSO or drug in DMSO were added to 
the mixture. Ciprofloxacin at 17 µM was used as a 
positive control. The table on the right shows the final 
concentrations in the reaction mixture. The mixture 
was incubated for 1 h 45 at 25°C. 30 µl of 
chloroform/isoamyl alcohol (24:1) and 30 µl of STEB 
were added to stop the reaction. The mixture was 
vortexed for 10 s and centrifuged 2 min at 13000 rpm. 
The aqueous layer was loaded on a 1% w/v agarose gel 
and run either overnight at 17 V or 3 h at 70 V. 
2.2.5 Agarose gel electrophoresis 
1% w/v of agarose was added to TAE buffer (40 mM Tris acetate, 1 mM EDTA). The 
mixture was boiled until complete dissolution of the agarose. The gel was allowed to cool 
down for 5 min. If the gel was run in presence of ethidium bromide, 1 µg/ml was added at this 
stage. The gel was poured into the rack with a comb. The gel was allowed to solidify at least for 
30 min. The comb was removed, and the gel with the rack was put in the tank. The gel was 
covered with TAE buffer (containing 1 µg/ml ethidium bromide if needed). The gel was run run 
either overnight at 17 V or 3 h at 70 V, which brings the bromophenol blue front to the end of 
the gel. If the gel was ethidium bromide free, it was then soaked in TAE containing 1 µg/ml 
ethidium bromide for 20 min. The gel was visualized under UV light after being destained in 
TAE buffer for 20 min. 
2.3 In vivo assays 
 
2.3.1 Slope plates 
Slope plates are designed to create a concentration gradient of a compound from one 
side of a square plate to the other. This gradient is generated by pouring 50 ml liquid LB-agar 
containing the compound at the higher concentration desired for the gradient on an angled 
square Petri dish. The plate is angled so the agar covers the whole surface but has a negligible 
height on one side. The agar is allowed to solidify, then 50 ml liquid LB-agar are poured on the 
Petri dish lying flat. The plate was streaked in the direction of the gradient with the different 
strains. Plates are incubated at 37°C overnight. 
SaGyrA 2.4 nM 
SaGyrB 23 nM 
relaxed pBR322 5.4 nM 
ATP 2 mM 
HEPES.KOH (pH = 7.6) 40 mM 
Tris.HCl (pH = 8) 10 mM 
Mg(OAc)2 10 mM 
DTT 11 mM 
EDTA 0.2 mM 
Glycerol 2% 
BSA 50 μg/ml 
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2.3.2 Resistant colonies plates 
E. coli NR698 was grown overnight in 10 ml LB, the cells were centrifuged for 3 min. at 
3000 g, the volume was adjusted to give an inoculating solution with a concentration of 4 X 109 
cells/ml. An LB-agar plate containing 2.5 µM MccB17 was inoculated with 2 X 109 cells (500 µl), 
and incubated overnight at 37°C.   
2.3.3 Glycerol stock 
Produced strains were stored at -80°C as glycerol stocks: 750 µl of overnight grown culture 
were added to a mixture of 107 µl DMSO and 214 µl glycerol, the mixture was briefly vortexed 
and flash frozen in liquid nitrogen before storage.  
2.4 MccB17 mutants production 
2.4.1 Template for MccB17 production 
The plasmid coding for MccB17 was extracted from the strain DH5α-pmccB17 as follows: 
2 X 5 ml of LB 0.1 mg/ml Amp were inoculated with colonies grown overnight on LB-agar 
containing 0.1 mg/ml Amp. The plasmid was extracted from the 2 X 5 ml using QIAprep® 
Miniprep kit from Qiagen. The miniprep yielded 2 X 50 µl containing 500-600 µg/µl of pUC19-
mcbABCDEF. The plasmid’s size was checked by digestion with EcoRI. 
2.4.2 Production of mutated mcb gene 
The template coding for MccB17 was amplified by PCR using primers carrying the 
desired mutation or stop codon as described in the table below. In a PCR tube, 5 µl of Pfu 
Turbo buffer (10X), 1 µl dNTP (10 mM), 1 µl of F-primer 200 nM, 1 µl of R-primer 200 nM, 1 µl 
of Pfu turbo (2.5 U), 1 µl of pmccB17 50 µg/µl and 40 µl MQ water were mixed and submitted 
to the sequence described in the table bellow. 25 µl of the amplification mixture were added to 
5 µl of NEB-buffer n°4, 2 µl of DPNI (40 units), and 18 µl of MQ water and incubated overnight 
at 37°C in order to remove the pUC19-mcbABCDEF template.  
2.4.3 Transformation  
DH5α high efficiency E. coli cells were transformed as follow. In an eppendorf 
microcentrifuge tube on ice, 2.3 µl of the DPNI digest was added to 50 µl of DH5α cells and left 
for 20 min. The mixture was heat-shocked 2 min at 42°C, and 500 µl LB were added. The 
culture was incubated 1 h at 37°C before being centrifuged at 3000 rpm for 1 min. The 
supernatant was discarded by inverting the tube, the cells were resuspended in the remaining 
supernatant before being plated on LB-amp agar and incubated overnight at 37°C. Up to three 
surviving colonies were picked up from the plate and used to inoculate 10 ml of LB-amp that 
was incubated overnight at 37°C. Glycerol stocks were prepared using the overnight cultures, 
and the plasmid containing the modified mccb17 gene was extracted from 5 ml using a 
QIAprep® Miniprep kit from Qiagen before being submitted to sequencing. 
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2.5 Alkaline hydrolysis of microcin B17 
Example: A 2.5 ml (2.3 µmol) of a 0.9 mM solution of MccB17 in DMSO, 2.5 ml MQ water, and 
0.16 ml of aqueous 5M NaOH (345 µmol), were introduced in a 10 ml round bottom flask 
equipped with a stirred, and a condenser. The mixture was stirred at 120°C for 7 days, water 
was added to complement evaporation. The solution was cooled, and the pH adjusted to 7. The 
mixture was diluted in water to reach 1/40 DMSO in water, and freeze dried. 
Variation: other experiments have been carried out in 20% DMSO with 0.9 mM MccB17. 
Raw MccB17 treatment: depending on the purification methods, the raw MccB17 was treated 
as described in Chapter III-1.2. 
2.6 Proteolysis experiments 
2.6.1 Endoprotease Glu-C 
The digestion of the Mcc (N53D, N59D) by endoprotease Glu-C was conducted as 
follows: On ice, 0.1 mg of endo Glu-C in 500 µl of 100 mM ammonium bicarbonate pH = 7 were 
introduced in an eppendorf, 10.8 µl of a 3 mM solution of Mcc(N53D, N59D) in DMSO were 
added. The mixture was incubated for 48 h at 37°C. A strata C18_EC QSPE reverse phase 
column was equilibrated with 30 ml acetonitrile and 30 ml MQ water. The reaction mixture 
was loaded onto the column, and the column was eluted with 30 ml MQ water and 30 ml 50% 
acetonitrile/MQ water, this last fraction was collected and freeze dried after being flushed with 
air. 
2.6.2 Subtilisin digest 
The digestion of MccB17 by subtilisin was conducted as follow: in an universal, 200 µl of 
5 mM solution of MccB17 in DMSO were added to 0.8 ml of reaction buffer (10 mM NaAcO, 5 
mM Ca(AcO)2). To the mixture placed on ice, was added 1 ml of 0.15 mg/ml subtilisin solution 
in the same ice-cooled buffer. The mixture was stirred and incubated at 37°C for 48 h. A strata 
C18_EC QSPE reverse phase column was equilibrated with 30 ml acetonitrile and 30 ml MQ 
water. The reaction mixture was loaded on the column, and the column was eluted with 30 ml 
MQ water and 30 ml 50% acetonitrile/MQ water, this last fraction was collected and freeze 
dried after being flushed with air. 
2.6.3 Aminopeptidase digest 
110 µl of 3 mM MccB17 solution in DMSO were added to 1 ml of reaction buffer (50 mM 
NaHPO3, pH = 7.2). On ice, 1 µl (~0.1 units) of leucine aminopeptidase commercial solution 
(Sigma-Aldrich L5006) was added to the mixture. The reaction mixture was incubated 6 h 30 
min at 37°C. The mixture was directly loaded on a 3 ml Oasis™ (Waters) column equilibrated 
with 6 ml CH3CN and 6 ml MQ water. The column was eluated with 9 ml MQ water, and 9 ml 
50% CH3CN/water, this last fraction was collected and freeze dried. 
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2.6.4 Carboxypeptidase digest 
110 µl of 3 mM MccB17 solution in DMSO were added to 1 ml of reaction buffer (25 mM 
TrisHCl, 500 mM NaCl, pH = 7.5). On ice, 2 µl (~3.5 units) of carboxypeptidase A commercial 
solution (Sigma-Aldrich C9268) was added to the mixture. The reaction mixture was incubated 
6 h 30 at room temperature (25°C). The mixture was directly loaded on a 3 ml Oasis™ (Waters) 
column equilibrated with 6 ml CH3CN and 6 ml MQ water. The column was eluated with 9 ml 
MQ water, and 9 ml 50% CH3CN/water, this last fraction was collected and freeze dried. 
2.7 Synthesis 
2.7.1 Synthesis of oxazole amino acid (H-oz-OH): 2-aminomethyl oxazole-4-
carboxylic acid  
 
2.7.1.1 Boc-oz-OMe: Methyl 2-(N-tert-butoxycarbonyl)aminomethyloxazole-4-
carboxylate 
On a ice-cooled bath, 5 g of N-(tert-butoxycarbonyl)glycine (28 mmol), 4.2 g of O-
methyl serine chlorhydrate (27 mmol), 5.5 g of N,N′-dicyclohexylcarbodiimide (27 mmol) were 
mixed in a round bottom flask under N2, equipped with a stirrer. 150 ml of anhydrous 
dichloromethane and 3.9 ml triethylamine (Et3N, 27 mmol) were added to the solids. The 
reaction mixture was stirred overnight at 0°C under N2. The solvent was removed in vacuo; the 
solid residue obtained was triturated with ethyl acetate, filtered, and the filtrate was 
concentrated under vacuum. The isolated residue was triturated with a small amount of 
tetrahydrofuran and filtered, the residual ammonium chloride discarded, and the filtrate 
concentrated in vacuo. The isolated residue was purified by silica gel column chromatography 
with AcOEt/MeOH (19/1) as eluent, the fractions were controlled by TLC in the same 
conditions, RFBocGlySerOMe = 0.5. 2.3 g (8 mmol) of N-Boc-Gly-Ser-OMe were isolated, and 
introduced in a round-bottom flask, equipped with a stirrer and under N2. 4 ml of bis(2-
methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor®, 9.2 mmol) in 64 ml anhydrous 
dichloromethane were added dropwise at -20°C. After stirring for 30 min at -20°C, 3 ml of 
bromotrichloromethane (30 mmol) were added dropwise to the mixture, followed by 4.6 ml of 
DBU (30 mmol). The reaction mixture was stirred for 8 h on an ice bath (T = 2-3°C) before being 
quenched with 100 ml of a saturated solution of NaHCO3. The mixture was extracted 3 X with 
AcOEt, the decantation was very slow and the last extraction was left overnight to separate. 
The organic phase was dried on anhydrous Na2SO4 and concentrated under vacuum. The 
residue was purified on silica gel column chromatography with n-hexane/AcOEt (1/1) as eluent. 
The fractions were controlled by TLC with the same eluent, RFBocozOMe = 0.34. 1.22 g of the 
expected product were isolated, yield = 17%. The structure was confirmed by 1H NMR (400Hz) 
DMSO-d6: 1.4 (s, 9H, Boc); 3.8 (s, 3H, OMe); 4.3 (s, 2H, CH2); 8.8 (s, 1H, CH (oxazole)). And MS-
ESI (+): m/z = 279.0 (M+Na+); m/z = 257.0 (M+H+); 201.0 (M-tBu) in source fragment, in 
agreement with MS2 data from m/z = 257.0: ->201.0->159.0. The spectroscopic data were in 
agreement with those previously reported (Videnov, Kaiser et al. 1996). 
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2.7.1.2 Boc-oz-OH: 2-(N-tert-butoxycarbonyl)aminomethyloxazole-4-carboxylic acid 
In a beaker, 40 mg of Boc-oz-OMe (0.15 mmol) was resuspended in 10 ml dioxan, and 5 ml of 1 
M NaOH was added. The mixture was stirred for 1 h at RT, then the solution was neutralized by 
addition of 1 M H2SO4 and extracted with 3 X 15 ml dichloromethane. The organic phase was 
dried on anhydrous Na2SO4 before removing the solvent in vacuo. The structure was confirmed 
by MS-ESI (+): m/z = 265.1 (M+Na+); m/z = 187.1 (M-tBu+Na+) in source fragment. MS-ESI(-): 
m/z = 286.7 (M+HCO2
-); m/z = 241.1 (M-H+). The spectroscopic data were in agreement with 
those previously reported (Videnov, Kaiser et al. 1996). 
2.7.1.3 H-oz-OH: 2- aminomethyloxazole-4-carboxylic acid 
The previous Boc-oz-OH (0.15 mmol) was redissolved in 2 ml TFA/CH2Cl2 (1/1) and 
stirred for 2 h at RT. The mixture was concentrated in vacuo and led to the final product: 38 
mg, yield 100%. The structure was confirmed by 1H NMR (400Hz) DMSO-d6: 4.33 (s, 2H); 8.9 (s, 
1H); MS-ESI (+): m/z = 143.0 (M+H+). The spectroscopic data were in agreement with those 
previously reported (Coquin 2005). 
 
2.7.2 Synthesis of thiazole amino acid (H-tz-OH): 
 2-aminomethyl thiazole-4-carboxylic acid  
2.7.2.1 Boc-glycine amide: N-tert-butoxycarbonylglycine amide 
In a round-bottom flask equipped with a stirrer, 4.8 g of Di-tert-butylcarbonate (0.22 
mol) were added to a solution of 2.2 g of glycylamide (0.2 mol) and 3 ml TEA (0.2 mol) in 30 ml 
of THF/H2O (4/1). The mixture was stirred for 5 h at RT. The mixture was extracted with 3 X 40 
ml of AcOEt. The organic phase was washed respectively with 100 ml of 1 M sodium 
hydrogencarbonate solution and 100 ml brine before being dried on anhydrous Na2SO and 
concentrated in vacu. 3.5 g of Boc-glycylamide were isolated, yield = 79 %. The structure was 
confirmed by 1H NMR (400Hz) DMSO-d6: 1.42 (s, 9H, Boc); 3.8 (s, 2H, CH2); 5.1 (s, 1H, NH); 5.45 
(s, 1H, NH2); 6.0 (s, 1H, NH2). The spectroscopic data were in agreement with those previously 
reported (Videnov, Kaiser et al. 1996). 
2.7.2.2 Boc-tz-OH: 2-(N-tert-butoxycarbonyl)aminomethylthiazole-4-carboxylic acid 
In a round-bottom flask, 62 g of Lawesson’s reagent (0.15 mol) were added to a solution of 
34.7 g of Boc-glycinamide (0.2 mol) in 500 ml dimethoxyethane (DME), the reaction mixture 
was stirred overnight at RT. The solvent was removed under vacuum. 500 ml AcOEt and 500 ml 
1M NaHCO3 were added to the residues and stirred for 10 min. The organic phase was 
recovered and the aqueous phase was washed with 2 X 250 ml AcOEt. The combined organic 
phases were washed with 300 ml brine, dried on anhydrous Na2SO4, and concentrated in 
vacuo. The solid residue was recrystalised in EtOAc/n-hexane and led to 29.3 g of Boc-
glycylthioamide. 19 g of N-Boc-2-glycylethioamide (0.15 mol), and 61 g of potassium carbonate 
(0.6 mol) were introduced in a round bottom flask under N2. 300 ml of anhydrous ethanol were 
added to the solids. A solution of 25 g of 3-bromo-2-oxopropanoic acid (0.23 mol) in 200 ml 
anhydrous ethanol was added dropwise. The reaction mixture was stirred for 4 h at RT. The 
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reaction completion is controlled by TLC (CHCl3/MeOH/H2O; 8/3/0.5). The reaction mixture is 
filtered, and the filtrate concentrated under vacuum. The residue isolated was recrystallized in 
AcOEt/n-hexane and led to m = 9.8 g of the expected product, yield = 25%. The structure was 
confirmed by 1H NMR (400Hz) DMSO-d6: 1.4 (s, 9H, Boc); 4.35 (d, 2H, CH2); 7.8 (t, 1H, NH); 8.3 
(s, 1H, CH, tz). And MS-ESI (+): m/z = 281.1 (M+Na+); m/z = 259.1 (M+Na+); m/z = 203.0 (M-
tBu+H+). MS-ESI (-): m/z = 302.9 (M+HCO2
-); m/z = 257.0 (M-H+). The spectroscopic data were in 
agreement with those previously reported (Videnov, Kaiser et al. 1996). 
2.7.2.3 H-tz-OH 
70 mg of N-Boc-tz-OH (0.27 mmol) was dissolved in 4 ml TFA/CH2Cl2 (1/1) and stirred 
for 2 h at RT. The mixture was concentrated in vacuo to lead to the TFA salt of H-tz-OH m = 73 
mg, yield = 100%. The structure was confirmed by 1H NMR (400Hz) DMSO-d6: 4.5(s,2H); 8.5 (s, 
1H). And MS-ESI (+): m/z = 159.0 (M+H+). The spectroscopic data were in agreement with those 
previously reported (Coquin 2005). 
 
2.7.3 Synthesis of H-oztz-OH 
2.7.3.1 Boc-oztz-OH: 
2-((N-tert-butoxycarbonyl)-2’-aminomethyloxazole-4’-yl)-thiazole-4-carboxylic acid 
In a round-bottom flask equipped with a stirrer, 0.50 g of Boc-oz-OMe (2 mmol) were 
dissolved in 30 ml methanol. 10 ml of 35% aqueous ammonia were added at once and the 
mixture was stirred at RT overnight. The reaction mixture was concentrated in vacuo, and 50 
ml of 1 M NaHCO3 were added. The solid residue was filtered and washed with water, and led 
to m = 0.37 g of Boc-glycinamide. In a round-bottom flask, 0.20 g of Lawesson’s reagent (0.8 
mmol) were added to a solution of 0.24 g of Boc-glycinamide (0.6 mmol) in 4 ml DME, the 
reaction mixture was stirred overnight at RT. The solvent was removed under vacuum. 10 ml 
AcOEt and 10 ml 1 M NaHCO3 were added to the residues and stirred for 10 min. The organic 
phase was recovered and the aqueous phase was washed with 2X 10 ml AcOEt. The combined 
organic phases were washed with 20 ml brine, dried on anhydrous Na2SO4, and concentrated 
in vacuo. The solid residue was recrystallized in EtOAc/n-hexane and led to 0.17 g of Boc-
oz(CS)-NH2. In a round-bottom flask under N2 equipped with a stirrer, 0.17 g Boc-oz(CS)-NH2 
(0.6 mmol) and 0.38 g of anhydrous potassium hydrogencarbonate (3.7 mmol) were added. 15 
ml of anhydrous DME were added. The mixture was stirred for 10 min before adding dropwise 
0.3 ml of ethylbromopyruvate (2.2 mmol). The reaction mixture was stirred overnight at RT. 
The mixture was filtered, washed with 3 X 15 ml brine, dried on anhydrous Na2SO4, and 
concentrated under vacuum. The residue was purified by silica gel column chromatography 
with EtOAc/n-hexane (2/1) as eluent, the fractions containing the expected product were 
identified by TLC in the same eluent, RFBocoztzOEt = 0.49. 0.9 g of Boc-oztz-OEt was obtained. In a 
beaker, 0.9 g of Boc-oztz-OEt (0.26 mmol) was dissolved in 3 ml dioxane, and 21 mg NaOH 
(0.52 mmol) in 1 ml water were added. The mixture was stirred 1 h at RT. The solution was set 
to pH = 6 by addition of 1M H2SO4. The dioxane was removed under vacuum, and the pH of the 
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solution was set to pH = 3. The mixture was extracted with 3 X 5 ml AcOEt. The organic phase 
was dried on anhydrous Na2SO4 and concentrated in vacuo. 0.6 g of the expected acid was 
isolated, yield = 19%. The structure was validated by MS-ESI (+): m/z = 348.0 (M+Na+); m/z = 
343.0 (M+NH4
+). m/z = 256 in source fragment-> 200 ->157 ->124 loss of Boc. 
2.7.3.2 H-oztz-OH 
In a beaker, 0.6 g of Boc-oztz-OH (0.19 mmol) were dissolved in 2 ml TFA/CH2Cl2 (1/1) 
and stirred 1h at RT. The mixture was concentrated in vacuo to lead to the TFA salt of H-oztz-
OH, m = 64 mg. Structure confirmed by 1H NMR (400Hz) DMSO-d6: 4.5 (s, 2H); 8.6 (s, 1H, tz); 
8.9 (s, 1H, oz); MS-ESI (+): m/z = 226. The spectroscopic data were in agreement with those 
previously reported (Coquin 2005). 
 
2.7.4 Synthesis of H-tzoz-OH: 
2-(2’-aminomethylthiazole-4’-yl)-oxazole-4-carboxylic acid 
2.7.4.1 Boc-tz-Ser-OMe: 
N-(2-(N’-tert-butoxycarbonyl)aminomethylthiazole-4-carbonyl)-Serine methyl ester 
In a round-bottom flask in an ice-cooled bath, under N2, 4 g Boc-tz-OH (15.5 mmol) 
were dissolved in 75 ml anhydrous dichloromethane. TEA (30 mmol), serine hydrochloride (30 
mmol) and DCC were added to the mixture. The reaction mixture was stirred overnight at 0°C. 
The solvent was removed in vacuo and the residue triturated with 100 ml AcOEt. The DCU was 
removed by filtration, and the filtrate concentrated under vacuum. A small amount of THF was 
added, the NH4Cl was allowed to precipitate before being removed by filtration. The filtrate 
was concentrated, and the residue purified by silica gel column chromatography with 
AcOEt/MeOH 19/1 as eluent. The structure was confirmed by 1H NMR (400Hz) DMSO-d6: 1.4 
(s, 9H, Boc); 3.6 (s, 3H, OCH3); 3.5-4 (m, 3H, CH & CH2, Ser); 4.4(s, 2H, CH2-tz); 5.2 (s, 1H, NH, 
amide); 7.8 (s, 1H, NH, Boc); 8.18 (1H, CH, tz). And MS-ESI (+): m/z = 382.1 (M+Na+); m/z = 
360.0 (M+H+). 
2.7.4.2 Boc-tzoz-OMe: 
Methyl-2-((N-tert-butoxycarbonyl)-2’-aminomethylthiazole-4’-yl)-oxazole-4-
carboxylate 
In a round-bottom flask, at -20°C, under N2, 0.256 g of Boc-tz-Ser-OMe (0.7 mmol) in 8 
ml of anhydrous CH2Cl2. DeoxoFluor® (0.77 mmol) was added dropwise to the reaction mixture. 
After stirring the mixture for 30 min at -20°C, 250 µl bromotrichloromethane (2.5 mmol) and 
383 µl DBU (2.5 mmol) were added. The reaction mixture was stirred on an ice bath for 8 h. 
The mixture was quenched with 10 ml of a saturated solution of NaHCO3, the CH2Cl2 was 
removed under vacuum and the remaining aqueous phase was extracted with 3 X 10 ml of 
AcOEt. The organic extract was dried and concentrated in vacuo. The residue was purified by 
silica gel column chromatography with AcOEt as eluent. 150 mg of the compound were 
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isolated, yield = 63%. The structure was confirmed by MS-ESI (+): m/z = 284.1 (M-tBu+H+); m/z 
= 357.0 (M+Na+); m/z = 362.1 (M +NH4
+). 
2.7.4.3 Boc-tzoz-OH: 
2-((N-tert-butoxycarbonyl)-2’-aminomethylthiazole-4’-yl)-oxazole-4-carboxylic acid 
In a beaker, 140 mg of Boc-tzoz-OMe (0.4 mmol) were dissolved in 3 ml dioxane. 16 mg 
of sodium hydroxide (0.4 mmol) in 1 ml water were added to the solution. The mixture was 
stirred at RT for 1 h. The dioxane was removed under vacuum, and the pH of the solution was 
adjusted to 3 before extraction with 3x 5 ml AcOEt. The organic phases were collected, dried 
with anhydrous Na2SO4, and concentrated in vacuo. 128 mg of the acid were isolated, yield = 
94%. The structure was confirmed by MS-ESI (+): m/z = 348.1 (M+K+); m/z = 343.0 (M+NH4
+). 
MS-ESI (-): m/z = 370.0 (M+HCO2
-); m/z = 324.1 (M-H+). 
2.7.4.4 H-tzoz-OH 
64 mg Boc-tzoz-OH (0.2 mmol) was dissolved in 2 ml TFA/CH2Cl2 (1/1), the mixture was 
stirred for 1 h at RT. The mixture was concentrated under vacuum and lead to the TFA salt of 
H-tzoz-OH. 68 mg were isolated, yield = 100%. The structure was confirmed by 1H NMR (400Hz) 
DMSO-d6: 4.4 (s, 2H); 8.5 (s, 1H, tz); 9.0 (s, 1H, oz). MS-ESI (+): m/z = 226.1 (M+H+). The 
spectroscopic data were in agreement with those previously reported (Coquin 2005). 
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Abbreviations 
A. baumannii: Acinetobacter baumannii 
AcOEt: ethyl acetate 
ATP: Adenosine triphosphate 
Boc: tert-butyloxycarbonyl 
CFX: ciprofloxacin 
CTD: C-terminal domain 
DBU: 1,8-Diazabicyclo[5.4.0]undec-7-ene. 
DCC: N,N′-dicyclohexylcarbodiimide 
Deoxo-Fluor®: bis(2-methoxyethyl)aminosulfur trifluoride 
DIEA: diisopropylethylamine  
DME: dimethoxyethane 
DMF: dimethylformamide 
DMSO: dimethyl sulfoxide 
DNA: Deoxyribonucleic acid 
E. coli: Escherichia coli 
EDTA: ethylenediaminetetraacetic acid 
eq: equivalent 
Et: ethyl 
Et3N : triethylamine 
GlcNAc: N-acetylglucosamine 
G-segment: gate segment 
GTP: guanosine triphosphate  
GyrA: gyrase A 
GyrB: gyrase B 
HEPES: (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid ) 
HOBt: N-Hydroxybenzotriazole 
HOBt: N-hydroxybenzotriazole  
H-oz-OH: 2-aminomethyloxazole-4-carboxylic acid 
H-oztz-OH: 2-[2’-aminomethyloxazole-4’-yl]thiazole-4-carboxylic acid 
HPLC: high-performance liquid chromatography 
H-tz-OH: 2-aminomethylthiazole carboxylic acid 
H-tzoz-OH: 2-[2’-aminomethylthiazole-4’-yl]oxazole-4-carboxylic acid 
IC50: inhibitory concentation for 50% inhibition 
kb: kilobases 
M. tuberculosis: Mycobacterium tuberculosis 
MALDI-ToF (MS): Matrix-assisted laser desorption/ionization  
coupled-time-of-flight (mass spectrometry) 
Mcc: microcin 
MccB17: microcin B17 
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MDR-TB: multidrug-resistant tuberculosis 
Me: methyl 
MeOH: methanol 
MetA: methylenomycin A 
MetC: methylenomycin C 
MIC: minimal inhibitory concentration 
MQ water: milli-q water, high purity ion-exchanged water. 
mRNA: messenger ribonucleic acid 
MRSA: meticillin-resistant Staphylococcus aureus 
MS: mass spectrometry 
MurNAc: N-acetylmuramic acid 
MW: molecular weight 
NTD: N-terminal domain 
PBP: penicillin binding protein 
PEG: polyethylene glycol 
PolyG: polyglycine 
QRDR: quinolone-resistance-determining region 
rRNA: ribosomal ribonucleic acid 
RT: room temperature 
S. aureus: Staphylococcus aureus 
S. cerevisiae: Saccharomyces cerevisiae 
SaGyrA: Staphylococcus aureus gyrase A 
SaGyrB: Staphylococcus aureus gyrase A 
SimD8: simocyclinone D8 
TBTU: 2-(1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate  
TBTU: O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 
TFA: trifluoroacetic acid 
THF: tetrahydrofuran 
TLC: thin layer chromatography 
Topo : topoisomerase 
Topo II: topoisomerase II 
Topo IV: topoisomerase IV 
tRNA: transfer ribonucleic acid 
T-segment: transported segment 
UDP: Uridine diphosphate 
VRE: vancomycin-resistant Enterococcus 
WHD: winged helix domain 
XDR-TB: extensively drug-resistant tuberculosis 
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